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Abstract 
 
Type 2 diabetes mellitus is a chronic condition caused by a deficiency in the secretion 
of insulin from the islets of Langerhans and/or impaired insulin signalling, resulting in 
hyperglycaemia. The role of the endocannabinoid system is well-recognised in the 
CNS and immune system, but its role in glucose homeostasis is poorly understood. 
The aim of this study was to define the roles of cannabinoids in insulin secretion, to 
provide insights into their therapeutic potential (or limitation) in the treatment of type 2 
diabetes. 
 
Isolated islets were used, from Wistar rats, in static incubation studies measuring 
changes in insulin secretion rates.  
 
The endocannabinoid anandamide (AEA) was found to inhibit insulin secretion in a 
glucose- and concentration-dependent manner, with an IC50 of 1.6M (95% CI: 227nM 
to 4.0M; n= 10). Upon further analysis of the concentration-response data islet 
sensitivity to AEA appeared to vary, with islets either appearing to be sensative (IC50 
220nM; 95% CI: 21.9nM to 2.2M; n= 5) or less sensative (IC50 12.3M; 95% CI: 
6.8M to 19.4M; n= 5) to AEA. Pre-incubation of islets with a fatty acid amide 
hydrolase inhibitor did not affect islet responsiveness to AEA. AEA-mediated inhibition 
of insulin secretion was not consistently affected by cannabinoid
 
receptor 1 (CB1) or 
CB2 antagonism. Surprisingly, the CB1 receptor antagonist AM251 was found to inhibit 
insulin secretion in a glucose- and concentration-dependent (IC50 1.6M; 95% CI: 
507nM to 3.3M; n= 6) manner. 
 
Results from this study suggest that differences in CB-receptor signalling pathways, 
rather than endocannabinoid metabolism, could be responsible for the variations in 
the potency of AEA between islet preparations. Characterisation of cannabinoid 
signalling in islets was hindered as the CB receptor antagonists used in this study also 
affected insulin secretion. This study highlights the dynamics of endocannabinoid 
signalling in islets, which may be linked to their physiological function. 
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1  
 
General introduction 
 2
This chapter will begin with a brief description of insulin, regarding its effects on 
peripheral tissue function, insulin signalling and its role in diabetes mellitus. This will 
then be followed by a review of three key areas of interest which form the basis of this 
thesis. The first area will focus on islets of Langerhans, and their physiological role in 
glucose homeostasis. A discussion on how glucose stimulates insulin secretion and 
how insulin secretion is physiologically regulated will be presented. The review will 
continue by describing the aetiology and treatments for type 2 diabetes mellitus, with 
a focus on -cell dysfunction and regulation of glycaemia. The final section will be an 
overview of the endogenous cannabinoid system describing the enzymes which 
produce and degrade the endogenous ligands (endocannabinoids), and their 
associated receptors. The introduction will then be concluded with a description of the 
project and its aims. 
 
1.1 Effects of insulin on peripheral tissues 
 
Insulin is a hormone formed from two peptides that is produced in the -cells of the 
islets of Langerhans (Section 1.2), and it is an important hormone in glucose 
homeostasis, as it lowers plasma glucose. As shown in Table 1.1, insulin signalling 
alters the activity of the liver, skeletal muscle and adipose tissue in order to lower 
plasma glucose levels. These effects are mediated through the insulin receptor, which 
upon binding insulin autophosphorylates, with the subsequent phosphorylation of a 
number of signalling proteins called insulin receptor substrate (IRS) molecules 
(Rhodes & White, 2002). In total, 5 IRS (IRS-1, -2, -4, -5 and -6) molecules have been 
identified in human tissues (Fritsche et al., 2008). Of the five isoforms, IRS-1 and IRS-
2 have received the most interest with regard to glucose homeostasis, as interference 
with their expression leads to peripheral insulin resistance and IRS-2 blockade in -
cells leads to type 2 diabetes (see review by Rhodes & White (2002)). Activation of 
IRS1/2 is known to activate phosphatidylinositol 3-kinase (PI3K), PI3K then activates 
mammalian target  
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Table 1.1  The effects of insulin and glucagon on hepatic, white adipose tissue and 
skeletal muscle metabolism 
 
Hormone Hormone effect Liver Skeletal Muscle Adipocyte 
Insulin  Gluconeogenesis1  Glucose uptake  Glucose uptake 
  -oxidation  -oxidation  Lipolysis 
  Glycogenolysis  Fatty acid uptake  Lipogenesis 
  Glycogenesis  Glycolysis   
  Glycolysis  Glycogenolysis   
  Lipogenesis  Glycogenesis   
Glucagon  Gluconeogenesis    Lipolysis 
  Glycogenolysis     
  Glycogenesis     
  Glycolysis     
  -oxidation     
  Lipogenesis     
1
 Reduction in gluconeogensis is achieved via the activation of hepatic (reduced 
transcription of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase) and 
hypothalamic (via the vagal nerve) insulin receptors (Fritsche et al., 2008; Lam et al., 
2009). Data has been adapted from data in Fritsche et al. (2008) , Lam et al. (2009), 
Bouzakri et al. (2006), Palanivel et al. (2006), Leney & Tavare (2009), Giorgino et al. 
(2005), Ali & Drucker (2009) and Klain (1977). 
 
of rapamycin (mTOR), protein kinase C (PKC) and Akt (also known as PKB; Fig 1.1). 
Insulin receptor activation also leads to the activation of mitogen-activated protein 
kinase (MAPK) and CAP/Cbl cascades (see reviews by Giorgino et al. (2005), Krook 
& Zierath (2009), Leclercq et al. (2007), and Fritsche et al. (2008)).  In peripheral 
tissues, promotion of cell survival, proliferation and differentiation in peripheral tissues 
is mediated by MAPK and Akt signalling and increased protein synthesis is mediated 
by mTOR and MAPK signalling (see reviews by Giorgino et al. (2005), Krook & 
Zierath (2009), Leclercq et al. (2007), and Fritsche et al. (2008)). Alterations in 
glucose transporter 4 (GLUT4) translocation and glucose uptake are controlled by 
PKC, Akt and CAP/Cbl signalling, while alterations in metabolism are mainly 
controlled by Akt but may also involve PKC signalling (see reviews by Giorgino et al. 
(2005), Krook & Zierath (2009), Leclercq et al. (2007), and Fritsche et al. (2008)). The 
two most important effects of insulin signalling in peripheral tissues (with regard to 
glucose clearance) are the reductions in hepatic glucose production and increased 
glucose uptake (by GLUT4 translocation to the plasma membrane from storage 
vesicles) in skeletal muscle and adipose tissue (Bouzakri et al., 2006; Fritsche et al., 
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2008; Lam et al., 2009; Leney & Tavare, 2009). In addition to glucose clearance, 
insulin signalling also causes hepatic cell, skeletal muscle, and adipocyte metabolism 
to switch from a catabolic state to an anabolic state (Table 1.1).  
 
IRS-1/2PI3K
PDK-1
PKC Akt mTOR MAPK
CAP/Cbl
CAP/Cbl
GLUT4 vesicle
Insulin Insulin
Intracellular
ExtracellularInsulin receptor
 
 
Figure 1.1  A schematic diagram of insulin receptor signalling. On binding insulin, the 
insulin receptor is then able to undergo autophosphorylation. This then allows various 
proteins to bind to and be phosphorylated by the receptor, which activates insulin 
receptor substrate 1 & 2 (IRS1/2), mitogen-activated protein kinase (MAPK) and 
CAP/Cbl signalling pathways. Block arrows represent direct activation, and broken 
arrows represent several steps. PI3K (phosphatidylinositol 3-kinase), PKC (protein 
kinase C), Akt (also known as PKB), mTOR (mammalian target of rapamycin). Figure 
is based on information in the reviews by Giorgino et al. (2005), Krook & Zierath 
(2009), Leclercq et al. (2007), and Fritsche et al. (2008). 
 
Together with the counter regulatory hormones, glucagon (Section 1.2.3), cortisol, 
growth hormone and adrenaline, insulin is involved in the complex regulation of 
glycaemia, ensuring that there is a sufficient (but not an excessive) supply of glucose 
during periods of fasting, feeding and exercise. Therefore, insulin plays a key role in 
glucose homeostasis as it is the only hormone to lower blood glucose. Diabetes 
mellitus is a chronic endocrine disorder caused by a deficiency in amount of insulin 
secretion and/or a deficiency in insulin signalling resulting in hyperglycaemia. It has 
been estimated that 171 million people worldwide had diabetes in 2000 (Wild et al., 
2004). The two most prevalent types of diabetes mellitus are type 1 and type 2 
diabetes. In 2005, it was estimated that ~10% and ~90% of the UK population who 
had diabetes mellitus had type1 and type 2 diabetes, respectively (Gonzalez et al., 
2009). Type 1 diabetes is caused by an absolute deficiency in insulin secretion, which 
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is thought to be the result of autoimmune-mediated destruction of the insulin secreting 
-cells (see the review by Santamaria (2010)). Type 2 diabetes is caused by islet 
dysfunction and/or insulin resistance in peripheral tissues (Ferrannini, 1998; Kahn, 
2003; Spellman, 2007). Islet dysfunction in type 2 diabetes was typically thought to be 
the result of insufficient insulin release from  cells, but evidence over recent years 
now suggests that excessive secretion of glucagon from -cells also contributes to 
persistent hyperglycaemia (Spellman, 2007; Burcelin et al., 2008). Briefly glucagon 
secretion during hypoglycaemia appears to be attenuated in type 2 diabetes, while 
glucose induced inhibition of glucagon is suppressed leading to increased 
hyperglycaemia by upregulating hepatic gluconeogensis (Burcelin et al., 2008; 
Quesada et al., 2008). A discussion of diabetes mellitus, and its management 
continues in Section 1.3. 
 
1.2 The islets of Langerhans and insulin secretion 
 
The islets of Langerhans are clusters of endocrine cells interspersed throughout the 
exocrine pancreas, and are formed from -, -, 	- and PP-cells which secrete 
glucagon, insulin, somatostatin-14 (sst-14) and pancreatic polypeptide (PP), 
respectively. Insulin and glucagon have opposing effects on plasma glucose levels, 
with insulin promoting glucose clearance while glucagon stimulates increases in 
plasma glucose levels (Table 1.1). Somatostatin-14 helps to regulate the secretion of 
glucagon and insulin (Hauge-Evans et al., 2009; Mazziotti et al., 2009). The effects of 
insulin and the roles of glucagon and sst-14 are discussed in more detail elsewhere 
(Sections 1.1 and 1.2.3). The effects of PP on islet function are not understood. As 
discussed in the review by Kojima et al. (2007), PP has been found to negatively 
regulate exocrine pancreatic activity, gastric emptying and appetite while increasing 
energy expenditure. There is also some evidence to suggest that there is a fifth 
endocrine cell within islets, the ghrelin-secreting 
-cells, but 
-cells may be only be 
important in foetal islet development (Heller et al., 2005; Andralojc et al., 2009). 
However, it should be noted that ghrelin has also been reported to be expressed in -
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cells in rat and human islets (Date et al., 2002; Heller et al., 2005), but the expression 
of ghrelin in human -cells has been disputed by Andralojc et al. (2009).  
 
Islet cell composition and the organisation of islets are also known to differ between 
different species. For instance, the study by Brissova et al. (2005) found that in murine 
islets, -cells accounted for approximately 80% of the islet cell population, whereas in 
humans, this number ranged from 28-75%. Primate islets (including human) have 
non- cells (- and 	-cells) interspersed throughout the islets, whereas rodent islets 
are highly organised with -cells forming the core of the islets surrounded by non- 
cells (Brissova et al., 2005). The composition of islets is known to vary between 
different regions of the pancreas, and islet function is influenced by their size (Tasaka 
et al., 1989; Elayat et al., 1995; Aizawa et al., 2001). Aizawa et al. (2001) found that 
islet size influenced islet responsiveness to glucose, with larger islets typically 
releasing more insulin at lower glucose concentrations than smaller islets. Weaver & 
Sorenson (1989) have also reported that blood flow from islets is dependent on islet 
size, with blood from smaller islets first draining into acinar tissues before entering the 
wider circulation (i.e. to the rest of the body), whereas blood from larger islets drains 
directly into the wider circulation as well as into acinar tissues (Weaver & Sorenson, 
1989). As to why islets vary is currently unclear and this aspect of islet organisation 
remains poorly understood. 
 
Islets are also highly vascularised and so islets contain numerous endothelial cells, 
which promote -cell survival, increase insulin content and improve insulin secretory 
responses through deposition of extracellular matrix proteins and growth factors 
(Johansson et al., 2006). In turn, -cells release various angiogenic growth factors, 
such as vascular endothelial growth factor A, which promote and maintain islet 
vascularisation (see review by Eberhard et al. (2010)). The islet capillaries are 
surrounded by a double basal membrane (Figure 1.2), which primarily consists of 
collagen IV and laminin extracellular matrix proteins (Virtanen et al., 2008; Eberhard 
et al., 2010). Islets are also encapsulated by a peri-insular cap (Figure 1.2). The peri-
 7
insular cap consists of glial (Schwann) cells, whose projections run along the islet 
perimeter and sometimes into the islet themselves, and a basment membrane 
(Donev, 1984; Wang & Rosenberg, 1999). The physiological function of the glial cells 
is currently unknown. The coverage of the peri-insular cap differs between species. 
Canine islets are fully enclosed by the peri-insular cap, human and rodent islets have 
intermediate coverage, while porcine islets have little or no coverage. The 
physiological relevance of this difference is unclear but may affect islet preparation 
yields (Section 2.4.1). In addition islets are also highly innervated, which alters the 
secretion of insulin, glucagon, sst-14 and PP in response to different stimuli and is 
described further in Section 1.2.4.  
 
-cell core
Capillary network
Peri-insular cap
Double basement 
membrane
Non--cell endocrine cells
 
 
Figure 1.2  A cross-sectional representation of a rodent islet (not to scale).  
 
1.2.1 Insulin 
Human insulin is produced from a single 110 amino acid precursor polypeptide 
preproinsulin, which consists of a signalling peptide (residues 1-24), the B-chain 
(residues 25-54), C chain (residues 55-89) and the A-chain (residues 90-110; NCBI 
(2010)). Preproinsulin is encoded by a single gene in humans (INS) and glucose is 
known to be involved in the regulation of preproinsulin mRNA transcription, stability 
and translation (see reviews by Melloul et al. (2002), Poitout et al. (2006) and Fred & 
Welsh (2009)). As described in the review by Fred & Welsh (2009), short-term 
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maintenance (>3 hours) of islet insulin levels in the presence of glucose is dependent 
on translation of preproinsulin mRNA, while longer-term maintenance of islet insulin 
levels is achieved through transcription of INS and stabilisation of preproinsulin 
mRNA. 
 
Once preproinsulin has been synthesised and inserted into the endoplasmic reticulum 
(ER), the signal peptide section of preproinsulin is proteolytically cleaved to yield 
proinsulin (Weiss, 2009; NCBI, 2010). Within the ER, proinsulin folds and forms two 
disulphide bridges between A- and B-chains (A7-B7 and A20-B19, as well as a third 
disulphide bridge within the A chain (A6-A11)). Once this has occurred, proinsulin is 
then translocated to the Golgi apparatus (Weiss, 2009). Once inside the Golgi 
apparatus, proinsulin is then sequestered into granules containing Zn2+, prohormone 
convertase 1 (PC1), PC2 and carboxypeptidase H (Goodge & Hutton, 2000). For 
proinsulin to be converted to insulin, the granules need to become acidified which, is 
achieved by the dual actions of Cl- (via the Cl- channel protein, chloride channel 
protein 3) and H+ (via V-type H+-ATPase, this integral membrane protein transports H+ 
ions across the vesicle membrane by converting ATP to ADP) influx (Barg et al., 
2001). It is hypothesised that Cl- influx allows acidification to occur by counteracting 
the increasing positive membrane potential caused by H+ influx. Once the granule has 
been acidified, PC1, PC2 and carboxypeptidase H then cleave the C-chain from the 
proinsulin polypeptide (Figure 1.3) forming insulin and C-peptide (Goodge & Hutton, 
2000). Upon removal of the C-chain, insulin crystallises with Zn2+ (6 insulin molecules: 
2 Zn2+), which is thought to stop fibrillation of insulin until exocytosis (fusion of the 
insulin granule to the -cell plasma membrane, see Section 1.2.2.2) occurs when the 
insulin crystals disassociate (Noormagi et al., 2010). 
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Figure 1.3  A schematic representation of the conversion of proinsulin and C-peptide 
by the proconvertases (PC), PC1 and PC2. The conversion of proinsulin to insulin 
requires endopeptidase cleavage of residues 32-33 (which reside between the B/C 
chain) by PC1 and residues 65-66 (which reside between the C/A chain) by PC2 
(Goodge & Hutton, 2000). At the end of each stage, carboxypeptidase H (CPH) 
removes the residues exposed by PC1 and PC2 activity (Goodge & Hutton, 2000). 
The preferred reaction is shown on the left hand side although conversion of insulin 
can occur by PC2 initiating the first step (Goodge & Hutton, 2000). For simplicity di-
sulphide bonds between A- and B-chains were not included. 
 
1.2.2 Glucose-stimulated insulin secretion (GSIS) 
Insulin is released from -cells in response to changes in plasma glucose levels but 
can also be induced by free fatty acids and certain amino acids (Henquin et al., 2006). 
How these metabolites stimulate insulin secretion is still not completely understood 
despite several decades of research. The following section will focus on glucose-
stimulated insulin release with amino acid and free fatty acid stimulated insulin 
secretion briefly described in Section 1.2.2.4. 
 
In man and the rat, constitutive (basal) insulin secretion approximately occurs at 
glucose concentrations up to  4mM glucose (Pick et al., 1998; Henquin et al., 2006). 
At glucose concentrations higher than 4mM glucose, insulin release is then regulated 
by glucose and is called glucose-stimulated insulin secretion (GSIS). Maximal rates of 
GSIS occur at glucose concentrations  16mM with ~50% of the maximal GSIS rates 
occurring at 8mM (Pick et al., 1998; Henquin et al., 2006). In mice, basal insulin 
secretion occurs at up to 8mM glucose and ~50% maximal and maximal GSIS occurs 
at 12 and 20mM glucose, respectively (Vieira et al., 2007). GSIS is biphasic, with the 
first phase of insulin secretion being a transient process lasting up to 10 minutes, 
while the second phase of insulin secretion persists until glucose levels return to non-
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stimulatory levels (Zawalich et al., 2000; Shigeto et al., 2006). The kinetics of insulin 
secretion are species-dependent, with humans and mice displaying a large primary 
phase and a smaller secondary phase, whereas in rats the opposite is true (Figure 
1.4). The regulation of the biphasic response is dependent on ion channel activities, 
metabolic activities and insulin granule processing but there is still an incomplete 
understanding of how these processes interact. Therefore, each component will be 
discussed separately.  
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Figure 1.4  Diagrammatic representation of species-specific differences in biphasic 
glucose-stimulated insulin secretion responses from perifused isolated islets. The 
solid line is representative of insulin secretion from human and mouse isolated islets; 
whereas the broken line represents biphasic insulin release from rat isolated islets. 
Low and high glucose concentrations refer to non-stimulatory and stimulatory levels of 
insulin secretion. The first phase of insulin secretion is transient (lasting 10-15 
minutes) whereas, the second phase persists until glucose returns to non-stimulatory 
levels. Figure is based on data from Henquin et al. (2006), Aizawa et al. (2001) and 
Hauge-Evans et al. (2009).  
 
1.2.2.1 ATP-sensitive K+ (KATP) channel-dependent insulin secretion 
The widely-accepted model of GSIS induction is the KATP channel-dependent 
signalling pathway (also known as the triggering pathway; Figure 1.5). During the 
resting state, KATP channel activity is primarily responsible for maintaining the -cell 
membrane potential at -70mV (Rorsman, 1997). Upon increases of plasma glucose 
above the threshold for GSIS, glucose enters the -cells via the glucose transporter 
(GLUT) 2 which has a Km of ~17mM glucose and a Vmax at glucose concentrations 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32mM glucose, thus allowing physiological concentrations of glucose to rapidly enter 
the -cell without uptake becoming saturated (Johnson et al., 1990). Upon entering 
the -cell, glucose is then phosphorylated by glucokinase which stops glucose from 
diffusing back out of the cell and is the first step in glycolysis (Ashcroft & Randle, 
1970; Giroix et al., 1984). With regard to GSIS, glucokinase is the most important 
glucose phosphorylating enzyme expressed in -cells as it has a low affinity of 16mM 
glucose and is not subject to glucose-6-phosphate feedback, thus allowing high rates 
of glycolysis to occur (Ashcroft & Randle, 1970; Giroix et al., 1984). Glucose is rapidly 
metabolised (by conversion to pyruvate in glycolysis and subsequent oxidation of 
pyruvate in the Krebs cycle) to produce ATP causing a shift in the ATP:ADP ratio 
(Longo et al., 1991). This leads to the closure of the KATP channels and the 
intracellular accumulation of K+ causes the -cell to depolarise (Rorsman, 1997). 
Once the membrane potential reaches -40mV, in rat and human -cells, this leads to 
the activation of L-type voltage-gated Ca2+ channels which allow the influx of 
extracellular Ca2+, and peak L-type Ca2+ channel activity occurs at 0mV (rat) and -
10mV (human) (Tamarina et al., 2003; Suga et al., 2004). This in turn leads to insulin 
granules fusing with the plasma membrane (exocytosis), allowing the insulin crystals 
to dissolve leading to the subsequent entry of insulin into the bloodstream. How the 
insulin granules are processed and reach the plasma membrane is discussed in more 
detail below in Section 1.2.2.2. Repolarisation of the -cell is known to be K+ channel 
activity dependent with voltage-gated, small conductance Ca2+-activated and/or large 
conductance Ca2+-activated K+ channels all being suggested (Roe et al., 1996; 
Tamarina et al., 2003; Suga et al., 2004). 
 
The rapid change in -cell membrane potential from a resting state to a depolarised 
state and subsequent repolarisation is referred to as an action potential. When islets 
are exposed to raised levels of glucose, the -cells will continually cycle between 
depolarised and repolarised states until glucose levels fall to non-stimulatory levels 
(see review by Rorsman (1997)). As mentioned above, depolarisation of the -cell is 
associated with increased concentrations of cytoplasmic Ca2+ ([Ca2+]c), whereas 
repolarisation of the -cell corresponds with reductions in [Ca2+]c when removal of 
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cytoplasmic Ca2+ exceeds Ca2+ influx (Hughes et al., 2006). The majority of the Ca2+ 
is used to replenish ER stores (by sarcoendoplasmic reticulum Ca2+ ATPase), while 
the remaining Ca2+ is exported (by Na+/Ca2+ exchanger and plasma membrane Ca2+ 
ATPase activity) out of the -cells (Hughes et al., 2006). To increase insulin secretion, 
the time between action potentials decreases which means that there is less time for 
[Ca2+]c to return to basal levels, thus allowing [Ca2+]c to rise, allowing for greater rates 
of insulin secretion to occur (Hughes et al., 2006). As with action potentials in 
membrane potential, [Ca2+]c eventually reaches a plateau corresponding with 
increasing amounts of glucose, whereas the amount of insulin secreted increases 
further, which has led to the notion of KATP channel-independent signalling (also 
known as the amplifying pathway); this is discussed further in Section 1.2.2.3. As 
GSIS is Ca2+-dependent, this results in insulin secretion being pulsatile; this is 
physiologically important as irregular patterns in pulsatile insulin release coincide with 
insulin resistance (Zarkovic et al., 1999). 
 
Glucose
Pyruvate
Acetyl CoA
K+
ATP : ADP
K+
[Ca2+]iTCA cycle
Pyruvate
dehydrogenase
Glycolysis
GLUT 2
-
-
+
+
Depolarisation Repolarisation
+
KATP 
channel
L-type Ca2+ 
channel
K+
channels
Insulin granule
Ex
o
cy
to
sis
Glucose Ca2+
Intracellular
Extracellular
 
 
Figure 1.5  KATP channel-dependent signalling. Briefly, glucose enters the -cells 
through the low affinity glucose transporter, GLUT2. It is subsequently metabolised 
leading to an increase in the ATP:ADP ratio this leads to the closure of the KATP 
channels. Closure of the KATP channels causes the -cell to depolarise and the 
subsequent influx of Ca2+, thus triggering insulin granule exocytosis by increasing the 
cytoplasmic calcium concentration ([Ca2+]c). Ca2+ either directly or through -cell 
depolarisation activate K+ channels which repolarise the -cells and inhibits further 
insulin secretion. Block arrows represent the direction the flow of substrates through 
integral membrane proteins (GLUT 2 transporter and the ion channels). Arrows with 
dotted lines represent complex processes. Arrows with + and – signs represent 
positive and negative influences respectively. 
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While the KATP channel-dependent signalling model accounts for a large proportion of 
insulin granule exocytosis in the first phase of insulin secretion, it has been found that 
this model does not account for the second phase of insulin secretion (Jing et al., 
2005; Shigeto et al., 2006). R- and P/Q-type voltage-gated Ca2+ channels in mouse 
and humans -cells (respectively) have been implicated to play a larger role than L-
type Ca2+ channels in the second phase of insulin secretion (Jing et al., 2005; Braun 
et al., 2008). In addition, voltage-gated Na+ channels (VGNC) have been also been 
suggested to play an important role in GSIS responses, as pharmacological blockade 
of these channels in MIN6 (-cell line) was observed to result in a loss of the first 
phase and much of the second phase of insulin release at 10mM glucose (Shigeto et 
al., 2006). In a recent study, the genetic knockout of a regulatory subunit of a VGNC 
(in C57Bl6/J mice) resulted in loss of glucose- and KCl-stimulated but not Ca2+ 
induced insulin secretion in isolated islets, and caused glucose intolerance in vivo  
(Ernst et al., 2009). 
 
1.2.2.2 Insulin granule processing 
The mobilisation of insulin granules to the plasma membrane, their subsequent 
processing and exocytosis is also a key factor in the phasic control of insulin 
secretion. The majority (~90%) of insulin granules reside in the cytoplasm, in what is 
referred to as the reserve pool, while the remaining granules (~10%) are located in 
close proximity to the plasma membrane and are usually called the docked pool 
(Straub & Sharp, 2002). The docked pool is thought to consist of granules in various 
states of readiness for exocytosis (Straub & Sharp, 2002). The process proposed by 
Straub & Sharp (2002) is that insulin granules dock below the plasma membrane, they 
then undergo a priming phase to form the readily-releasable pool which consists of 
mature insulin granules. Additionally, a subset of the readily-releasable pool 
associates with the exocytotic machinery to form the immediately-releasable pool 
(Straub & Sharp, 2002). The first phase of insulin in response to depolarising agents 
(e.g. KCl at concentrations  30mM) and/or KATP channel-dependent signalling is 
linked to the exocytosis of the immediately-releasable granules which make up ~0.5-
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2% of the total islet granule population (Straub & Sharp, 2002; Wang & Thurmond, 
2009). The study by Ohara-Imaizumi et al. (2007) suggests that not all insulin 
granules involved in the first phase originate from the docked pool, but there is an 
involvement of the reserve pool. Similarly, the maintenance of the second phase of 
insulin secretion is dependent on insulin granule mobilisation from the reserve pool 
(Straub & Sharp, 2002; Ohara-Imaizumi et al., 2007). The processing of granules is 
dependent on -cell cytoskeleton re-arrangement which is, in turn, dependent on 
various classes of small GTPases (guanosine triphosphate hydrolases, which are also 
involved in granule processing and eventual exocytosis), which have been reviewed 
by Wang & Thurmond (2009). In summary, movement of granules from the reserve 
pool involves transport of granules to the plasma membrane docking area along 
microtubules; where filamentous-actin (F-actin) remodelling is required for the 
replenishment of the docked pool and for granule exocytosis. Finally, the process of 
exocytosis is dependent on soluble [N-ethylmaleimide sensitive fusion factor] 
attachment receptor (SNARE) proteins, of which several vesicle SNARE (v-SNARE), 
t-SNARE (membrane-associated) and accessory factors (t-SNARE associated) are 
known to be expressed by islets (refer to the review by Wang & Thurmond (2009)). 
The composition of the t-SNARE complexes appears to be phase-dependent, with t-
SNARE complexes believed to be pre-assembled for the first phase of insulin 
secretion, whilst in the second phase of insulin secretion, t-SNARE complexes must 
first undergo calcium-dependent assembly before granule exocytosis can occur 
(Ohara-Imaizumi et al., 2007; Takahashi et al.). 
 
1.2.2.3 KATP channel-independent signalling 
As discussed in the review by Wang & Thurmond (2009), in addition to increasing the 
ATP:ADP ratio (which triggers KATP channel-dependent signalling), glucose 
metabolism leads to the generation of other metabolic signalling which amplifies the 
insulin secretory response. With respect to changes in [Ca2+]c (cytoplasmic 
concentration of Ca2+) in response to higher levels of GSIS, this is achieved by 
increased duration of action potentials (Section 1.2.2.1) rather than significant 
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alterations in the amplitude of action potentials (Wang & Thurmond, 2009). As 
demonstrated in the study by Heart et al. (2006), mean changes in [Ca2+]c correlate 
poorly with GSIS beyond 8mM in mouse islets, whereas increases in mitochondrial 
membrane potential strongly correlate with increases in glucose and insulin secretion. 
This indicates that mitochondrial activity plays an integral role in GSIS aside from ATP 
generation. In addition, various second messenger molecules are also produced 
during GSIS which are known to potentiate insulin secretion (Wolf et al., 1991; 
Tamarina et al., 2005; Kim et al., 2008a). 
 
Due to high rates of glycolysis in GSIS, -cells require high rates of NADH (reduced 
form of nicotinamide adenine dinucleotide) conversion to NAD+ (oxidised form) to 
maintain metabolic rates. As lactate dehydrogenase activity in -cells is low, NAD+ 
regeneration is dependent on glycerol-3-phosphate (G3P) and malate/aspartate 
shuttles which link the oxidation of cytoplasmic NADH to the production of ATP in the 
mitochondria
 
(Tan et al., 2002; McKenna et al., 2006; Jitrapakdee et al., 2010).  
Briefly, in the malate-aspartate cycle, NADH is oxidised to NAD+ by the conversion of 
cytoplasmic aspartate to malate. Malate is then transported into the mitochondria 
where it is converted back to aspartate (this is transported back into the cytoplasm) 
and is also used to reduce mitochondrial NAD+ to NADH. In the glycerol-3-phosphate 
NAD+ shuttling system, cytoplasmic NADH is used to reduce dihydroxyacetone 
phosphate to glycerol-3-phosphate, which regenerates NAD+. Oxidation of G3P (to 
dihydroxyacetone phosphate) is used to oxidise Coenzyme Q by mitochondrial 
glycerol-3-phosphate, using flavin adenine dinucleotide as an intermediate in the 
redox reaction. Both shuttling systems are described in greater detail in the review by 
McKenna et al. (2006).  
 
Another important aspect of the -cell is the expression of pyruvate carboxylase. 
Pyruvate carboxylase converts pyruvate to oxaloacetate which increases the input of 
carbon atoms into the tricarboxylic acid (TCA, also referred to as the Krebs cycle) 
cycle (Jensen et al., 2008; Nolan & Prentki, 2008; Jitrapakdee et al.). Pyruvate 
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carboxylase allows cataplerosis (removal of substrates from the TCA cycle) to occur, 
so that TCA substrates can be used for the potentiation of insulin secretion. 
Pharmacological inhibition of pyruvate carboxylase causes a large inhibition GSIS in 
rat islets, thus demonstrating its importance (Farfari et al., 2000). One particular use 
of TCA substrates is in the generation of NADPH (reduced form of nicotinamide 
adenine dinucleotide phosphate) as intracellular levels of NADPH increase in 
proportion to glucose (Sener et al., 1984; Rocheleau et al., 2004). Three shuttling 
systems have been proposed as being important (see reviews by Jensen et al. 
(2008), Jitrapakdee et al. (2010), and Nolan & Prentki  (2008)). In all three shuttling 
systems, intermediates from the Krebs cycle are imported into the cytoplasm by 
specific carrier models. In the pyruvate-malate shuttle, NADPH is produced by the 
conversion of malate to pyruvate by the cytosolic malic enzyme (see reviews by 
Jensen et al. (2008) and Jitrapakdee et al. (2010)). In the pyruvate-citrate shuttle, 
citrate is converted to oxaloacetate and acetyl Coenzyme A (acetyl CoA) by 
adenosine triphosphate citrate lyase. The oxaloacetate is converted to malate and 
then pyruvate producing NADPH, while the acetyl CoA is converted to malonyl-coA by 
acetyl CoA carboxylase, which is then used in the production of long chain acyl-
Coenzyme As (see reviews by Jensen et al. (2008) and Jitrapakdee et al. (2010)). In 
the pyruvate-isocitrate cycle, isocitrate is imported into the cytoplasm from the 
mitochondrial matrix by the 2-oxoglutarate carrier, it is then converted to -
ketoglutarate (by NADP-dependent isocitrate dehydrogenase) which generates 
NADPH (Ronnebaum et al., 2006; Odegaard et al., 2010). However, use of siRNA 
(small interfering ribonucleic acid) has only been successful in demonstrating the 
importance of the pyruvate-isocitrate cycle in GSIS in islets (Ronnebaum et al., 2006; 
Odegaard et al., 2010) but not the other two shuttling systems, which may be caused 
by compensatory alterations in other enzyme activities (Jensen et al., 2006; Pongratz 
et al., 2007). GTP, produced by the GTP-producing form of succinyl-CoA synthase 
and potentially the phosphoenolpyruvate cycle, may also be another molecule 
produced by mitochondria that leads to the potentiation of GSIS, as reduction of 
intracellular -cell GTP levels negatively affects GSIS (Kibbey et al., 2007; Stark et al., 
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2009). It remains unclear how GTP potentiates insulin secretion (Metz et al., 1993), 
however it is likely that GTP is at least partially utilised by the small GTPases involved 
in granule processing (see Section 1.2.2.2).  
 
-cells are also capable of generating arachidonic acid (AA), inositol-1,4,5-
trisphosphate (IP3), diacylglycerol (DAG) and cyclic adenosine monophosphate 
(cAMP) that contribute to the amplification of insulin release in response to increased 
levels of glucose (Wolf et al., 1991; Tamarina et al., 2005; Kim et al., 2008a). AA 
potentiates insulin release by increasing [Ca2+]c (through activation of arachidonic-acid 
regulated Ca2+ channels on the plasma membrane and ER ryanodine receptors) as 
well as down-regulating voltage-gated K+ channel activity (Woolcott et al., 2006; 
Jacobson et al., 2007; Yeung-Yam-Wah et al., 2010). In primary -cells, AA 
production has been linked to the activities of phopholipase (PL) A2 (three isoforms 
PLA2 that are thought to be involved in different stages of GSIS) and a Ca2+-
dependent diacylglycerol lipase (Konrad et al., 1994; Ma et al., 1998; Juhl et al., 2003; 
Bao et al., 2008). IP3 and DAG are generated by PLC (either by glucose, or following 
activation of GqPCRs) from phosphatidylinositol-4,5-bisphosphate (Wolf et al., 1988). 
IP3 then binds to IP3 receptors which leads to the increased release of Ca2+ from 
intracellular Ca2+ stores which increases [Ca2+]c (Blondel et al., 1993). The increase in 
[Ca2+]c and DAG levels in the -cells then activates several different isoforms of 
protein kinase C (PKC) that are thought to play different roles in -cell function 
(Ishikawa et al., 2005; Shimono et al., 2005). Functions of PKC signalling in -cells 
include insulin granule processing, insulin granule exocytosis, -cell proliferation and 
the regulation of several genes, including those encoding GLUT2 and both subunits of 
the KATP channel (Buteau et al., 2001; Hashimoto et al., 2005; Ishikawa et al., 2005; 
Warwar et al., 2006; Uchida et al., 2007). Finally, cAMP is generated from ATP by 
adenylyl cyclase (either during GSIS or folloing activation of G
sPCRs) and leads to 
the activation of PKA and Epac 2 (also known as cAMP-dependent guanine 
nucleotide exchange factor II), which are both known to potentiate insulin secretion 
(Kashima et al., 2001; Hatakeyama et al., 2006; Kim et al., 2008a). Islets also express 
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Epac1, an isoform of Epac2, but Epac1 has received less interest with regards to 
GSIS (Kang et al., 2006). PKA-mediated potentiation of insulin secretion is thought to 
involve multiple mechanisms such as activation of iPLA2 (a Ca2+-independent 
isoform of PLA2) and Ca2+ release from intracellular stores through the activation of 
IP3 receptor activity (Dyachok & Gylfe, 2004; Bao et al., 2008). PKA is also known to 
phosphorylate several ion channels leading to increased closure of KATP channels, 
increased voltage-gated L-type Ca2+ activity and decreased voltage gated K+ ion 
channel activity (Holz et al., 1993; Kanno et al., 1998; Kim et al., 2005). Epac2 
signalling leads to the potentiation of GSIS by increasing the number of insulin 
granules that translocate to the plasma membrane but Epac2 signalling does not 
appear to induce exocytosis (Eliasson et al., 2003; Shibasaki et al., 2007). Research 
in transfected non-- and -cell lines suggest that Epac1 activation, by cAMP, may 
also potentiate insulin secretion by increasing KATP channel ATP sensitivity and 
activation of PLC (Evellin et al., 2002; Suzuki et al., 2006; Kang et al., 2008). It should 
be noted that the positive effects of the incretin hormones (see Sections 1.2.5 & 1.3.3) 
on -cell function, mass and survival, are mediated though the activation of adenylyl 
cyclase and the subsequent activaties of PKA and Epac2 (Eliasson et al., 2003; Kwon 
et al., 2004; Kawasaki et al., 2005).  
 
1.2.2.4 Stimulation of insulin secretion by amino acids and free fatty acids 
In addition to glucose, insulin secretion can also be stimulated by certain amino acids 
(Sener & Malaisse, 2002; Zhou et al., 2010). Of the amino acids, only leucine has 
been demonstrated to stimulate insulin secretion from islets by itself in the absence of 
glucose (Sener & Malaisse, 2002; Li et al., 2003), while glutamine and alanine can 
only stimulate insulin secretion in the presence of other compounds, such as leucine 
(Sener & Malaisse, 2002; Zhou et al., 2010). With respect to glutamine, leucine and -
ketoisocaproate were found to allow glutamine to stimulate insulin secretion, which 
are thought to lead to the conversion of glutamate to -ketoglutarate by two separate 
mechanisms (Zhou et al., 2010). Potentiation of leucine-stimulated insulin secretion by 
glutamate is known to occur as leucine positively stimulates glutamate 
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dehydrogenase activity, which converts glutamate to -ketoglutarate (Li et al., 2003). 
With regard to free fatty acids (FFA), it is known that FFA such as palmitate and 
oleate potentiate glucose-stimulated insulin secretion but cannot stimulate insulin 
secretion alone (Latour et al., 2007). It has since been observed that islets express 
high levels of GPR40 (also known as free fatty acid receptor 1). Studies that have 
measured insulin secretion from islets isolated from WT (wild type) and GPR40 KO 
(knock out) mice suggest that oleate- and palmitate-mediated potentiation of GSIS 
occurs through this receptor alone (Latour et al., 2007; Tan et al., 2008). 
 
1.2.3 Autocrine and paracrine regulation of islet secretory 
activities 
It is known that -cells express insulin receptors as well as IRS-1 and IRS-2 
suggesting that insulin signalling occurs within -cells and may affect its own secretion 
(Burks & White, 2001). As discussed in the review by Leibiger et al. (2008), the 
earliest experiments with insulin suggest that it negatively regulates its own secretion. 
However, this view point has become more controversial as various studies have 
reported that insulin either has no effect or potentiates its own secretion (Leibiger et 
al., 2008). A study by Hee-Park et al. (2007) suggests that some of this confusion may 
been due to the effects of insulin being dependent on when insulin was applied to 
islets in relation to the addition to glucose. Hee-Park et al. (2007) reported that when 
islets were first exposed to insulin, glucose-stimulated increases in [Ca2+]i (which 
coincides with the release of insulin) were inhibited. Yet if insulin were added after 
glucose, insulin transiently increased [Ca2+]i suggesting a positive regulation of insulin 
release. Insulin signalling is known to be essential in -cells as loss of insulin receptor 
signalling results in reductions in -cell mass, decreased insulin content, attenuated 
GSIS and mitochondrial dysfunction (Otani et al., 2004; Cantley et al., 2007; Okada et 
al., 2007; Liu et al., 2009b).  
 
In addition to autocrine signalling, insulin release is also affected by paracrine 
signalling from - and 	-cells (Zambre et al., 1999; Sorensen et al., 2006). However, 
 20
there is controversy surrounding the role of paracrine signalling within rodent islets as 
the most widely supported model of blood flow within islets is the inner-to-outer model 
(Figure 1.6A), in which blood flows from the core of the islet to the periphery and 
finally into wider circulation (Nyman et al., 2008). As the core of rodent islets is 
populated by -cells, this suggests that molecules involved in paracrine signalling can 
only flow from -cells to non--cells. A counter argument in rodent islets have been 
that paracrine signalling in islets occurs at cell-to-cell interfaces and the signalling 
molecules difuse through the interstitial spaces (Hauge-Evans et al., 2009). The study 
by Nyman et al. (2008) using in vivo imaging techniques, suggests that there are three 
patterns of blood flow through murine islets (Figure 1.6). Nyman et al. (2008) suggests 
that in ~ 40% of islets, non- cell to -cell paracrine signalling can occur through by 
the release of signalling molecules into the islet capillaries. 
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Figure 1.6  Diagrammatic representations of three different islet blood flow patterns 
reported to occur in vivo in mouse pancreas by Nyman et al. (2008). In each of the 
three figures, islets are represented as a ring with the inside representing the -cell 
core and the shaded areas representing the periphery where -, 	- and PP-cells are 
found. Arrows represent the direction of blood flow. A) Inner-to-outer flow. Blood 
enters the core of the islet and flows outwards to the periphery. This blood flow 
pattern supports - to non -cell paracrine interactions and was found in 60% of islets. 
B) This blood flow pattern occurred in 35% of islets tested where blood enters through 
one side of the islet and flows through the islet. This blood flow pattern supports non 
- to - to non -cell paracrine interactions. C)s Outer-to-inner flow. Capallaries pass 
through the islet periphery and proceed to the core where blood empties into a 
venule/s. This was observed in 5% of islets and supports non - to -cell paracrine 
interactions. 
 
The release of glucagon is influenced by glucose, with glucagon secretion highest in 
the absence of glucose and decreases to a minimal (basal) secretory rate at the 
glucose concentrations which first induce GSIS. During hypoglycaemia (when plasma 
glucose levels  3.3mM), cognitive function is impaired as the brain is dependent on 
glucose and prolonged periods of hypoglycaemia can result in loss of consciousness, 
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neuronal cell death, and ultimately death (Warren & Frier, 2005; Suh et al., 2007). 
Therefore, glucagon is an important counter to insulin, as it prevents plasma glucose 
levels from falling too low by increasing plasma glucose levels through hepatic 
glucose production (Gelling et al., 2009).  
 
Paracrine interactions from - and 	-cells have been observed to decrease the rate of 
glucagon release in whole islets (Vieira et al., 2007). Despite this, glucose is believed 
to be the main contributing factor in the control of -cell secretory activity (MacDonald 
et al., 2007; Vieira et al., 2007). Glucagon is known to directly potentiate insulin 
release by activating -cell glucagon receptors, which are G
s-protein-coupled, 
leading to the activation of adenylyl cyclase (Gelling et al., 2009). Loss of glucagon 
receptor signalling in islets (through receptor knock-out) does not affect basal or 
intermediate rates of insulin release in relation to wild-type islets (Sorensen et al., 
2006). However, insulin secretion at 16.7mM and 22.2mM glucose from islets with 
defective glucagon receptor signalling, was attenuated in comparison to wild-type 
mice (Sorensen et al., 2006). Therefore, glucagon released from -cells acting via 
glucagon-receptor signalling in -cells is required for achieving higher rates of 
glucose-stimulated insulin secretion. 
 
The release of sst-14 from 	-cells in islets is positively correlated with the external 
glucose concentration (Vieira et al., 2007). Animal and clinical data suggest that the 
physiological role of somatostatin signalling in islets is to reduce the amount of 
glucagon and insulin released from - and -cells, respectively, rather than to alter the 
glucose responsiveness of either cell type (Hauge-Evans et al., 2009; Mazziotti et al., 
2009). The four main islet cell types in rodent and human islets are known to express 
all five somatostatin receptors (SSTR-1, -2, -3 -4 and -5, which are also referred to as 
sst1-5) but each islet cell type may not express each somatostatin receptor subtype to 
the same level (Ludvigsen et al., 2004; Ludvigsen et al., 2005; Taniyama et al., 2005). 
In addition, SSTR expression patterns may also be sensitive to pathological state as it 
has been observed in non-obese diabetic (NOD) mice that SSTR receptor expression 
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patterns for -, -, 	- and PP-cell types differed between non-diabetic and diabetic 
mice (Ludvigsen et al., 2005). While each SSTR can be expressed by each islet cell 
type, the consensus from numerous studies suggests that SSTR2 is responsible for 
the inhibition of glucagon release (Table 1.2). Both SSTR2 and SSTR5 have been 
suggested to be the primary sst-14 receptor responsible for the inhibition of insulin 
secretion, but the majority of these studies indicate that SSTR5 is key receptor 
responsible for sst-14 mediated inhibition of GSIS. 
 
1.2.4 Neuronal regulation of islet secretory activities 
Islets are known to be highly innervated by sympathetic, parasympathetic, and 
sensory neurons (Ahren, 2000). Islets are also innervated with cholecystokinin (CCK) 
releasing neurons, and when activated potentiate insulin secretion (Ahren, 2000). The 
effects of sympathetic and parasympathetic signalling on islet secretory activities and 
their physiological effects have been extensively reviewed by Ahren (2000) and Ahren 
et al. (2006). In summary, parasympathetic neurotransmission increases rates of 
insulin, glucagon, sst-14 and PP secretion, while sympathetic signalling upregulates 
glucagon and PP signalling but downregulates insulin and sst-14 secretion. 
Parasympathetic signalling has been found to potentiate insulin secretion at the onset 
of feeding but before the initial rise in blood glucose occurs (cephalic phase). 
Parasympathetic signalling also occurs during hypoglycaemia and stimulates both 
glucagon and PP secretion. The parasympathetic neurotransmitter receptors 
expressed by islets include the GqPCR muscarinic receptor type 3 (m3) and GsPCR 
pituitary adenylyl cyclase activating polypeptide 1 receptor type 1 and vasoactive 
intestinal polypeptide receptor 2 (Ahren, 2000). Sympathetic signalling occurs during 
exercise and increases plasma glucose levels by stimulating hepatic glucose output. It 
was observed, through loss of sympathetic nerve terminals, that sympathetic 
signalling also affects glucose-stimulated insulin secretion, insulin gene expression 
and -cell mass. The sympathetic neurotransmitter receptors expressed by islets are 
the 2 (GiPCR, inhibits insulin secretion) and 2 (GsPCR, potentiates glucagon 
secretion) adrenoceptors and the G
iPCR (inhibits insulin secretion) neuropeptide Y  
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Table 1.2  The role of somatostatin receptor (SSTR) signalling on insulin and glucagon secretion 
 
Study Model used Approach used Effects of SSTR on hormone secretion Glucagon Insulin 
Strowski et al. (2003) Islets from WT and SSTR5-KO mixed breed mice 
sst-28 and SSTR-specific 
agonists at 20mM glucose   
SSTR5  
SSTR2  (minor) 
Wang et al. (2004) 
Islets from WT and double 
SSTR1- and SSTR5-KO 
mice 
sst-14 and sst-28 at various 
glucose concentrations   
SSTR1 & 
SSTR5  
Strowski et al. (2000) Islets from WT and SSTR2-KO C57BL/129 mice 
sst-14 and sst-28 at various 
glucose concentrations 
SSTR2  SSTR5  
SSTR5 - SSTR2 - 
Cejvan et al. (2003) Wistar rat isolated islets 
sst-14 and a SSTR2-specific 
antagonist at 3.3/5.5mM 
glucose + 20mM Arg 
SSTR2  SSTR2 - 
Rossowski & Coy  (1994) In vivo CD rats sst-14 and SSTR receptor-
specific antagonists SSTR2  SSTR5  
Yao et al. (2005) Mixed breed hamster islets 
and HIT-T15 -cells 
SSTR5-selective agonists 
and sst-14 with a SSTR2-
specific antagonist at 20mM 
glucose 
  
SSTR1, 3,4 
and 5 - 
SSTR2  
Atiya et al. (1997) Isolated perfused human pancreas 
anti-sst-14 antibody with 
SSTR receptor-specific 
agonists at 16.7mM glucose 
  
SSTR2  
SSTR5 - 
Zambre et al. (1999) Human islets 
24-hour incubation at 6.1mM 
glucose with SSTR-specific 
agonists 
  
SSTR2 - 
SSTR5  
Singh et al. (2007) Human islets 
sst-14 or SSTR-specific 
agonists 
Insulin secretion at 20mM 
glucose, glucagon secretion 
stimulated by 20mM Arg 
SSTR2  SSTR2  
SSTR1  SSTR5   
SSTR5  (minor) SSTR1   
 
Minor refers to relative level of inhibition caused by activation of the specified receptors on insulin secretion. - no effect. 
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receptor Y1 (Moltz & McDonald, 1985; Lacey et al., 1991; Ahren, 2000; Ahren et al., 
2006). 
 
With regard to sensory neurons, there are two types associated with islets, substance 
P and calcitonin gene-related peptide (CGRP) containing neurons (Ahren, 2000). The 
effects of CGRP and substance P are controversial, as factors such as species 
differences, concentrations used and model used (isolated islets vs. perifused 
pancreas) appear to influence the effects of these neurotransmitters on islet secretory 
activities (Chiba et al., 1985; Hermansen & Ahren, 1990; Kogire et al., 1991; 
Rasmussen et al., 1998; Ahren, 2000). However, evidence over recent years is 
mounting that sensory neuron activities in islets may contribute to -cell dysfunction. 
TRPV1-associated neurons have linked sensory neuron dysfunction to autoimmune-
mediated destruction of  cells in a spontaneously type 1 diabetic mouse model 
(Razavi et al., 2006). In addition, ablation of sensory neurons in the Zucker Diabetic 
Fatty rat model of type 2 diabetes  was also found to improve glucose tolerance by 
increasing insulin secretion both in vivo and in vitro (Gram et al., 2007).  
   
1.2.5 Gastrointestinal tract-mediated regulation of islet secretory 
activities 
The study by McIntyre et al. (1965) was one of the first studies to identify that orally 
ingested glucose produced greater insulin secretory responses than that produced by 
an identical amount of glucose directly infused into the blood stream. This 
phenomenon is known as the incretin effect and, as described in the review by Peters 
(2010), this was later found to be due to the actions of glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).  
 
Glucose-dependent insulinotropic polypeptide (GIP) is primarily secreted by K-cells, 
endocrine cells present in the duodenum and distal jejunum (Damholt et al., 1999). A 
truncated form of GIP, GIP(1-30), is also actively secreted by -cells in mouse, python 
and human islets (Fujita et al., 2010). Both forms of GIP, at physiological levels, 
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potentiate GSIS (but not basal rates of insulin secretion), and glucagon secretion too 
(De Marinis et al., 2010; Fujita et al., 2010). In addition to affecting islet secretory 
function, use of exogenous GIP has been found to increase -cell mass and reduce 
rates of -cell apoptosis under physiological conditions, but its protective effects are 
diminished in diabetic states (Winzell & Ahren, 2007; Maida et al., 2009).  
 
GLP-1 is produced by L-cells and, like GIP, potentiates GSIS (but not basal insulin 
secretion rates) but inhibits the release of glucagon from -cells (De Marinis et al., 
2010; Fujita et al., 2010). As such, manipulation of GLP-1 signalling has been 
exploited in the treatment of type 2 diabetes (discussed below). With regard to 
information generated from animal models of diabetes, GLP-1 receptor signalling in 
islets has been found to not only improve glycaemic control as it also promotes -cell 
proliferation as well as causing a reduction in the rates of -cell apoptosis (Maida et 
al., 2009; Lupi et al., 2010).  
 
Ghrelin is an appetite-stimulating peptide that is primarily produced by A-like cells (an 
endocrine cell) in the stomach (Yada et al., 2008). It exists in two forms, an acylated 
form (referred to as ghrelin) which can activate the ghrelin receptor, and a non-
acylated (also referred to a des-acyl-/desacyl-ghrelin) form which cannot act via the 
ghrelin receptor (Granata et al., 2007). The in vivo and in vitro effects of ghrelin on 
glucose homeostasis and -cell function have been reviewed by Yada et al. (2008), 
which has primarily focused on ghrelin receptor antagonism and genetic knock-out 
studies. Ghrelin receptor signalling in islets promotes a hyperglycaemic state by 
potentiating glucagon secretion and inhibiting insulin release. Therefore, use of ghrelin 
receptor antagonists have received interest with regard to improving glucose 
tolerance (Salehi et al., 2004; Yada et al., 2008). It is also of note that there appears 
to be at least one other ghrelin receptor expressed in -cell lines and islets, which can 
bind both forms of ghrelin (Camina, 2006; Granata et al., 2007). Granata et al. (2007) 
suggest that this receptor induces -cell proliferation and reduces apoptotic signalling. 
As discussed in Section 1.2, the ghrelin is also expressed in islets by 
-cells (appear 
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to be important in feotal islet development) and may also be secreted by -cells. With 
regard to -cells, ghrelin may be used in autocrine and paracrine signalling as its 
known to potentiate glucagon secretion and inhibit insulin secretion (Salehi et al., 
2004; Dezaki et al., 2006).    
 
1.3 Diabetes mellitus 
 
As described above (Section 1.1), diabetes mellitus is a chronic endocrine disorder, 
with type 1 and type 2 diabetes being the two most prevalent forms of the disease and 
is clinically defined by several criteria (Table 1.3). Type 1 diabetes is known to have a 
prevalent genetic element with ~50 chromosomal locations linked to the development 
of type 1 diabetes (see the review by Santamaria (2010)). As discussed in the reviews 
by Todd (2010) and Santamaria (2010), highest risk of type 1 diabetes is conferred by 
specific alleles of class I and II MHC (major histocompatibility complex) proteins that 
are expressed by antigen-presenting cells. During the onset of type 1 diabetes, these 
cells present -cell specific autoantigens (such as preproinsulin) to naïve T-cells, 
which generates autoantigen recognising CD8+ cytotoxic T-cells which then destroy 
the -cells. However, the onset of type 1 diabetes requires an environmental trigger; 
Schulte et al. (2010) suggest that the infection of -cells by enteroviruses is an 
environmental trigger, which leads to the phagocytosis of -cells by dendritic cells (an 
antigen presenting cell). Unlike type 1 diabetes, environmental factors instead of a 
genetic disposition are thought to be the major factors in the onset of type 2 diabetes 
and have been discussed in more detail below in Section 1.3.1. 
 
Hyperglycaemia is associated with a wide array of secondary complications ranging 
from short-term to long-term health issues. Short term symptoms of hyperglycaemia 
include abnormal thirst, abnormal hunger, increased urination frequency, blurred 
vision and/or increased susceptibility to infection (American Diabetes Association, 
2010). If the hyperglycaemia is left untreated, this can lead to diabetic ketoacidosis 
(type 1 diabetes) or hyperosmolar hyperglycaemic state (type 2 diabetes; Umpierrez 
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et al., 1996; American Diabetes Association, 2010). Long-term complications of 
chronic hyperglycaemia are blindness (retinopathy), nephropathy (potentially leading 
to end stage kidney failure), peripheral neuropathy and amputations due to advanced 
infection. Additionally, patients with diabetes are at a significantly increased risk of 
cardiovascular disease (Schramm et al., 2008). Therefore, effective management of 
plasma glucose levels is essential in any form of diabetes. Due to the loss of -cells, 
glycaemic management in type 1 diabetes is currently dependent on insulin 
replacement therapy. As type 2 diabetes is caused by a progressive loss of -cell 
function and/or insulin resistance (Section 1.1) there are different regimes available 
for its treatment discussed in more detail in Section 1.3.3. 
 
Table 1.3  Criteria for the diagnosis of diabetes mellitus. 
 
Criteria Pre-diabetes / at risk Gestational Diabetes Diabetes IFG IGT 
FBG (mM) 6.1 - 6.9 < 7  5.3  7.0 
75g OGTT 2 
hour plasma 
glucose (mM) 
< 7.8 7.8 < 11.0  8.6  11.1 
Random glucose 
(mM) - - -  11.1 
HbA1C 
(millimoles/mole) - - -  65 
 
IFG- impaired fasting glucose, IGT- impaired glucose tolerance, FBG- fasting blood 
glucose (taken after a  8 hour fasting period), OGTT- oral glucose tolerance test, 
random glucose- plasma glucose levels taken from a non-fasted individual, HbA1C- 
glycosylated haemoglobin- units expressed as mmol/mol (HbA1c/total Hb). Information 
has been primarily taken from the World Health Organisation (2006) with gestational 
diabetes and HbA1c data taken from American Diabetes Association (2010). 
 
1.3.1 Type 2 diabetes risk factors 
The progression of type 2 diabetes takes place over many years, so considerable 
effort has been made to identify factors which influence the occurrence of the disease. 
People with either impaired glucose tolerance (IGT, Table 1.3), impaired fasting 
glucose (IFG, Table 1.3), or IGT together with IFG are known to be at higher risk of 
developing type 2 diabetes and so have been classed as “pre-diabetic states” (Unwin 
et al., 2002; Li et al., 2008; Hippisley-Cox et al., 2009; Tabak et al., 2009; Wang et al., 
2010). Similarly, women who become diabetic during pregnancy (gestational diabetes; 
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Table 1.3) are another group at higher risk of developing type 2 diabetes as they also 
display defects in -cell function and insulin signalling (Kousta et al., 2003). 
 
The occurrence of type 2 diabetes has been found to coincide with numerous other 
risk factors. Age has been described as a risk factor, as the incidence of type 2 
diabetes is significantly higher in people who are aged 40 years or over but can also 
occur in people under the age of 10 (Ramachandran et al., 2004; Gonzalez et al., 
2009; Amed et al., 2010). The incidence of type 2 diabetes has been found to 
significantly increase at BMIs above 23, with highest risks observed at BMI scores  
35, but it should be noted that BMI is a contributing, not a causative, factor 
(Ramachandran et al., 2004; Nijpels et al., 2008; Lehtovirta et al., 2010; Lorenzo et 
al., 2010). The incidence of type 2 diabetes is also increased in certain ethnic 
populations (Hippisley-Cox et al., 2009), is associated with low birth weight (as 
discussed in the review by Pinney & Simmons (2010)) and increased in people with 
first order relatives who have type 2 diabetes (Lorenzo et al., 2010). The latter risk 
factor indicates that there are specific alleles associated with the incidence of type 2 
diabetes, and in 2009 single nucleotide polymorphisms in 19 genes were implicated 
as conferring increased risk (see reviews by Elbein (2009) and McCarthy & Zeggini 
(2009)). 
 
1.3.2 Onset of type 2 diabetes 
The progression from being at risk of developing type 2 diabetes to developing overt 
type 2 diabetes in not clearly understood but is linked to further decreases in -cell 
function and/or insulin resistance.  Leahy (2009) suggests that the progression from 
pre-diabetic to developing type 2 diabetes is linked to how resilient an individual’s -
cells are, as 17 out of 19 genes (as mentioned above) implicated in susceptibility for 
type 2 diabetes are either involved in -cell survival, function or development. 
Histological studies of pancreata obtained from non-diabetic and type 2 diabetic 
people all suggest that -cell mass is decreased without similar decreases in -cell 
and 	-cell numbers (Butler et al., 2003; Yoon et al., 2003; Iki & Pour, 2007). The loss 
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of -cell mass and function has been ascribed to glucotoxicity, glucolipotoxicity and/or 
-cell fatigue and are briefly described below (for more detailed mechanisms see 
reviews by Leahy (2009), Poitout & Robertson (2002) and Robertson (2009)). 
Glucotoxicity refers to chronic exposure of -cells to supraphysiological levels of 
glucose, associated with a non-reversible reduced transcription of insulin mRNA, 
which leads to reductions in islet insulin content and GSIS (see reviews by Poitout & 
Robertson (2002) and Robertson (2009)). It is also recognised that glucotoxicity 
increases the incidence of apoptosis through oxidative stress in -cells (Robertson, 
2009; Zhang et al., 2010). -cell fatigue is based on a similar concept as glucotoxicity. 
This hypothesis suggests that the effects of glucotoxicity are reversible, by resting the 
-cells (i.e. no longer actively secreting insulin), before a point where their insulin 
reserves fall  too low (as discussed in the reviews by Leahy (2009) and Robertson 
(2009)). The concept of glucolipotoxicity is based on the observation that chronic 
exposure of -cell lines and islets to high concentrations of saturated fatty acids (e.g. 
palmitate) does not affect -cells survival unless cultured under elevated glucose 
concentrations  11mM (El-Assaad et al., 2003). Additionally, under glucolipotoxic, 
conditions palmitate has also been found to reduce maximal levels of GSIS (Sun et 
al., 2008; Popescu et al., 2010).  
 
1.3.3 Current treatments for type 2 diabetes 
On diagnosis of type 2 diabetes, a patient is given advice on permanent changes in 
diet which are aimed not only to reduce the peak amount of glucose absorbed into the 
blood stream but as a means to regulate the intake of specific types of lipids too (Holt 
& Kumar, 2010). In addition to changes in diet, 30 minutes of moderate aerobic 
exercise 5 days a week is recommended as excercise improves peripheral insulin 
sensitivity. Collectively, these alterations not only aid weight loss in overweight 
patients but also help regulate glycaemia and improve several risk factors associated 
with cardiovascular disease (Sibal & Home, 2009; Holt & Kumar, 2010). If HbA1c 
(Glycated haemoglobin) levels are > 70 millimoles/mole or patients are displaying 
symptoms (e.g. retinopathy), then oral drugs are prescribed, in addition to changes in 
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lifestyle modifications to manage hyperglycaemia. According to the study by Gonzalez 
et al. (2009), the most commonly prescribed oral drugs by people with type 2 diabetes 
to regulate their hyperglycaemia were metformin, sulphonylureas and 
thiazolidinediones (also known as glitazones). Since 2005, GLP-1 receptor agonists 
and dipeptidyl peptidase 4 (DPP4) inhibitors have also been introduced for the 
treatment of type 2 diabetes (Janosz et al., 2009). It should be noted that 
subcutaneous injections of insulin are also used in the treatment of type 2 diabetes, 
either alone or in combination with oral drugs, as a final resort should other treatments 
fail to effectively regulate glycaemia (Gonzalez et al., 2009; Sibal & Home, 2009).  
 
Metformin is typically the first oral drug to be used for the management of 
hyperglycaemia and is known to reduce hepatic gluconeogenesis (and lipogenesis) 
via the activation of adenosine monophosphate kinase signalling (Shaw et al., 2005). 
Additionally, metformin may also increase skeletal muscle and other peripheral tissue 
insulin sensitivity, reduce plasma lipid levels, inhibit DDP4 activity and increase GLP-1 
production (see reviews by Setter et al. (2003) Tahrani et al. (2010)). Another benefit 
of metformin is a low occurrence of hypoglycaemia but a concern with metformin is 
that it can also induce, albeit rarely, lactic acidosis (as discussed in the review by 
Setter et al. (2003)). Sulphonylureas bind to the SUR1 subunit on -cell KATP channels 
which causes channel closure leading to insulin release (see above), and are used to 
enhance insulin secretion from -cells (see review by Gribble & Reimann (2003)). 
Sulphonylureas have significant drawbacks, including weight gain and increased 
occurrence of hypoglycaemia (Sibal & Home, 2009). Additionally, the study by 
Tzoulaki et al. (2009) suggests that sulphonylurea monotherapy is associated with 
significantly higher risks of myocardial infarction, congestive heart failure and general 
mortality rates in comparison to metformin monotherapy. 
 
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor gamma 
(PPAR) agonists and are primarily associated with increasing peripheral tissue 
insulin sensitivity (Kahn et al., 2006; Scheen et al., 2009). In the ADOPT trial (Kahn et 
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al., 2006), rosiglitazone (a TZD) treatment was not only attributed to the improvement 
in insulin sensitivity but increased preservation of -cell function with respect to the 
metformin and sulphonylurea treatment groups. These effects have been confirmed in 
animal models of diabetes and in human islets in vitro, where TZD treatment was 
found to preserve islet mass, islet morphology, islet insulin content, insulin secretory 
activity and it reduced islet triglyceride content (Shimabukuro et al., 1998; Ishida et al., 
2004; Kawasaki et al., 2005; Vandewalle et al., 2008).  In vitro studies suggest that 
the protective effects of rosiglitazone (a TZD) in islets are primarily due to PPAR 
receptor-dependent signalling but rosiglitazone is also able to reduce some aspects of 
palmitate-induced oxidative stress by antagonising free fatty acid receptor 1 signalling 
(Meidute Abaraviciene et al., 2008; Vandewalle et al., 2008). There are several health 
concerns associated with TZDs, which include weight gain (observed in both ADOPT 
and PROactive trials), as well as increased risk of fractures, oedema and 
cardiovascular events (Scheen et al., 2009; Tzoulaki et al., 2009; Tahrani et al., 
2010). 
 
GLP-1 was identified as a potential drug for type 2 diabetes as it is an incretin 
hormone which potentiates insulin secretion and also inhibits glucagon secretion 
(Section 1.2.5). However, in vivo GLP-1 is rapidly degraded by DPP4, which led to the 
development of GLP-1 receptor agonists and DPP4 inhibitors, with both approaches 
proving successful in the treatment of type 2 diabetes (see reviews by Mentlein (1999) 
and Peters (2010)). With regard to the efficacy of GLP-1 receptor agonists in 
comparison to DPP4 inhibitors, the reviews by Janosz et al. (2009) and Tahrani et al. 
(2010) suggest that GLP-1 agonists offer greater glycaemic control and also are 
associated with weight loss too. Both classes of drugs are associated with improved 
-cell function and survival as well as improvements in cardiovascular risk factors 
through reductions in plasma triglycerides and blood pressure (Janosz et al., 2009; 
Tahrani et al., 2010). However, there are concerns that both forms of treatment may 
be associated with pancreatitis (see review by Butler et al. (2010)). The 2008 National 
Collaborating Centre for Chronic Conditions (NCC-CC, 2008) guidelines are the latest 
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(full) guidelines for the treatment of type 2 diabetes used by the UK’s National Health 
Service but the section dealing with the clinical use of oral anti-hyperglycaemic drugs 
was updated in 2009 (NICE, 2009). 
 
As discussed above, type 2 diabetes is a progressive disease with many secondary 
complications and it has a considerable economic cost if quality of life is to be 
assured. Therefore, studies are now focusing on how to prevent the onset type 2 
diabetes in people who at highest risk of developing the disease. The meta-analysis 
by Gillies et al. (2007) suggests that lifestyle interventions (diet, exercise or both) 
reduced the incidence of type 2 diabetes by ~50%. Overall, lifestyle interventions 
were found to be more effective than oral diabetics such as acarbose (-glucosidase 
inhibitor that reduces intestinal absorption of carbohydrates) and metformin (Gillies et 
al., 2007; Tahrani et al., 2010). 
 
1.4 The endogenous cannabinoid system 
 
Cannabis has been used for medical and recreational purposes for thousands of 
years (Pacher et al., 2006), but it was not until the 1960’s that the main psychoactive 
component of cannabis, 9-tetrahydrocannabinol (THC), was discovered (Gaoni & 
Mechoulam, 1964). Despite this it wasn’t until the early 1990’s that the first 
cannabinoid (CB) receptor, CB1, and an endogenous ligand, N-
arachidonoylethanolamide (otherwise known as anandamide or AEA) were 
discovered (Matsuda et al., 1990; Devane et al., 1992). Since then, another 
cannabinoid receptor (CB2) and the endocannabinoid, sn-2 monoacylglycerol 2-
arachidonoylglycerol (2-AG), have been identified (Munro et al., 1993; Mechoulam et 
al., 1995; Sugiura et al., 1995). Early investigations into the effects of anandamide 
reported that AEA had anti-nociceptive, hyperphagic (over-eating) and vasorelaxatory 
effects, suggesting that the endocannabinoid system was involved in several 
physiological systems (Randall et al., 1996; Stein et al., 1996). The endocannabinoid 
system is now known to be expressed in a wide range of cells and tissues throughout 
 33
the body. The endocannabinoid system is involved in the physiological regulation of a 
number of systems and is discussed further in Section 1.4.3, with regard to receptor-
specific signalling.  
 
Several other compounds have been suggested to be putative endocannabinoids. 
They include noladin ether (2-arachidonyl glyceryl ether), virodhamine (O-
arachidonoylethanolamine) and N-arachidonoyl dopamine (Hanus et al., 2001; Huang 
et al., 2002; Porter et al., 2002). While these compounds have been found to be 
cannabinoid agonists, it remains unclear whether they are endogenous ligands as 
biosynthetic pathways have not been established. Additionally, it has been found that 
AEA is part of a wider class of lipid signalling molecules called N-acylethanolamines, 
which include N-oleoylethanolamide (OEA) and N-palmitoylethanolamide (PEA). 
However, OEA and PEA are devoid of CB receptor activity and are subsequently 
called endocannabinoid-like molecules (Matias et al., 2007).  
 
1.4.1 Endocannabinoid synthesis 
Described below are the biosynthetic pathways for three endocannabinoids. A key 
aspect of their production is that they are made de novo as they can readily diffuse 
across membrane and so cannot be stored intracellularly. 
 
1.4.1.1 N-acylethanolamine (NAE) synthesis 
The de novo production of N-acylethanolamines involves two key stages, the 
formation of N-acyl-phosphatidylethanolamine (NAPE) and then the removal of the N-
acylethanolamine from the NAPE (Figure 1.7). The formation of NAPE first involves 
the transfer of a sn-1 fatty acid moiety from a phosphatidylcholine (PC) 
glycerophospholipid to the ethanolamine head group of a phosphatidylethanolamine 
(PE) glycerophospholipid (Cadas et al., 1996; Cadas et al., 1997); Ca2+-dependent or 
-independent N-acyltransferase (CaNAT and iNAT, respectively) catalyse this step 
(Cadas et al., 1996; Cadas et al., 1997; Jin et al., 2007). The second stage is the 
liberation of the N-acylethanolamine from NAPE; for AEA this can be achieved by 
multiple pathways. One pathway is the direct hydrolysis of AEA from NAPE by a 
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Figure 1.7  The different biosynthetic pathways by which anandamide (N-
arachidonoylethanolamine) can be produced. PE, phosphatidylethanolamine; PC, 
phosphatidylcholine; PA, phosphatidic acid; LPA, lysophosphatidic acid; DAG, 
diacylglycerol; NAPE, N-acyl-phosphatidylethanolamine;  Ca-NAT, Ca2+-dependent N-
acyltransferase; iNAT, Ca2+-independent N-acyltransferase; NAPE-PLD, NAPE-
specific phospholipase D; PLC, phospholipase C; PTPN22, protein tyrosine 
phosphatase, non-receptor type 22; sPLA2, secretory  phospholipase A2; GP-NAE, 
glycerol-3-phosphate N-acylethanolamine; NAE, N-acylethanolamine; Abh4, /-
hydrolase 4; GDE1, glycerophosphodiesterase 1; SHIP1, Phosphatidylinositol-3,4,5-
trisphosphate 5-phosphatase 1; FA, fatty acid. The figure has been taken from Ueda 
(2010).  
 
NAPE-specific phospholipase D (NAPE-PLD), whose activity is known to be Ca2+-
dependent (Cadas et al., 1996). In a second pathway, the fatty acid at the sn-1 
position is removed by type IB secretory phospholipase A2 to produce lyso-NAPE, 
from which AEA is liberated by lyso-PLD (Sun et al., 2004). A third pathway involves 
phospholipase C hydrolysing NAPE producing a phosphorylated form of AEA, which 
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is then dephosphorylated by PTPN22 (protein tyrosine phosphatase, non-receptor 
type 22) yielding AEA (Liu et al., 2006). There are additional pathways and alternate 
enzymes by which AEA can be produced from NAPE which are described in the 
review by Ueda et al. (2010). 
 
The expression of these pathways differs between tissues. For instance, the activities 
of CaNAT and NAPE-PLD are highest in the brain (Cadas et al., 1997; Leung et al., 
2006). This may also reflect tissue-specific requirements in endocannabinoid 
signalling, as mouse NAPE-PLD knock-out studies suggest that N-acylethanolamine 
formation in the brain is primarily dependent on NAPE-PLD, whereas in testis N-
acylethanolamines are produced by NAPE-PLD independent pathways (Leung et al., 
2006). The utilisation of different NAPE-PLD hydrolytic pathways may allow cells to 
produce specific NAEs. This was observed in the study by Leung et al. (2006), as 
saturated and monounsaturated NAE levels in brains from NAPE-PLD KO mice were 
significantly reduced but the levels of polyunsaturated NAEs, such as AEA, were least 
affected. However, this could also be explained by a compensatory mechanism in 
which another AEA synthetic pathway was upregulated in specific regions of the brain.  
 
1.4.1.2 2-Arachidonyl glycerol (2-AG) synthesis 
As discussed in the review by Sugiura et al. (2002), the existence of 2-AG, a 
monoacylglycerol (MAG), was long known before its identification as an 
endocannabinoid, with 2-AG as an intermediate in the production of triacylglycerols, 
glycerophospholipids, and arachidonic acid. With regard to the production of 2-AG, for 
the purposes of endocannabinoid signalling, it is viewed that the biosynthetic 
pathways are Ca2+-dependent (Bisogno et al., 1997; Stella et al., 1997). This led to 
the identification of two Ca2+-dependent signalling pathways which produce the 
diacylglycerol (DAG), sn-1-acyl-2-arachinodyl-glycerol (Bisogno et al., 1997; Stella et 
al., 1997). The pathway identified by Stella et al. (1997) was the production of DAG 
from phosphatidylinositol (PI) by a PI-specific phospholipase C. The second pathway 
indentified by Bisogno et al. (1997) was the production of DAG from phosphatidic acid 
(PA) by PA phosphatase. As with NAE biosynthesis, there may also be cell-specific 
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expression of the two DAG producing pathways, as Stella et al. (1997) used 
hippocampal neurons, whereas Bisogno et al. (1997) used the N18TG2 neuroblastoma 
cells (neuronal cell line). Both studies recognised that the conversion of DAGs to 
MAGs was catalysed by a Ca2+-dependent DAG lipase (DAGL), of which two isoforms 
were identified, DAGL and DAGL (Bisogno et al., 2003). Both isoforms were found 
to be co-expressed together in tissues but the two isoforms show differential activities 
for DAGs. DAGL showing equal preference for linoleic-, oleic-, arachidonic-, and 
stearic-acid based DAGs, whereas DAGL had the highest activity for linoleic-acid  
oleic-acid > arachidonic-acid > stearic-acid based DAGs (Bisogno et al., 2003).  
 
1.4.1.3 N-arachidonoyl dopamine (NADA) synthesis 
N-arachidonoyl dopamine is the only putative endocannabinoid (of those listed above) 
to have its biosynthetic pathway at least partially characterised. NADA appears to be 
restricted to dopaminergic nerve terminals in rat brain, and two possible biosynthetic 
pathways have been described (Hu et al., 2009). The first pathway proposed that N-
arachidonyl (NA) tyrosine (produced from arachidonic acid [AA] and tyrosine) was 
converted to NA-dopamine and then to NADA, but this pathway was discredited as 
only one intermediate (N-arachidonyl tyrosine) was found to be present in rat brain. 
The second pathway proposed by Hu et al. (2009) was a fatty acid amide hydrolase 
(FAAH)-dependent formation of NADA from AA and dopamine, which was observed in 
vivo and in rat brain membrane assays. However, the formation of NADA by micelles 
containing FAAH was poor, suggesting that other proteins may be involved (Hu et al., 
2009).  
 
1.4.2 Endocannabinoid degradation 
Another key feature of endocannabinoid signalling is that endocannabinoids are 
rapidly degraded by cells. As the degradative enzymes are expressed intracellularly, 
endocannabinoids first need to be internalised and so endocannabinoid degradation is 
typically considered to be a two-stage process. Three main endocannabinoid 
degrading enzymes are involved (FAAH, N-acylethanolamine-hydrolysing acid 
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amidase and monoacylglycerol lipase) and these are discussed further in the following 
sub-sections. The main endocannabinoid degradative pathways are represented in 
Figure 1.8. In addition to these pathways, endocannabinoids can also be oxygenated 
to form compounds with different pharmacology (van der Stelt et al., 2002). Briefly, 
cyclooxygenases (COX) and lipoxygenases (LOX) are the two main classes of 
enzymes that can oxygenate endocannabinoids (van der Stelt et al., 2002). Both COX 
and LOX can also oxygenate AA to produce biologically active molecules (Han et al., 
2002; Lichtman et al., 2002). 
 
Arachidonic acidEthanolamine Glycerol
Anandamide 2-Archidonoylglycerol
NAAA FAAH MAGL
EMT EMTEMT
Intracellular
Extracellular
Anandamide 2-Archidonoylglycerol
 
 
Figure 1.8  The major degradative pathways of anandamide and 2-
arachidonoylglycerol. For anandamide and 2-arachidonoylglycerol to be degraded, 
they first need to enter the cell: this can occur either by diffusion across the plasma 
membrane or through endocannabinoid membrane transport (EMT) proteins 
(Kaczocha et al., 2009). Once in the cytoplasm, the endocannabinoids can then be 
metabolised by FAAH (fatty acid amide hydrolyase), NAAA(N-acylethanolamine-
hydrolysing acid amidase) or MAGL (monoacylglycerol lipase), with enzyme 
involvement being dependent on the endocannabinoid and cell type (Sun et al., 2005; 
Tsuboi et al., 2005; Blankman et al., 2007). 
 
The study by Ortega-Gutierrez et al. (2004), using neuronal cells isolated from FAAH 
wild type and knock-out mice, found that AEA uptake was dependent on multiple 
factors. They concluded that 24% of AEA uptake was FAAH-dependent, 18% CB1 
receptor-dependent, 30% EMT-dependent and 28% diffusion-dependent. However, 
the diffusion-dependent uptake of AEA is reliant on the metabolism of cytosolic AEA in 
order to prevent the intracellular and extracellular concentrations of AEA from 
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equilibrating. Maccarrone et al. (2000) suggested that CB1 receptor-stimulated AEA 
uptake occurs through potentiation of nitric oxide (NO) synthase leading to increased 
intracellular NO levels, which they hypothesised to upregulate EMT uptake rates. With 
regard to EMTs, the study by Kaczocha et al. (2009) identified that certain fatty acid 
carriers, fatty acid binding proteins (FABP), contributed to AEA uptake. More 
specifically, it was found that N18GT2 cells express FABP5, and that its inhibition 
reduced AEA uptake by 57% over a 5-minute period. Therefore, it appears likely that 
AEA uptake and the uptake of other endocannabinoids are achieved through diffusion 
gradients and membrane transport proteins, with the maintenance of the diffusion 
gradient being dependent on endocannabinoid clearance. As discussed in the review 
by Yates & Barker (2009), endocannabinoids that diffuse into cells may be 
sequestered into intracellular compartments. It has been proposed that 
endocannabinoids which enter the plasma membrane may also be captured in 
endocytotic vesicles. 
 
1.4.2.1 Fatty acid amide hydrolase (FAAH) 
FAAH (also known as FAAH-1) is conserved between mouse, rat (91% homology with 
mouse) and human (shares ~83% homology with mouse and rat FAAH genes). FAAH 
is a serine hydrolase, and hydrolyses AEA to form AA and ethanolamine (see review 
by McKinney & Cravatt (2005)). FAAH has an optimal pH of 9 and is typically reported 
to have highest activities for oleamide (a primary amide) and AEA (Ueda et al., 1995; 
Giang & Cravatt, 1997; Sun et al., 2005; Wang et al., 2008). In vitro studies also 
suggest that FAAH can also hydrolyse 2-AG and other MAGs, but in vivo the 
contribution of FAAH in regulation of MAG levels is minor (Lichtman et al., 2002). 
FAAH is expressed in the wide number of tissues, with FAAH being the major AEA 
degradative enzyme in brain, spinal cord and liver but does not appear to be 
expressed in heart or skeletal muscle (Cravatt et al., 2001; Sun et al., 2005; Mulder & 
Cravatt, 2006; Wei et al., 2006).  
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In addition to FAAH, there is a second FAAH, FAAH-2, which is 20% homologous to 
FAAH and is expressed in humans but not in rodents (Wei et al., 2006). Wei et al. 
(2006) found that the optimal pH of FAAH-2 was between pH 8 and 9 and that it 
displayed the highest catalytic activity for oleamide with only minor NEA hydrolytic 
activity. FAAH-2 is expressed in a wide range of human tissues, in particular the 
heart, but was not found to be expressed in brain, small intestine or liver (Wei et al., 
2006). Both FAAH and FAAH-2 are globular proteins with a single membrane-
spanning helix and so are integral membrane proteins (Wei et al., 2006). Both FAAH 
and FAAH-2 are expressed intracellularly with the globular domain of FAAH facing the 
cytosol, while the globular domain of FAAH-2 is expressed on the luminal sides of 
membranes (Wei et al., 2006). In the study by Morozov et al. (2004), > 80% of FAAH 
was present on small vesicles, 10% was found on the outer mitochondrial membrane 
and 5% was expressed on the cytosolic side of the plasma membrane. 
 
1.4.2.2 N-acylethanolamine-hydrolysing acid amidase (NAAA) 
Ueda et al. (1999) identified a FAAH-like enzyme activity in human megakaryoblastic 
cells, which hydrolysed AEA to AA and ethanolamine, but, unlike FAAH, it had an 
optimal pH of 5 and was not inhibited by FAAH inhibitors. The FAAH-like enzyme was 
subsequently named N-acylethanolamine-hydrolysing acid amidase (NAAA), and 
these characteristics have been reproduced by other studies, and it has been found 
that NAAA is catalytically distinct from FAAH, as well as showing the highest 
hydrolytic activity for PEA over other NAEs including AEA (Sun et al., 2005; Tsuboi et 
al., 2005). Both Sun et al (2005) and Tsuboi et al. (2005) examined the expression 
(mRNA) in mouse and rat tissues (respectively) and showed that NAAA is widely-
distributed throughout the body but is expressed at low levels in liver and small 
intestine. Cellular analysis of NAAA has revealed that NAAA appears to be expressed 
within lysosomes or is associated with the lysosomal membrane (see review by Ueda 
et al. (2010)) 
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1.4.2.3 Monoacylglycerol lipase (MAGL) 
Monoacylglycerol lipase (MAGL) is the only enzyme of its class to be expressed in 
mammals and is a serine hydrolase that hydrolyses medium to long chain fatty acids 
MAGs, MAGL-mediated hydrolysis of 2-AG produces AA and glycerol (Karlsson et al., 
1997). MAGL is a cytosolic membrane-associated enzyme and is expressed in brain, 
intestinal tract, islets and liver (Blankman et al., 2007; Saario & Laitinen, 2007; 
Duncan et al., 2008; Starowicz et al., 2008; Tharp et al., 2008). It was found that in 
mouse brain, 90% of 2-AG hydrolysis was membrane-localised, with MAGL 
accounting for 85% of this (Blankman et al., 2007). Of the remaining membrane-
localised 2-AG hydrolysis, FAAH accounted for < 1% of activity (Blankman et al., 
2007). In porcine brain preparations, MAGL was found to have an optimal pH of 7 
(Goparaju et al., 1999), but has also been described elsewhere as having an optimal 
pH of 8 (see review by Blankman et al (2007)). MAGL is typically described as having 
a higher activity for 2-AG over other MAGs (see review by Blankman et al. (2007)) but 
the study by Dinh et al. (2002) found that MAGL hydrolysed 2-oleyl glycerol at a faster 
rate (~2 fold) than 2-AG.  
 
1.4.4 “Classical” Cannabinoid receptors 
To date, there are two confirmed (‘classical’) cannabinoid receptors, CB1 and CB2, 
both of which have been identified as inhibitory G protein coupled receptors 
(G
i/oPCR), and were originally believed to localised to the CNS and immune tissue, 
respectively (Bayewitch et al., 1995; Howlett et al., 2002; Jarrahian et al., 2004). 
Studies over recent years have confirmed the expression (at least mRNA) of CB1 
receptors in peripheral tissues such as liver, islet, adipose tissue and gastrointestinal 
tract (Juan-Pico et al., 2006; Starowicz et al., 2008; Izzo & Sharkey, 2010). CB1 
receptors are involved in a wide range of physiological systems such as the regulation 
of neuronal activity in the CNS by post-synaptic inhibition, nociception, and regulation 
of blood vessel dilation (as discussed in the review by Pacher et al. (2006)). The study 
by Liu et al. (2009a) has also reported the expression of CB2 receptor mRNAs in non-
immune tissues such as brain, kidney, and testes. However, the expression of CB2 
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may have gone previously undetected as its expression may be inducible; for 
instance, the study by Viscomi et al. (2009) found that CB2 expression by neurons in 
the cerebellum was only induced under conditions of neurodegeneration. In 
physiological and pathological conditions, CB2 receptor signalling in the immune 
system has an immunosuppressive effect which is thought to be protective as it 
prevents excessive immune responses (see review by Patel et al. (2006)). CB2 
receptor signalling also serves a protective role in other tissues; in pathological states 
as it reduces inflammation and injury in the cardiovascular system, reduces liver 
fibrosis and stimulates neurogenesis in the CNS (as discussed in the review by 
Pacher et al. (2006)) 
 
CB1 and CB2 receptor activation is known to result in inhibition of adenylyl cyclase 
activity, and activation of mitogen-activated protein kinase (MAPK) signalling 
cascades (see the review by Bosier et al. (2010)). Additionally, CB1 receptors are 
known to inhibit the activities of voltage-gated calcium channels but activate G 
protein-coupled inwardly rectifying potassium channels (see review by Turu & 
Hunyady (2010)). It should be noted that in several studies, it has been observed that 
some cannabinoids (typically AEA) have been found to inhibit ion channel activities 
independently of the CB1 receptor (Shimasue et al., 1996; Chemin et al., 2001; 
Maingret et al., 2001; Sade et al., 2006).  
 
Both CB1 and CB2 receptors have been described as possessing constitutive activity; 
this is primarily based on observations of CB-receptor antagonists having the opposite 
effect to CB-receptor agonists in studies in vivo and in vitro (this concept is discussed 
further by Pertwee (2003)). Briefly, if receptors have two states, dormant and active, 
the receptor can only switch to the active state upon binding of an agonist. The 
receptor will remain in the active state until the agonist dissociates from the receptor. 
In this model, antagonists block the binding of agonists to the receptor, preventing it 
from switching on, whereas receptors which are constitutively active can switch 
between the dormant and active states in the absence of any agonist. However, only 
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a portion of the constitutively-active receptors will be in the active state at any one 
time. Upon binding of an agonist, the active state of the constitutively-active receptor 
will be stabilised (i.e. it will not switch back to the dormant state) until the agonist 
dissociates from the receptor. An antagonist that blocks the binding of the agonist but 
does not affect either state of the receptor is referred to as a neutral antagonist, 
whereas an antagonist that also stabilises the dormant state of the receptor is called 
an inverse agonist. There is disagreement as to whether certain CB1 and CB2 
receptors antagonists are inverse agonists; one such argument is that the constitutive 
CB receptor activity may be a result of low level endocannabinoid production. As 
discussed in the study by Savinainen et al. (2003), observations of inverse agonism 
by the putative CB1 receptor antagonist/inverse agonist rimonabant, at micromolar 
concentrations, in cerebellar membranes may have been due to blockade of 
adenosine A1 receptor signalling. 
 
In addition to acting at cannabinoid receptors, it has been recognised that there may 
be additional receptors at which the endocannabinoids and endogenous cannabinoids 
exert their effects. In brain membrane preparations from CB1 receptor KO mice, it was 
observed that AEA stimulated GTP binding in a concentration-dependent manner 
which was not affected by CB1 or CB2 receptor antagonism, thus, indicating that there 
was at least one extra uncharacterised CB-like GPCR expressed in mouse brain (Di 
Marzo et al., 2000). Similarly, cannabinoid studies in the vascular system have also 
indicated that there is another cannabinoid-like receptor expressed by the 
endothelium aside from the CB1 receptor (see review by Kunos et al. (2002)). This 
was first suggested by Wagner et al. (1999) as AEA-mediated vessel relaxation in 
mesenteric arteries did not appear to be CB1 receptor-mediated and the effects of 
AEA were not reproduced by 2-AG or THC (Kunos et al., 2002). The following 
sections describes several receptors which are either associated with cannabinoid 
signalling or are currently classed as putative cannabinoid receptors. 
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1.4.5 Peroxisome proliferator-activated receptors (PPARs) 
There are three isoforms of PPAR receptors, , , and /	 (which have different 
physiological functions, different ligand selectivity and different tissues distributions), 
expressed by a wide range of tissues (Braissant et al., 1996). The PPAR receptors 
when activated are known to heterodimerise with the retinoid X receptor, which bind to 
peroxisome proliferator response elements and recruit co-activators to form active 
transcription complexes (Desvergne & Wahli, 1999; Zoete et al., 2007). Kozak et al. 
(2002) was the first study to suggest a link between the endocannabinoid system and 
PPAR receptors by observing that the 15-LOX metabolite of 2-AG was a PPAR 
agonist. As discussed in O'Sullivan & Kendall (2010), there is reasonable evidence to 
suggest that cannabinoid signalling can either directly or indirectly (via oxygenation by 
COX and LOX) agonise PPAR and/or PPAR receptor. Data from several in vitro 
studies suggest that AEA (either directly or via COX-2 metabolism) may produce a 
significant PPAR-mediated signalling event (Rockwell & Kaminski, 2004; Bouaboula 
et al., 2005; O'Sullivan et al., 2009). 
 
Briefly, PPAR is typically expressed in tissues with high levels of fatty acid oxidation 
(e.g. skeletal muscle) and its activation results in the increased expression of genes 
required for fatty acid uptake and -oxidation (see review by Ferre (2004)). PPAR 
receptors are targetted by the fibrates, which are PPAR agonists that are used in the 
treatment of dyslipidemia because they reduce plasma triglyceride levels, raise high 
density lipoprotein (HDL)-cholesterol levels, and have been found to have positive 
effects on CVD (Keech et al., 2005). As discussed in the review by Stienstra et al. 
(2007), PPAR activation is also associated with anti-inflammatory effects. The 
expression of PPAR/	 in rat tissue has been found to be wide-spread (Braissant et 
al., 1996). PPAR/	 function is the least understood amongst the PPAR isoforms but 
appears to be involved in the regulation of fat mass, type 1 skeletal fibre formation, 
cardiomyocyte growth as well as increasing fatty acid metabolism (see review by 
Wagner & Wagner (2010)). Two separate isoforms of PPAR have been identified, 
PPAR1 and PPAR2, with PPAR2 expression being most prevalent in adipose 
tissue (Tontonoz et al., 1994). PPAR signalling is a key step in the adipocyte 
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differentiation, regulates lipid deposition and also has anti-inflammatory actions 
(Leesnitzer et al., 2002; Ferre, 2004; Stienstra et al., 2007; Scheen et al., 2009). As 
discussed in section 1.3.3, PPAR agonists (the TZDs) are currently used in the 
treatment of type 2 diabetes as peripheral insulin sensitisers but may also exert 
benifical effects of -cell function and activity too.  
 
1.4.6 Transient receptor potential vallinoid type 1 (TRPV1) 
The TRPV1 channel was first characterised by Caterina et al. (1997) and was 
originally called vallinoid receptor 1.  TRPV1 channels were found to open in response 
to noxious heat and acidic pH, allowing the influx of positive mono- and divalent ions 
into TRPV1-expressing cells (Caterina et al., 1997). TRPV1 was found to have 
highest permeability for Ca2+ ions, and its expression is limited to sensory neurons 
(Caterina et al., 1997). Since this study, expression of TPRV1 channels has also been 
found in tissues such as brain, smooth muscle and lungs (Jara-Oseguera et al., 
2008). Zygmunt et al. (1999) was the first study to establish AEA as an endovallinoid 
as well as an endocannabinoid, as it was observed that AEA caused vasorelaxation in 
arteries via TRPV1 channels expressed by vessel-associated sensory neurons. As 
discussed in the review by Jara-Oseguera et al. (2008), TRPV1 activity is associated 
with various inflammatory disorders and pain perception but is also associated with 
protective effects in the cardiovascular system and gastrointestinal tract.  
 
1.4.7 GPR119 
The expression of GPR119 mRNA has been reported, albeit at low levels, in a large 
number of tissues including brain, heart, spleen and stomach (Soga et al., 2005; Chu 
et al., 2008). The highest levels of GPR119 expression has been reported in islets, -
cell lines, and intestinal L-cells (Sakamoto et al., 2006; Chu et al., 2008; Lan et al., 
2009). Evidence largely suggests that GPR119 is a G
sPCR as its activation leads to 
increases in cAMP levels and potentiates the secretion of insulin, GLP-1 and GIP from 
islets and L-cells, respectively (Soga et al., 2005; Overton et al., 2006; Chu et al., 
2007; Chu et al., 2008). GPR119 has received interest with regard to cannabinoid 
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signalling as the NAEs, including AEA, have been reported as endogenous ligands (in 
order of potency, OEA> PEA > SEA> AEA), as have the lysophosphatidylcholines 
(Soga et al., 2005; Overton et al., 2006). However, the study by Lan et al. (2009) in 
which GPR119 KO mice were used, found that the effects of OEA and 
lysophosphatidylcholine on insulin secretion were similar in islets isolated from WT 
and KO mice. This may suggest that OEA and lysophosphatidylcholine were 
potentiating insulin secretion via non-GPR119 receptors. 
 
1.4.8 GPR18 
Expression of GPR18 has primarily been found in spleen, thymus, testis and 
leukocytes, with N-arachidonoyl glycine (NAGly, produced from AEA) and N-palmitoyl 
glycine being suggested as endogenous agonists for GPR18 (Gantz et al., 1997; 
Rimmerman et al., 2008; Bradshaw et al., 2009). Evidence for NAGly as an 
endogenous GPR18 agonist is still controversial as studies in cell lines disagree as to 
whether NAGly possess significant GPR18 agonistic behaviour (Kohno et al., 2006; 
Rimmerman et al., 2008). Data suggest that GPR18 is a G
iPCR, the activation of 
which results in the influx of Ca2+ influx (Ikeda et al., 2005; Kohno et al., 2006; 
Rimmerman et al., 2008). The physiological role of GPR18 remains unknown but 
there are suggestions that GPR18 may regulate sensory neuron activity and immune 
cell function (Rimmerman et al., 2008).  
 
1.4.9 GPR55 
The expression of the GPR55 (mRNA) has been reported in a wide number of tissues, 
with highest expression levels reported in adrenal glands, brain and small intestine 
(Sawzdargo et al., 1999; Ryberg et al., 2007; Lauckner et al., 2008; Waldeck-
Weiermair et al., 2008; Whyte et al., 2009). The physiological effects of GPR55 
signalling, thus far, are the regulation of bone mass and hyperalgesia (increased 
sensitivity to painful stimuli) in response to inflammatory and neuropathic pain (Staton 
et al., 2008; Whyte et al., 2009). Activation of GPR55 in natively-expressing cells has 
been suggested to lead to activation of RhoA (Ras homologue gene family, member 
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A) and Rho-Associated Kinase (ROCK) mediated by either G
12 or G13 proteins 
(Lauckner et al., 2008; Waldeck-Weiermair et al., 2008; Henstridge et al., 2009; Oka 
et al., 2009; Whyte et al., 2009). In addition, activation of GPR55 has also been linked 
to PLC, via Gq activation (Sawaki et al., 1993; Iismaa et al., 2000; Duttaroy et al., 
2004; Waldeck-Weiermair et al., 2008; Henstridge et al., 2009). While there is strong 
consensus that lysophosphatidylinositols are endogenous ligands for GPR55, there is 
controversy surrounding which cannabinoids also have GPR55 activity although there 
are more studies that suggest that the CB1 receptor antagonists AM251 and 
rimonabant are GPR55 agonists than those that do not (Waldeck-Weiermair et al., 
2008; Kapur et al., 2009; Oka et al., 2009; Yin et al., 2009; Henstridge et al.). 
 
1.4.10 The endocannabinoid system with respect to insulin 
signalling and islet function  
While the stimulatory effects of cannabis on appetite were widely-known before the 
discovery of the endocannabinoid system, it was not until studies such as Williams & 
Kirkham (1999) that endocannabinoid signalling was shown to induce hyperphagia. 
Given the rise in the prevalence of obesity, the development of appetite suppressors 
has received interest as a means of weight control. Therefore, research was (and still 
is being) conducted to assess whether CB1 receptor antagonists could be used as 
viable anti-obesity treatments (Ravinet Trillou et al., 2003; Pi-Sunyer et al., 2006; 
Nogueiras et al., 2008). This research subsequently led to the discovery that the 
endocannabinoid system, in particular CB1 receptor signalling in the CNS and in the 
periphery, plays a central role in energy homeostasis (Ravinet Trillou et al., 2003; 
Janiak et al., 2007; Nogueiras et al., 2008).  
 
In a recent review by Andre & Gonthier (2010), the physiological role of the 
endocannabinoid system is to promote food intake and food assimilation while 
decreasing fatty acid oxidation and increasing lipogenesis. In obese states, the 
endocannabinoid system is believed to become overactive and contributes to 
dyslipidaemia and insulin resistance in hepatic, adipose and skeletal muscle tissues 
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(Andre & Gonthier, 2010). Overactivity of the endocannabinoid system in peripheral 
tissues will inadvertently affect -cells, because greater amounts of insulin release will 
be needed from the -cells in order to compensate the peripheral insulin resistance. 
Therefore, dysfunctional endocannabinoid signalling in non-islet tissues may indirectly 
contribute towards islet dysfunction in obese pre-diabetic states.  
 
Review of the literature regarding the in vivo effects of cannabinoids on glucose 
tolerance and insulin secretion in humans is limited but it has been reported that 
injection of a 6mg dose of THC induces glucose intolerance (determined by 100g 
OGTT; Hollister & Reaven, 1974). This data appears to coincide with the study by 
Bermudez-Silva et al. (2006) that found that administration of AEA and ACEA (a CB1 
receptor agonist) prior to intraperitoneal glucose loading in Wistar rats also induced 
glucose intolerance. In a follow up study to Bermudez-Silva et al. (2006), it was found 
that administration of 2-AG and JWH-133 (a CB2 receptor agonist) prior to 
intraperitoneal glucose loading in Wistar rat promoted glucose tolerance (Bermudez-
Silva et al., 2007). Therefore, this would suggest that THC in the study by Hollister & 
Reaven (1974) was acting as a CB1 receptor agonist, assuming that the roles of the 
cannabinoid receptors in glucose homeostasis are conserved between rats and 
humans. Hollister & Reaven (1974) also measured changes in plasma insulin levels 
and found there was not a significant alteration in -cell secretory activity. While it is 
uncertain whether THC induced glucose intolerance by peripheral insulin resistance, 
Hollister & Reaven (1974) did find a potentiation of plasma growth hormone levels, 
especially in the most glucose intolerant subjects, that corresponded with the time 
periods where plasma glucose were significantly higher than vehicle control data. This 
may suggest that excessive activation of CB1 receptors in obese pre-diabetic states 
may contribute towards glucose intolerance by increasing hepatic glucose production 
and/or promoting peripheral insulin resistance. 
 
Despite the observation by Hollister & Reaven (1974) that THC administration did not 
affect GSIS there are now several studies that have found that CB receptor activation, 
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in isolated islets and primary -cells, affects insulin secretion. However, there is 
controversy regarding the effects of CB1 and CB2 receptor signalling on insulin 
secretion from islets and primary -cells, which, does not appear to specie-dependent. 
Briefly, the studies by Juan-Pico et al. (2006) and Nakata & Yada (2008) suggest that 
CB1 receptors are negatively coupled to insulin secretion, whereas, the studies by 
Bermudez-Silva et al. (2008), Li et al. (2010) and Vilches-Flores et al. (2010) have 
found that CB1 receptor agonism potentiates insulin secretion. With regard to CB2 
receptor signalling, Juan-Pico et al. (2006) and Bermudez-Silva et al. (2008) both 
reported CB2 receptor activation led to an inhibtion of insulin secretion whereas, data 
presented in the study by Li et al. (2010) suggests that the CB2 receptor activation 
potentiates insulin secretion. 
 
With regard to endocannabinoid dysfunction in islets, the study by Matias et al. (2006) 
reported that AEA and 2-AG were produced in RIN-m5F cells (a glucose 
unresponsive, insulin-secreting -cell line). It was found that 2-AG biosynthesis by 
RIN-m5F cells cultured at 25mM glucose for 24 hours (compared to cells cultured at 
13mM glucose) was upregulated in response to 33mM glucose. A subsequent study 
by the same group also found that PEA and OEA were produced by RIN-m5F cells, 
and that regulation of their production was also affected by hyperglycaemia (Matias et 
al., 2007). Several studies have now been conducted regarding the expression of 
endocannabinoid synthesising and metabolising enzymes in islets and islet cell lines, 
which are detailed in Table 1.4. 
 
Matias et al. (2006) also reported that CB1 receptor-signalling in RIN-m5F cells kept at 
25mM glucose for 24 hours (compared to cells cultured at 13mM glucose) potentiated 
insulin secretion indicating that CB1 receptor signalling may have also become 
dysregulated as a result of hyperglycaemia. Therefore, the results from Matias et al. 
(2006) may indicate that dysregulation of the endocannabinoid system in islets 
contributes to -cell dysfunction, suggesting that correction of endocannabinoid 
dysfunction in islets may become a future treatment of type 2 diabetes. As described 
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Table 1.4  Expression of endocannabinoid synthesising and degrading enzymes in islets and -cell lines 
 
Study Techniques 
used Resolution 
Cell-
line/tissue 
used 
NAPE-PLD FAAH DAGL and DAGL MAGL 
Detected 
Cell 
specific 
distribution 
Detected 
Cell 
specific 
distribution 
Detected 
Cell 
specific 
distribution 
Detected 
Cell 
specific 
distribution 
Matias et 
al. (2006) RT-PCR N/A 
RIN-m5F 
-cell line Y  Y  Y  Y  
Starowicz 
et al. 
(2008) 
RT-PCR 
IHC 
 
non- 
C57BL/6J 
mouse 
islet 
Y Non- ++ 
 + 
Y   Y 
 N  Y  
Tharp et 
al. (2008) IHC , , 	 
ZF rat 
islet ND  Y 
 ++ 
 + 
ND  Y 	 
Human 
islet ND  Y 
 ++ 
 + 
ND  ?  
Bermudez-
Silva et al. 
(2008) 
Western 
blotting 
Whole 
islet 
Human 
islet N  Y  
 Y 
 Y  Y  
 
For RT-PCR (reverse transcriptase polymerase chain reaction) and western blotting whole islet sample were used. For western blotting and 
immunohistochemistry (IHC) enzyme specific antibodies were used and for immunohistochemistry cell specific distributions were confirmed by hormone-
specific antibodies. Y expression detected, N expression not detected, ND not determined, ? Authors reported unreliable staining, ++ refers to high levels of 
expression detected in the cell type, + refers to low levels of expression detected in the cell type. 
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above (Section 1.4.5), cannabinoids are also known to be capable of PPAR receptor-
mediated signalling thus, the apparent dysfunction in -cell endocannabinoid 
production may instead be a positive adaptation of the endocannabinoid system to 
increase -cell survival in glucotoxic conditions. Again, this may suggest that 
manipulation of the endocannabinoid system might offer benefits in the treatment of 
type 2 diabetes.  
  
1.5 Aims and Objectives 
 
The role of the endocannabinoid system is well-recognised in the CNS and immune 
system but its role in glucose homeostasis is poorly understood. The principal aim of 
this study was to investigate the role of cannabinoid receptors and endogenous 
cannabinoids in the acute control and modulation of insulin secretion. Once the acute 
effects of cannabinoid signalling was established, the chronic effects of PPAR 
receptor and cannabinoid signalling on islet function and insulin secretion were to be 
characterised under conditions similar to those found in type 2 diabetes. 
 
To achieve these aims, rat isolated islets and -cell lines were used as model 
systems. The initial stages of study focused on the use of the endocannabinoids and 
CB-receptor (CB1- and CB2-receptor specific) antagonists to pharmacologically 
characterise the acute effects of cannabinoid signalling on insulin secretion. A FAAH 
inhibitor was used to ascertain the effects of local metabolism either alone or with 
additionally applied endocannabinoids. 
 
This study aimed to define the roles of cannabinoids in insulin secretion and provide 
insights into their therapeutic potential in the treatment or limitation of impaired  cell 
function in Type 2 diabetes. 
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2  
 
Materials and Methods 
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2.1 Animals 
 
Wistar and Zucker rats were purchased from Charles River UK (Kent, UK) and kept 
in-house for at least 4 days prior to experimentation. Animals were housed at 20-22ºC 
and kept in a standard 12-hour light cycle (on 7am: off 7pm). Water and standard rat 
chow (Taklad Global ~70% carbohydrate; Harlan, WI, USA) were available ad libitum. 
Animals were either killed according to Schedule 1 killing practices by asphyxiation 
(using CO2) or stunning followed by cervical dislocation or decapitation.  
 
2.2 Materials 
 
Bovine serum albumin (BSA; Fraction V) and collagenase P (from Clostridium 
histolytiam, non-sterile) were purchased from Roche Diagnostics (Mannhein, 
Germany). Sac-Cel (Donkey anti-guinea pig secondary Ab coupled to cellulose) was 
purchased from Immunodiagnostic Services (Bolton, UK). Goat anti-guinea pig anti-
serum was purchased from Equitech-Bio Inc. (Texas, USA). AEA (N-(2-Hydroxyethyl)-
5Z,8Z,11Z,14Z-eicosatetraenamide), R-(+)-methanandamide ((R)-N-(2-Hydroxy-1-
methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide), AM251 (N-(Piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide), O-2050 
((6aR,10aR)-3-(1-Methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-
trimethyl-6H-dibenzo[b,d]pyran), ACEA (N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-
eicosatetraenamide), JWH-133 ((6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-
tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran), AM630 (6-Iodo-2-methyl-1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone), GW9662 (2-Chloro-5-
nitro-N-phenylbenzamide), and BIM 23056 (D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-D-Nal-
NH2) were purchased from Tocris (Bristol, UK). Guinea-pig anti-bovine insulin anti-
serum, RPMI-1640 media, URB597 (cyclohexylcarbamic acid 3´-carbamoyl-biphenyl-
3-yl ester), somatostatin-14 and LPI (L--lysophosphatidylinositol) sodium salt (from 
Glycine max) were purchased from Sigma-Aldrich (Dorset, UK). [3H]-AEA was 
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purchased from American Radiolabeled Chemicals (MO, USA). Any other chemicals 
used were of reagent grade.  
 
AEA, methanandamide, and ACEA solutions were purchased as 5mg/ml solutions 
pre-dissolved in ethanol. O-2050, GW9662, JWH 133, and URB597 were first 
dissolved in 100% ethanol to produce 1mg/ml stock solutions. AM251 and AM630 
1mg/ml stock solutions were prepared by dissolving the drug in DMSO. LPI was 
dissolved in ddH2O to produce a 10mM solution. A 1mM somatostatin-14 stock was 
prepared by dissolving the peptide in 10% (v/v) acetic acid/ 1% (w/v) BSA. BIM 23056 
was first dissolved in 10% (v/v) DMSO solution to produce a 1mg/ml solution. All drug 
stock solutions were kept at -20ºC. The stock solutions that were either made up in 
DMSO or water (i.e. frozen when stored at -20ºC) were aliquoted in order to order to 
minimise degradation from repeated freeze/thaw cycles. Where appropriate, drug 
stocks were diluted to the required concentration by serial dilution, with no greater 
than a 10-fold dilution per step. If the concentration of the stock solution was < 1mM, 
then solutions were diluted in ddH2O. In the case of AEA, methanandamide and 
ACEA, where serial dilution steps used stock solutions at concentrations  1mM, then 
50% (v/v) ethanol solution was used instead of ddH2O to avoid emulsion formation. 
 
2.3 Buffers and cell culture media 
 
2.3.1 Gey & Gey buffer 
NaCl2 111mM, NaHCO3 25.2mM, KCl 5mM, MgCl2 1mM, MgSO4 0.3mM, Na2HPO4 
0.4mM, KH2PO4 0.3mM and CaCl2 1mM. Gassed for 10 minutes with 95% O2/ 5% 
CO2 at the start of the experiment to oxygenate the buffer and adjust the pH of the 
buffer to 7.4.  Gey & Gey buffer was periodically re-gassed to ensure the pH of the 
buffer was maintained at 7.4. 
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2.3.2 Insulin Assay Buffer (IAB) 
Na2HPO4 15.9mM, KH2PO4 9.9mM, NaCl 154mM, EDTA 10mM and BSA 5% (w/v). 
Buffer pH is 6.5. 
 
2.3.2 RPMI-1640 media 
RPMI-1640 media were supplemented with 5% (v/v) foetal calf serum, 2mM 
glutamine, 10mM HEPES, 1mM sodium pyruvate, 50M 2-mercaptoethanol and either 
5mM or 11.1mM glucose. 
 
2.4 Insulin secretion studies 
 
Insulin secretion can be studied by various methods which have been reviewed in 
Table 2.1. The use of isolated exocrine-free islets, as in this study, is advantageous 
as the effects of treatments on insulin secretion directly reflect alterations in islet cell 
activities. A limitation of this approach is the potential damage to cell surface proteins 
during the isolation procedure which could affect islet function. This can be 
circumvented by culturing the islets to allow protein expression recovery. The isolated 
islets will not solely consist of the islet endocrine cells but the islets may also contain 
endothelial cells as islets are highly vascularised (Weaver & Sorenson, 1989; Olsson 
& Carlsson, 2006).  
 
2.4.1 Islet preparations 
As the islets are interspersed throughout the pancreas, they first need to be isolated 
from the surrounding exocrine tissue before any isolated islet experiments can be 
performed. A two-step method employing collagenase digestion of pancreata is a 
commonly used for the isolation of islets. Collagenase enzymes are either applied in 
solution to chopped tissue or injected via the pancreatic bile duct (van Suylichem et 
al., 1992). The collagenase enzymes specifically hydrolyse the collagen fibres which 
connect the endocrine and exocrine tissues together. However, care must be taken 
with collagenase enzymes as given enough time the enzymes will degrade the 
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intercellular proteins which form physical connections between the islet cells, causing 
the islets to disperse. Both methodologies require an isolation step to obtain exocrine-
free islets. This is achieved either by manually picking the islets or through the use of 
density gradient purification techniques (van Suylichem et al., 1992; Wang & 
Rosenberg, 1999). 
 
While collagenase-based islet isolation techniques have been used for several 
decades, it is still not fully understood why preparations are more efficient in some 
species compared to others. The efficacy of islet isolation by collagenase is in part 
mediated by the peri-insular cap (Section 1.2). For instance, rat islets are mostly 
covered by a peri-insular cap and high yields are obtained from collagenase-based 
isolation techniques (van Deijnen et al., 1992), whereas porcine islets have poor 
coverage and islet yields by collagenase digestion are poor (van Deijnen et al., 1992). 
However, canine islets are fully covered by the peri-insular cap but are associated 
with intermediate yields indicating that other aspects of islet structure also contribute 
to efficacy of collagenase based islet isolation techniques (van Deijnen et al., 1992). 
 
It must be noted that there are several complications in isolating large quantities of 
islets by collagenase digestion especially as an estimated 50% of islets are lost in the 
most efficient of islet preparations (van Suylichem et al., 1992). Commercial 
collagenases contain contaminating protease activity from other proteases, such as 
trypsin, which may affect islet activity by hydrolysing extracellular regions of cell 
surface proteins. In addition, proteases and other digestive enzymes are also 
released from the exocrine tissues which may further add to cell damage and 
reduction in islet yields. In this study, it was also found that the age of the rat was also 
a confounding factor as the older rats (with body weights > 300g) generally had more 
fibrous pancreata than younger rats (with body weights  300g). Fibrosis of the 
pancreas is known to occur as a result of aging (Reaven et al., 1979) and can also be 
caused by hyperglycaemia (see review by Czako et al. (2009)). This had a negative 
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Table 2.1  Different cell model systems used to study insulin secretion.  
 
System Tissues which may affect insulin secretion Insulin secretion Neuronal1 Peripheral2 Exocrine Endothelial3 Paracrine Measurement4 Kinetics 
In vivo Y Y Y Y Y Direct Y 
Perfused 
pancreata Y
5
 N Y Y Y Direct Y 
Isolated 
islets N N N Y Y Direct/indirect Y
6
 
Primary -
cells N N N N N Direct
7/Indirect Y8 
-cell line9 N N N N N Direct7/Indirect Y8 
Pseudo 
islets9,10 N N N N N Direct
7/Indirect Y6 
 
1
 Neuronal refers to parasympathetic, sympathetic and sensory as well as other nerve types which do not fall into these categories but also associated with 
islets 
2
 Peripheral tissues include the liver and adipose tissues 
3
 Endothelial refers to the endothelial cells which are part of the capillaries which permeate the islets 
4
 Measurement refers to the manner in which insulin secretion is typically measured in studies which employ the specified system. Direct refers to 
quantification of insulin (e.g. radioimmunoassay) and indirectly refers to a qualitative measure of insulin secretion (e.g. changes in intracellular Ca2+) 
5
 This is based on study by Park et al. (1999) which found that severed neurons could be activated by electrical field stimulation. 
6
 Based on the use of islets in a perifusion system. 
7
 This is based on dispersed -cells being used in reverse haemolytic plaque assays (Malaisse et al., 1998). 
8
 Based on a technique described in Ashcroft et al. (1987) where dispersed -cells were kept inbetween two layers of gel, which were porous enough to allow 
solutes (including insulin) to pass through but not the -cells, in a perifusion system. 
9
 Based on the assumption that a -cell line is used alone and not co-cultured with non- cell lines 
10 This is based on the studies such as by Brenner & Mest (2004) which formed islet-like structures from islet cell lines by suspension culture of the cells. 
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effect as pancreata from older/larger animals, at times led to inefficient handling of the 
tissue (distension, chooping; see later) and subsequently uneven digest. 
 
2.4.1.1 General Procedure 
The method used for the isolation of islets described below is based upon the protocol 
described in Howell & Taylor (1968). The protocol uses Gey & Gey buffer (Section 
2.3.1) which is a bicarbonate-buffered physiological saline solution and has been 
supplemented with 4mM glucose for use in this protocol. 
 
Either one or two pancreata were used per preparation. Once the pancreas had been 
isolated, further cleaning was required to remove contaminating tissue from the 
pancreatic tissue, including spleen, adipose tissue, lymph nodes and large blood 
vessels. The remaining tissue was then thoroughly distended using a needle and 
syringe to inject Gey and Gey buffer into the tissue. This step is important as it 
physically separates the tissues and allows oxygenation of the tissue. The tissue was 
then roughly chopped into ~1mm3 pieces and transferred to a conical tube, where it 
was centrifuged (Eppendorf Centrifuge 5810R) at 3000rpm for 3 seconds in 12ml of 
buffer. The supernatant was poured off and the pellet was transferred to a 25ml 
plastic conical flask (Nalgene, NY, USA), to which collagenase P (~2.4mg 
collagenase per pancreas) and 1-2 equivalent volumes of buffer to tissue were added. 
The mixture was then shaken vigorously (~200 shakes/minute) at 37°C for ~5-6 
minutes using a Griffin flask shaker (Griffin and George Ltd., UK). The conical flask 
was then hand-shaken until the digest was smooth and homologous in appearance. 
Samples of the digest were taken periodically during hand-shaking and viewed under 
a dissecting binocular SZ4045 microscope (Olympus, Essex, UK). The digestion 
procedure was terminated when samples of the digest contained a majority of 
exocrine-free islets. The digest was then spun for a further 3 seconds at 3000rpm, the 
supernatant was then poured off and the pellet resuspended in 10ml of buffer. 
Exocrine-free islets were then manually isolated from the digest and transferred to a 
conical tube containing buffer, using a drawn-out Pasteur pipette under a dissecting 
binocular microscope. Typical preparations yielded between 75-180 islets per 
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pancreas. Islets isolated from Wistar rats typically had a uniform morphology as the 
islets were white in colour and were spheroid shape. For this reason, islets were 
picked in a black coated-Petri dish as islets could be easily distinguished from 
exocrine tissues which are diffuse in appearance and grey in colour except for acinar 
bodies. Acinar bodies have a similar morphology to islets but are smaller in size, are 
brighter in appearance and have a slight blue colouration. 
 
2.4.2 Islet static incubation studies 
The buffer used for these studies (Gey & Gey buffer; Section 2.3.1) was 
supplemented with 4mM glucose and 1% (w/v) BSA. Initially, LP3 tubes were used for 
the islet incubation experiments but 96-well plates were used for the majority of the 
islets studies as they were more convenient. The following protocol describes the use 
96-well plates. For conditions where higher glucose concentrations were required 
glucose solution was used to adjust stocks of 4mM glucose Gey & Gey buffer. The 
adjustment of the buffer glucose concentration was performed prior to addition of the 
buffer to wells. 
 
Two microlitres of drug stock solution (at 100x the final concentration) were first added 
to the wells followed by the addition of 200μl buffer (at the required glucose 
concentration). Batches of 3 islets were carefully added to each well using a drawn-
out Pasteur pipette; extra care was taken to avoid the addition of buffer to the well. 
The 96-well plates were then incubated at 37ºC in a 95% O2 /5% CO2 atmosphere 
using a Sanyo CO2 incubator, with an incubation period of 60 minutes. An additional 5 
minutes were added to the incubation period to allow buffer to warm to 37ºC. Where 
LP3 tubes were used instead of 96-well plates 5μL of 100x drug stock and 500μl of 
buffer was added to each tube. After the addition of the islets the tubes were briefly 
gassed with 95% O2 / 5% CO2, capped and then incubated at 37ºC for 60 minutes in a 
water bath. At the end of the incubation period, the 96 well-plate was agitated to allow 
mixing and transferred to a fridge/freezer for 5 minutes to inhibit further insulin 
release. Samples of the incubation media were then taken from each well and the 
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insulin content was determined by radioimmunoassay (RIA; Section 2.6.1) or samples 
were stored at -20ºC for later use. Insulin secretion rates were determined as ng of 
insulin secreted/islet/hour. 
 
2.4.2.1 Basic experimental setup 
In all experiments, islets were incubated at 4mM and 20mM glucose in order to 
assess for islet viability. These two concentrations represent basal and maximal levels 
of glucose-stimulated insulin secretion, see Figure 2.1. The islets were deemed viable 
(i.e. the islets are functioning normally) if there was a  2-fold difference in insulin 
secretion rates between 4mM and 20mM glucose. All experiments, unless stated 
otherwise, were compiled from a n of  5 experiments (performed with separate islet 
isolations). Compilation and statistical testing of experimental data were carried out as 
described in Section 2.4.5. 
 
 
Figure 2.1  The effects of glucose on insulin secretion from Wistar rat isolated islets of 
Langerhans. Islets were incubated at the indicated glucose concentrations for 1 hour 
at 37ºC. Results shown are the mean insulin secretion rate ± 1 SD from a single 
experiment. n = 4-6 replicates per condition. 
  
2.4.3 INS-1 823/13 -cell secretion studies 
INS-1 823/13 cells were used to assess whether cannabinoid signalling was directly 
affecting -cell activity. INS-1 823/13 cells were seeded in 48-well plates at a density 
of 5x104 cells per well in 0.5ml of RPMI-1640 media containing 11.1mM glucose 
(Section 2.3.3) and were kept under a 95% O2/5% CO2 atmosphere at 37 ºC until cells 
reached 70% confluency. 18 hours before experimentation, the RPMI-1640 media 
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was changed to RPMI media containing 5mM glucose. The glucose concentration of 
the media was reduced prior to experimentation to improve the glucose 
responsiveness of the INS-1 823/13 cells. 
 
On the day of the experiment, the RPMI-1640 media was aspirated off, 1ml of pre-
warmed Gey & Gey buffer (Section 2.3.1) was added to each well and then aspirated 
off. This washing step was repeated twice more and then 0.5ml of pre-warmed Gey 
and Gey buffer, supplemented with 3mM glucose and 1% (w/v) BSA, was then added 
to each well and the plate was incubated at 95% O2/5% CO2 atmosphere at 37 ºC for 
30-60 minutes. Once this time period had elapsed, the media was then aspirated and 
0.5ml of pre-warmed 1% (w/v) BSA supplemented Gey and Gey buffer (with the 
required amount glucose) was added to each well. 5l of drug (at 100x the required 
concentration) or appropriate vehicle solution was added to each well as required. 
The plate was then gently agitated and then incubated at 95% O2/5% CO2 
atmosphere at 37 ºC for 1 or 2 hours. Once the time period had elapsed, the plate 
was agitated and then transferred to a fridge/freezer for 5 minutes. Then, a 0.25ml 
samples were taken from each well to determine the amount of insulin secreted by 
RIA. Insulin secretion was determined as ng of insulin secreted/islet/hour. 
 
Glucose (3mM) was used to determine basal insulin secretion rates for INS-1 823/13 
cells instead of 4mM glucose which was used for islets. Compilation, normalisation 
and statistical testing of experimental data were carried out as described in Section 
2.4.5.  
 
2.4.4 Islet perifusion studies 
The buffer used for the islet perifusion studies was Gey & Gey buffer supplemented 
with 4mM glucose and 1% (w/v) BSA (fraction V) which was kept under a 95% O2/5% 
CO2 atmosphere. The perifusion system was housed in a Stuart Scientific S160D 
incubator (Staffordshire, UK) and the temperature was kept at 39ºC for the duration of 
the perifusions to maintain the islets at 37 ºC. Batches of 65-75 islets were loaded into 
glass wool plugged chambers. The chambers were perifused with buffer at a rate of 
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1ml of buffer per minute using a Minipuls 3 peristaltic pump (Gilson, USA). The 
glucose concentration was adjusted by addition of an appropriate volume of 1M 
glucose stock solution to the perifusion buffer reservoir (the volume of glucose 
solution added was dependent on reservoir volume). Vehicle or drug (at 100x the 
working concentration) was infused at a rate of 10l/minute by a second Minipuls 3 
peristaltic pump. Figure 2.2 shows a simplified diagram of how the equipment was 
arranged. The islets were equilibrated for 20-40 minutes (once the temperature had 
stabilised) before the start of each experiment, after which the media was collected in 
LP3 tubes in 2 minute fractions. The fractions were either used immediately for RIA or 
stored at -20ºC for assaying at a later time point. Insulin secretion rates were 
determined as pg of insulin secreted/islet/minute. 
 
95% O2/ 5%CO2
LP3 tubeBuffer 
reservoir
Drug 
reservoir
Peristaltic 
pumps
Needle
Islet
chamber
Glass 
wool plug
Islets
 
Figure 2.2  A diagrammatic representation of the perifusion equipment. Buffer is 
peristaltically pumped from the buffer reservoir, through the islet chamber and 
collected in LP3 tubes. Drug is peristaltically pumped from the drug reservoir and 
infused into buffer line. For simplicity, multiple islet chambers and lines (with individual 
drug/vehicle reservoirs), and the S106D incubator (in which the equipment was 
housed) were excluded from the diagram. For the duration of the experiment, the 
buffer reservoir was kept under a 95% O2/5% CO2 atmosphere. Buffer was pumped 
(at a rate of 1ml/minute) from the reservoir to the islets and then collected in LP3 
tubes. When appropriate, the glucose concentration of the buffer was adjusted by the 
addition of 1M glucose solution directly to the reservoir which was then agitated to 
ensure thorough mixing. When required drug stock (or vehicle control) was infused at 
100 times the required concentration, by peristaltic pump at a rate of 10l/minute, 
upstream of the islets through the buffer line which fed to the appropriate islet 
chamber.  
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2.4.5 Data analysis 
For pharmacological studies (e.g. use of endogenous compounds/receptor 
agonists/receptor antagonists at fixed concentrations), the mean insulin secretion rate 
were determined for each group (both control and test groups). Outliers were removed 
based on objective judgement to reduce variation (standard error of the mean  10, if 
possible) and was based on the following rules: each group within the experiment 
were considered separately, no more than half the replicates were removed with no 
less than three replicates left per condition; the mean insulin secretion rates within the 
experiment were then standardised against the 20mM glucose control group (unless 
stated otherwise). The mean insulin secretion rate for each condition, from each 
individual experiment, was then averaged again to give the overall mean insulin 
secretion rate. Mean insulin secretion rates were expressed as a percentage of the 
20mM glucose control (which was always 100%). Variation was expressed as the 
mean ± 1 SD unless stated otherwise. One-way ANOVA analysis was used in co-
junction with Tukey’s post-hoc testing. For experiments where the glucose-dependent 
effects of a compound were being tested all conditions were included in the statistical 
analysis. However, for studies where the effects of treatment/s were exclusively 
examined at 20mM glucose, the 4mM glucose control was not included in the 
statistical analysis because it was only used to asses islet viability. For all experiments 
a P value < 0.05 was considered significant. 
 
Firstly for concentration-response curves, different methods were used to establish 
IC50 values, and to produce the figures showing the average rate of insulin secretion 
at 20mM glucose at all drug concentrations. The IC50 value refers to the concentration 
of drug required to cause a 50% inhibition of the variable being examined. IC50 values 
were first calculated for each experiment with the raw insulin secretion data using 
Prism 5.0 software by the following method (GraphPad software Inc., CA, USA). The 
drug concentrations were then converted to logarithms. The data were then 
normalised using the built-in functions, whereby the smallest value in each data set 
was set to 0% and the largest to 100%. The log10IC50 for each experiment was 
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calculated using the built-in non-linear regression for variable slope analysis 
(log[inhibitor] vs. normalised response). The equation for the variable slope analysis 
was Y=100/(1+10^((Log10IC50-X)*HillSlope))). The fitting method for the non-linear 
regression for variable slope analysis was the least squares ordinary fit and no 
constraints or weighting methods were used. Data from these experiments were 
expressed as the antilog of the mean log10IC50 value with the 95% confidence 
intervals (95% CI). The 95% confidence intervals were calculated from the antilog 
pIC50 values using the built-in PRISM column analysis feature. The figures used to 
display concentration-response data were compiled from 20mM glucose control 
normalised data in the same way as the basic pharmacological studies but were not 
used for calculation of IC50 data. Variation is expressed as mean ± 1 SD. Statistical 
significance (P< 0.05) was determined from all the data sets performed at 20mM 
glucose by one-way ANOVA analysis with Dunnett’s post-hoc test using the 20mM 
glucose control as the control group. 
 
Post-hoc tests were only used in conjunction with one-way and two-way ANOVA 
analysis when the ANOVA analysis determined that there was significant variation 
between the means. Where significant differences were found (P< 0.05), only 
comparisons of interest were displayed/reported in the results chapters. For example, 
if the insulin secretion rates were significantly different (P< 0.05) between the 8mM 
glucose control and the “20mM glucose + agonist” groups, this information was not 
included because the conditions were not directly comparable. 
 
2.4.5.1 Justification for the statistical analysis tests used 
The data are typically expressed as a percentage of the mean insulin secretion rate of 
the 20mM glucose control (unless stated otherwise). The data were normalised to 
reduce the amount of inter-experimental variation, as the difference between basal 
and maximal secretion insulin rates can vary between two to tenfold which further 
contributes to variation within the data sets. This variation can have a profound effect 
as a treatment may have a consistent effect inter-experimentally (e.g. 50% inhibition 
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at a specific glucose concentration compared to control) but this is not apparent in the 
compiled un-normalised data. By normalising the data, the variation is reduced but 
this does not result in a loss of data as the relative changes in insulin secretion rates 
are more informative than the changes in quantity of insulin released. Indeed, no 
external controls were included in the radioimmunoassay, meaning there was no inter-
assay standardisation; it cannot be assumed that the assays estimated insulin levels 
to a comparable degree. The normalised data was then entered into Prism 5 software 
(Graphpad, CA, USA) for statistical analysis. 
 
As data sets were standardised to a control, the use of non-parametric testing would 
have been statistically appropriate as normal distribution of data cannot be assumed 
as small experimental n numbers were used. Yet non-parametric testing has lower 
statistical power compared to parametric testing and use of non-parametric testing 
may have resulted in higher rates of type 2 statistical (false negative) errors. It was 
assumed that insulin secretion rates show normal distribution (as observed in most 
biological systems) and this was used to justify the use of parametric testing instead 
the use of non-parametric testing. 
 
2.5 Endocannabinoid metabolism assay 
 
The endocannabinoid metabolism assay is based on the methods described by Holt 
et al. (2005) and Boldrup et al. (2004). AEA consists of a hydrophilic ethanolamine 
head group covalently attached to a hydrophobic arachidonic acid (AA) molecule. 
When the [3H]-AEA is hydrolysed, the [3H]-ethanolamine resides in polar phases, 
whereas the liberated AA moiety and non-hydrolysed [3H]-AEA will reside in non-polar 
phases. By measuring the level of -radiation emitted from samples from the 
hydrophilic phase then the level of AEA hydrolysis can be determined by the use of 
internal controls included in the assay and the quantity of AEA added. 
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2.5.1 Pancreatic and liver tissue protocol 
The buffer used for the preparation of the tissue homogenates was Gey & Gey buffer 
(Section 2.3.1) supplemented with 4mM glucose and 1% (w/v) BSA. Pancreatic and 
liver tissue (taken from the small liver lobe which was situated at the bottom of the 
stomach and behind the duodenum) were taken from the same male Wistar rat and 
were immediately placed in buffer on ice. Contaminating tissue from the pancreatic 
tissue including the spleen, adipose tissue, lymph nodes and large blood vessels was 
removed and the pancreatic tissue was placed back into buffer. The amount (wet 
weight) of tissue to be homogenised was weighed, after which liver tissue was 
transferred to a 1.5ml microfuge tube and pancreatic tissue was transferred to a 25ml 
universal tube. To each tube, ice cold fresh buffer was added until a pre-determined 
volume was reached. The tissues were then homogenised using an Ultra Turrax T8  
homogeniser (Ika, Staufen, Germany) on the fourth setting for 10-30 seconds on ice 
until smooth and homogeneous in appearance. 
 
The buffer used for the endocannabinoid metabolism assays was Gey & Gey buffer 
supplemented with 4mM glucose and 1% (w/v) BSA. Each condition consisted of 
three replicates of 190l of tissue homogenate in 6ml polypropylene scintillation tubes 
(Sarstedt, Leicester, UK) and two additional scintillation tubes that contained 190l of 
the Gey & Gey assay buffer which were used as controls (non-enzymatic AEA 
hydrolysis and total radiation). Where appropriate, 3l of 1M glucose and/or 2l of 
100M URB597 were added to conditions in order to achieve a glucose or URB597 
concentration of 20mM and 1M, respectively. The homogenates were then incubated 
and agitated for 15 minutes at 37ºC using a shaking water bath. Once the 15 minutes 
had elapsed, then 10l of 40M [3H]-AEA solution was added to each condition to 
give a final AEA concentration of 2μM. The 40M [3H]-AEA solution was prepared by 
the addition of 2l [3H]-AEA to 200l of non-radiolabeled 40M AEA solution (to give 
~20 000cpm/l). The tubes were then further incubated and agitated for 30 minutes. 
At the end of the second incubation period, 400l of 0.5M HCl solution with 4% (w/v) 
charcoal was added to each sample and one of the controls (non-enzymatic AEA 
hydrolysis). For the total radiation control, 400l of 0.5M HCl solution (without 
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charcoal) was added. Each tube was then vortexed and left to stand. After 30 
minutes, the tubes were then centrifuged at 3000rpm for 5 minutes using a Centuar 2 
centrifuge (MSE, London, UK). 200l of the supernatant was then transferred to fresh 
scintillation tubes. To each tube, 3ml of scintillation fluid (PerkinElmer, MA, USA) was 
added and the -radiation levels for each tube were counted for 3 minutes using a 
Packard 1900TR liquid scintillation analyser (Perkin-Elmer, MA, USA). AEA hydrolytic 
activity was expressed as pmol of AEA hydrolysed per minute per mg of wet weight 
tissue. 
 
2.5.2 Islet protocol 
The pancreatic and liver tissue protocol was altered in the following ways for use with 
islets. 190l of buffer at the required glucose concentration were added to 1.5ml 
microfuge or scintillation tube. To this, 3-20 islets were added to each tube. URB597 
was used at a final concentration of 10μM and islets were pre-incubated for 30 
minutes. This was done in order to validate, the URB597 pre-incubation protocol 
described in Section 3.2.3.1. All other variables were kept constant. AEA hydrolytic 
activity was expressed as pmol of AEA hydrolysed per minute per islet. 
 
2.6 Radioimmunoassay 
 
Radioimmunoassays are competition based assays that allow the quantification of ng 
levels of protein. The assays utilise antigen-specific (e.g. anti-insulin) antibodies, 
which will bind to a target ligand (referred herein as antigen) with high specificity (but 
not irreversibly) to form an antibody-antigen complex. In radioimmunoassays, a 
sample consists of a fixed volume of sample containing either a known or unknown 
amount of non-radiolabeled target (“cold”) antigen, to which fixed amounts of 
radiolabeled (“hot”) antigen and a limited amount of antibody are added in each assay 
sample. The samples are then left for a set amount of time to allow a stable 
equilibrium (in the ratio of antibody bound “hot” and “cold” antigen) to form. At the end 
of the equilibration period, a separation step is performed to separate antibody-
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antigen complex from unbound reagents. Typically, this involves the precipitation of 
an antigen-antibody complex, which can be separated from the unbound “hot” and 
“cold” antigen by centrifugation to form a pellet. The amount of radioactivity in the 
pellet will be dependent on the ratio of “cold”-to-“hot” antigens. Thus, the level of 
radioactivity in the pellet will be inversely proportional to the concentration of “cold” 
antigen. Standard samples, of known amounts of “cold” antigen, are included in an 
assay to allow a standard (also known as a calibration) curve can be constructed, 
where concentration of the cold antigen (x -axis) is plotted against radioactivity (y-
axis). From this standard curve, the concentration of antigen in a sample can be 
estimated by the amount of radioactivity in the antigen-antibody complex. 
 
2.6.1 Insulin RIA 
All solutions were made using the insulin assay buffer (IAB, Section 2.3.2). 
Recombinant human insulin was used as the standard and a stock was initially 
prepared in 10% (v/v) acetic acid/ 1% (w/v) BSA at a concentration of 1mg/ml. The 
standard curve consisted of insulin standards (0.125-8ng/ml) constructed by two-fold 
serial dilution of the 8ng/ml standard in IAB. The standard curve also includes non-
specific binding and total radioactivity controls. All samples and standards were 
assayed in duplicate. 50μl sample or standards were incubated with 50μl of 1:6000 
guinea pig anti-bovine insulin anti-serum and 50μl of 125I labelled insulin (to give 
approximately 2500cpm/tube), at 4ºC, overnight.  
 
Two different methods were employed to separate the primary antibody from solution. 
The first method used 50μl of 1:1 Sac-Cel solution(Donkey anti-guinea pig secondary 
Ab coupled to cellulose : IAB), which was added to each assay sample, mixed and left 
for 20-30 minutes at room temperature before 1ml ddH2O was added to each tube 
and the tubes were then centrifuged at 4000rpm (Eppendorf Centrifuge 5810R) for 5 
minutes at room temperature. The supernatant was then carefully aspirated off, 
making sure not to disturb the pellet. The second method used 50l of 1:10 goat anti-
guinea pig secondary antibody, the tubes were mixed and then incubated at 4ºC for 
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10 minutes. 500l of 5% (w/v) PEG (molecular weight 8000) solution to the tubes 
which were then further incubated for a further 2-4 hours at 4ºC. The PEG solution 
acts as a precipitating agent for the secondary-primary antibody complex which would 
otherwise normally need an additional overnight incubation period (Peterson & 
Swerdloff, 1979). The PEG solution also contains a small quantity of Brilliant Blue 
(Sigma Aldrich; Dorset, UK) which is used to visually identify the pellet. The samples 
were then centrifuged at 3000rpm (Eppendorf Centrifuge 5810R) for 15 minutes at 4 
ºC and the supernatant was then carefully aspirated off, making sure not to disturb the 
pellet. 
  
The amount of  radiation being emitted by the pellets was counted using a Packard 
Cobra 2 -counter (Perkin-Elmer, MA, USA). The insulin content within each sample 
was automatically determined, as ng of insulin/ml, by interpolation of the RIA standard 
curve by the Packard Cobra 2 -counter. 
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3  
 
The acute effects of the 
endocannabinoid anandamide 
on insulin secretion from 
Wistar rat isolated pancreatic 
islets 
 
 70
3.1 Introduction 
 
The endocannabinoid system, as reviewed in Section 1.4, is involved in a number of 
systems, with intensive research being conducted with respect to role of the 
endocannabinoid system in energy homeostasis. Chronic dosing of mice with 
rimonabant (SR141716A, a CB1 receptor antagonist/inverse agonist) has been used 
in studies in vivo to examine whether CB1 receptor antagonism would act as an 
appetite suppressant, therefore, promoting weight loss (Ravinet Trillou et al., 2003). It 
was found that mice treated with rimonabant had reduced food intake and weighed 
less than vehicle-treated animals; however, the effects on food intake were transient, 
whereas weight loss persisted (Ravinet Trillou et al., 2003). Rimonabant has also 
been used in clinical trials and has been found to cause similar persistent weight loss 
in people who were either overweight or obese (Despres et al., 2005; Pi-Sunyer et al., 
2006).  As it was found to be an effective weight loss therapy, rimonabant was 
available for clinical use in 2006 as an anti-obesity treatment, until its withdrawal from 
clinical use in 2009 (see below). It is now thought that the effects of chronic 
rimonabant treatment are mediated through the central nervous system and 
peripheral tissues (Ravinet Trillou et al., 2003; Janiak et al., 2007; Nogueiras et al., 
2008).  
 
As described in Section 1.3.3, weight loss is recommended in patients with type 2 
diabetes who are obese, as even modest weight loss reduces the risk of 
cardiovascular events. Hence, rimonabant was also trialled in overweight/obese 
people who have type 2 diabetes (Scheen et al., 2006; Rosenstock et al., 2008). It 
was found in these clinical trials that people not only lost weight but rimonabant 
treatment also significantly reduced levels of glycated haemoglobin, fasting plasma 
glucose levels and insulin resistance (Scheen et al., 2006; Rosenstock et al., 2008). 
The reductions in glycated haemoglobin, fasting plasma glucose levels and insulin 
resistance were not primarily due to weight loss, indicating that other therapeutic 
effects were occurring. This suggests that blockade of CB1 receptor signalling may be 
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a novel treatment for type 2 diabetes. The blood glucose lowering effects of 
rimonabant has subsequently been reported in 12-month old Zucker obese rats 
(genetic model of obesity; Chapter 6) which appeared to be diabetic or have impaired 
fasting blood glucose with a mean blood glucose level of 10mM after 24-hour fasting 
(Janiak et al., 2007). It was also found in the same study that rimonabant treatment 
prevented loss of  cell mass and increased  cell numbers per islet suggesting that 
rimonabant protected islet viability (Janiak et al., 2007). The clinical use of rimonabant 
is no longer permitted in the USA and EU countries due to concerns over the 
development of depression and the risk of suicide (Johansson et al., 2009). Therefore, 
a greater understanding of how the endocannabinoid systems works in the periphery 
may allow more targeted modulation of endocannabinoid signalling to be developed 
for the treatment of type 2 diabetes without significant CNS side-effects.  
 
In further support of a possible role of the endocannabinoid system in the treatment of 
type 2 diabetes, it has been reported in rodent studies in vivo that acute application of 
CB1 and CB2 receptor specific agonists and antagonists prior to intraperitoneal 
glucose loading affects the subsequent clearance of excess plasma glucose 
(Bermudez-Siva et al., 2006; Bermudez-Silva et al., 2007). As described in Section 
1.1, the regulation of blood glucose is the result of the interplay of the islet hormones 
(glucagon and insulin) and their subsequent effects on peripheral tissues. Therefore, 
the observed decreases in glucose clearance caused by CB1 receptor agonism and 
CB2 antagonism prior to glucose loading may be due to decreased insulin release 
from islets and/or decreased peripheral insulin sensitivity. Several studies have 
reported that various components of the endocannabinoid system are expressed 
within mouse, rat and human islets, suggesting that the endocannabinoid system is 
active in these tissues (Juan-Pico et al., 2006; Bermudez-Silva et al., 2007; 
Bermudez-Silva et al., 2008; Nakata & Yada, 2008; Starowicz et al., 2008; Tharp et 
al., 2008; Bermudez-Silva et al., 2009). While the expression levels and cell 
distributions of different components of the endocannabinoid system still remains 
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controversial, it appears that the in vivo effects of cannabinoids on glucose tolerance 
may have involved a direct effect of islet function.  
 
Despite the lack of information regarding what role(s) the endocannabinoid system 
plays within islets, data from in vivo rodent and clinical studies suggest that that 
endocannabinoid system may play a direct role in preserving islet function in 
pathological disease states. To determine whether endocannabinoid signalling within 
islets may offer novel treatments for type 2 diabetes, it is first necessary to 
characterise the system in islets which have been isolated from lean non-diabetic rats. 
Therefore, the principal aim of this chapter was to examine whether endocannabinoid 
signalling acutely effects insulin secretion. In order to achieve this, anandamide (AEA) 
was used in freshly isolated islets of Langerhans from male Wistar rats. 
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3.2 Methods 
 
3.2.1 Materials 
All drugs and buffers were prepared as described in Sections 2.2.  
 
3.2.2 Animals 
All procedures were performed using tissues obtained from male Wistar rats whose 
weights ranged from 230-350g. Animals were housed and killed as described in 
Section 2.1.  
 
3.2.3 Insulin secretion studies 
Islets were isolated from male Wistar rats according to the isolation procedure 
described in 2.4.1.1.  
 
3.2.3.1 Static incubations 
Freshly isolated islets were used in static incubation studies, as described in 2.4.2. 
Once the hour incubation had finished, then samples were taken from each condition 
and the amount of insulin in the samples was determined by RIA as described in 2.6. 
Analysis of experimental data was carried out as described in 2.4.5. Where indicated, 
the Spearman rank (non-parametric) correlation test was used to determine whether 
there was a significant correlation between two parameters.  
 
For experiments where 10M URB597 (a fatty acid amide hydrolase specific inhibitor) 
was used, islets were pre-incubated for 30 minutes at 4mM glucose with either 
URB597 or vehicle (ethanol at a final concentration of 0.34% (v/v)). A pre-incubation 
period of 30 minutes was chosen as a high level of FAAH inhibition should occur 
within this time-frame (Ahn et al., 2007) without compromising islet function, which 
diminishes with time. While other studies have found FAAH to be expressed within 
islets, the level of FAAH activity within islets has not been characterised (Bermudez-
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Silva et al., 2008; Starowicz et al., 2008; Tharp et al., 2008). It was decided that 
URB597 would be used at 10M, despite the possibility of non-specific actions 
occurring, as it was uncertain whether URB597 at lower concentrations would 
successfully penetrate the islets in sufficient time to successfully inhibit FAAH activity 
(Ahn et al., 2007; Zhang et al., 2007). Following the pre-incubation period, test 
reagents were added and the 96-well plate was then agitated by hand to ensure 
thorough mixing before the plate was incubated for a further hour. AEA was used at 
10M in these URB597 experiments as the largest difference in insulin secretion rates 
was observed at this concentration between AEA responsive and non-responsive 
islets (based on compiled data, Figure 3.3). 
 
3.2.3.1 Islet perifusion 
The perifusion equipment was set up as described in 2.4.4. For the first ten minutes of 
the experiment, islets were exposed to 4mM glucose and after this time point the 
islets were exposed to 20mM glucose. Islets were then left for 20 minutes at 20mM 
glucose to establish glucose responsiveness. Islets were either continuously exposed 
to 30M AEA or vehicle control (ethanol 0.6% (v/v) - final concentration) at 20mM 
glucose for 30 minutes. A concentration of 30M AEA was chosen as it was found to 
cause a 50% (and reproducible) inhibition of insulin secretion in statically-incubated 
islets (Section 4.3.1). 
 
Islets were considered to be glucose-responsive if the islets from the vehicle group 
were found to display a biphasic response of insulin release as a result of exposure to 
20mM glucose, see Section 1.2.2. Additionally for experimental data to be useful, 
islets from the AEA treatment group had to show similar responses to glucose within 
the first 30 minutes as the control group (i.e. prior to exposure to AEA). This was to 
demonstrate islet viability and that insulin secretion rates were comparable between 
vehicle and test groups during the first 30 minutes- prior to the addition of AEA or 
vehicle. Insulin secretion for each individual time point was expressed as a 
percentage of the mean basal insulin secretion rate (the first 10 minutes, which was 
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set at 100%). The area under curve (AUC) was then calculated using the integration 
function in Prism 5 using the trapezium rule. The AUC was compiled into 10 minute 
bins and was subjected to two-way ANOVA analysis. 
 
3.2.4 Endocannabinoid metabolism assays 
Preparation of homogenised tissues and isolated islets were performed as described 
in Section 2.5. The experiments were performed and AEA hydrolytic rates calculated 
as described in Section 2.5. 
 
Homogenised pancreatic tissue or freshly isolated islets were incubated at either 4mM 
or 20mM glucose to determine whether there was glucose-dependent hydrolysis of 
AEA. In addition to this, pancreatic and liver tissue homogenates or islets were 
incubated in either the absence or presence of URB597 in order to establish FAAH 
activity. For homogenised pancreas studies, a pre-incubation period of 15 minutes 
with vehicle or 1M URB597 was used. For whole islet assays, cells were pre-
incubated for period of 30 minutes with vehicle (ethanol 0.34% (v/v) final 
concentration) or 10M URB597. Conditions were carried out in duplicate or triplicate. 
Liver homogenates were used at 4mM glucose and employed as a positive control for 
AEA hydrolysis and URB597 mediated inhibition of FAAH activity. FAAH activity was 
calculated as the difference in the AEA hydrolytic rates between the control and 
URB597 pre-treated experimental means. Significant difference between the means 
(FAAH activity was not included as this was not raw data) was then tested using one-
way ANOVA followed by Tukey’s post-hoc test. All data are expressed as the mean ± 
SD. 
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3.3 Results 
 
3.3.1 Glucose- and concentration-dependent effects of 
anandamide on insulin secretion in isolated islets of Langerhans 
In static incubations, rat isolated islets were incubated for one hour in the absence or 
the presence of 1M AEA at basal (4mM), intermediate (8mM), and maximal (20mM) 
levels of glucose-stimulated insulin secretion. AEA did not affect basal or intermediate 
levels of glucose-stimulated insulin secretion but AEA significantly inhibited insulin 
secretion at 20mM glucose (Figure 3.1). Islet perifusions were performed to determine 
the effects of AEA on the kinetics of insulin secretion at 20mM glucose. On exposure 
of the islets to 20mM glucose (t= 10 minutes), there was a small, transient increase in 
insulin secretion rates which lasted for ~10 minutes (first phase), immediately followed 
by a much larger and sustained second phase of insulin secretion (Figure 3.2A). The 
time-course and biphasic response in insulin secretion concur with other studies using 
perifused rat islets, however the level of response, especially the first phase, was 
lower than that typically reported (Section 1.2.2). Area under curve analysis of the 
compiled perifusion data demonstrated that differences between the vehicle and AEA 
groups were not statistically significant prior to and during exposure of the islets to 
30M AEA or vehicle (Figure 3.2B). 
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Figure 3.1  The effects of anandamide (AEA) on glucose-dependent insulin secretion. 
Islets were incubated at 4mM, 8mM or 20mM glucose in the absence (control) or 
presence of 1M AEA. All graphs are produced from the same data set that have 
been normalised according to different criteria. All results are presented as mean 
insulin secretion rates ± SD (n= 10). A) Insulin secretion rates have not been 
normalised. ** P< 0.01 vs. 20mM glucose control. B) Results from each experiment 
have been normalised against the 20mM glucose control. *** P< 0.001 vs. 20mM 
glucose control. C) Results from each experiment have been normalised against the 
difference (glucose response) between the insulin secretion rates observed for the 
4mM (0%) and 20mM (100%) glucose controls. ** P< 0.01 vs. 20mM glucose control. 
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Figure 3.2  The effects of 30M anandamide (AEA) on insulin secretion at 20mM 
glucose from perifused islets. A) Islets were perifused at 37ºC in medium containing 
4mM glucose for 30 minutes prior to the start of the experiment (at  t= 0). Insulin 
secretion was determined at 2 minute intervals. At t= 10 minutes, 20mM glucose was 
introduced into the medium. AEA (30M) or vehicle (control, 0.6% (v/v) final 
concentration) was infused at t= 30 minutes (indicated by the arrow). Results 
represent the mean insulin secretion rates ± SD for three individual experiments. B) 
Area under curve for 10-minute blocks was calculated from the data in Figure A 
according to the protocol in Section 3.2.3.1. 
 
To ascertain whether the effects of AEA were concentration-dependent, 
concentration-response experiments were performed at 20mM glucose. It was found 
that AEA inhibited insulin secretion in a concentration dependent manner with AEA 
fully inhibiting insulin secretion at 100M. The mean IC50 for 10 of the 13 AEA 
concentration-response data set (the statistical software was unable to fit the data 
from 3 experiments to a sigmoidal curve) was calculated as 1.6M (95% CI: 227nM to 
4.0M; Figure 3.3A). The mean Hill slope was calculated as -2.5 ± 2.6. 
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Figure 3.3  The effects of increasing concentrations of anandamide (AEA) on insulin 
secretion at 20mM glucose. A) Islets were incubated at 20mM glucose with various 
concentrations of AEA. Basal insulin secretion rates for all (n= 13), responsive (n= 5) 
and non-responsive groups (n= 8) were 34.7 ± 10.8%, 37.6 ± 7.9% and 32.9 ± 12.4% 
respectively. Results are presented as mean insulin secretion rates ± SD * P< 0.05, 
*** P< 0.001, +++ P< 0.001 vs. 20mM glucose control. B) Distribution frequency of 
log10IC50 values (calculated by fitting individual AEA concentration-response 
experimental results to sigmoidal curves; n= 10). 
 
On further analysis of the data, it appeared that in 8 of the 13 experiments, AEA 
displayed a lack of inhibitory effect on insulin secretion at 1M. The compiled 
concentration-response data from these 8 experiments suggest that AEA, at 
concentrations  10μM, was unable to cause a substantial (> 25%) reduction in insulin 
secretion rates. These islets were labelled as being “non-responsive” to AEA and 
exhibited an IC50 of 12.3M (95% CI: 6.8M to 19.4M; n= 5, the statistical software 
was unable to fit the data to a sigmoidal curve for 3 of the 8 experiments; Figure 
3.3A). The mean Hill slope for the non-responsive islets was calculated as -3.6 ± 3.0. 
The islets from the remaining five experiments were deemed to be responsive to AEA, 
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with AEA displaying a clear concentration-dependent effect as a marked inhibition of 
insulin secretion was observed at 100nM with the IC50 for the AEA responsive islets 
calculated as 220nM (95% CI: 21.9nM to 2.2M). The mean Hill slope for the 
responsive islets was calculated as -1.3 ± 1.6. In both populations of islets, 100M 
AEA was found to fully reduce glucose-stimulated insulin secretion to within basal 
insulin secretion levels (Figure 3.3A). The distribution of all AEA IC50 values was not 
found to be normally distributed, instead AEA-response and non-responsive islets 
appear to be distributed about two separate means (Figure 3.3B) 
 
As the effects of 1μM AEA were glucose-dependent the responsiveness of islets may 
have been linked to how glucose responsive the islets were. Further analysis of all the 
1μM AEA at 20mM glucose data did not reveal a significant correlation between the 
glucose- and AEA-responsive states of the islets (Figure 3.4). The AEA concentration-
response data was also re-analysed with the insulin secretion rates normalised 
against the glucose response (Figure 3.5.A). The distribution of the log10IC50 values 
for AEA calculated by this method were found to occur independently (P> 0.05) of the 
islets glucose responsiveness as determined by the Spearman rank correlation test 
(Figure 3.5.B). 
 
 
Figure 3.4  The individual experimental effects of 1μM AEA at 20mM glucose plotted 
against the glucose responsiveness of the islets. Data has been taken from the 1μM 
AEA glucose response and AEA concentration-response data sets. % inhibition of the 
glucose response was calculated as 100x (20mM glucose control - 1μM AEA at 20mM 
glucose)/(20mM glucose control - 4mM glucose control). 
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Figure 3.5  The effects of increasing concentrations of anandamide (AEA) on insulin 
secretion at 20mM glucose expressed as a function of glucose responsiveness. A) 
Islets were incubated at 20mM glucose with various concentrations of AEA. Results 
have been normalised against the difference (glucose response) between the insulin 
secretion rates observed for the 4mM (0%) and 20mM (100%) glucose controls. 
Results are presented as mean insulin secretion rates (n= 13). B) The AEA 
responsive state of the islets (represented by the individual log10IC50 values calculated 
from the data presented in figure A) plotted against the corresponding glucose 
responsiveness of the islets (n= 10). 
 
3.3.2 N-acylethanolamine metabolism in islets 
As described above, there appeared to be two populations of islets based on the level 
of inhibition caused by 1M AEA on 20mM GSIS (glucose stimulated insulin 
secretion). One possible cause of the apparent variability could have been due to 
variations in local metabolism of anandamide and so additional experiments were 
carried out with the metabolically stable analogue, methanandamide. 
Methanandamide (10M) consistently inhibited insulin secretion at 20mM glucose but 
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did not affect insulin secretion at basal and intermediate levels of GSIS (Figure 3.6A). 
The concentration-response curve for methanandamide appeared similar to that of the 
AEA responsive data as there was a clear concentration-dependent inhibition of 
insulin secretion. The IC50 of methanandamide was 682nM (95% CI: 94.2nM to 
4.9M; Figure 3.6B) and the mean Hill slope was calculated as -3.0 ± 3.2. However, 
the mean IC50 value for methanandamide was not statistically different from the mean 
IC50 values calculated for the either the anandamide responsive or anandamide non-
responsive groups. 
 
A 
 
B 
 
Figure 3.6  The glucose and concentration-dependent effects of methanandamide on 
insulin secretion. A) Islets were incubated at 4mM, 8mM, or 20mM glucose in the 
absence (control) or presence of 10M methanandamide. Results are presented as 
mean insulin secretion rates ± SD (n= 5) ***P< 0.001 vs. 20mM glucose control B) 
Islets were incubated at 20mM glucose with increasing concentrations of 
methanandamide. The basal insulin secretion rate for the methanandamide 
concentration-response curve data was 33.2 ± 18.1 %. Results are presented as 
mean insulin secretion rates ± SD (n= 5) ** P< 0.01, *** P< 0.001 vs. 20mM glucose 
control. 
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The fatty acid amide hydrolase (FAAH) specific inhibitor URB597 (10M) alone did not 
affect insulin secretion at 4mM or 20mM glucose (Figure 3.7A). Hence, pre-incubation 
of the islets with 10μM URB597 was deemed appropriate for future use with AEA. It 
was found that pre-incubation of islets with 10M URB597 did not affect islet 
responses to AEA (Figure 3.7B). Upon further analysis of the data in Figure 3.7B, 
islets where 10M AEA inhibited insulin secretion, 10M URB597 also inhibited 
insulin secretion, whereas if 10M AEA did not affect insulin secretion, neither did 
10M URB597 (Figure 3.7C). Subsequent re-analysis of the URB597 glucose-
response data found there were two experiments where pre-incubation with URB597 
inhibited insulin secretion by > 25% (Figure 3.7A).  
 
In light of the URB597 static incubation experiments, endocannabinoid metabolism 
assays were performed to ascertain the amount of AEA hydrolysis occurring in islets 
and to determine whether URB597 pre-treatment was effective at blocking AEA 
hydrolysis. It was found that much larger quantities of homogenised pancreas were 
required in comparison to homogenised liver to detect measurable levels of AEA 
hydrolysis (Figure 3.8A). Additionally AEA hydrolytic rates in homogenised pancreatic 
samples were unaffected by glucose. In total, three endocannabinoid metabolism 
assays were performed with whole tissue homogenates. The level of AEA hydrolysis, 
when standardised against the amount (wet weight) of tissue used, in homogenised 
liver samples was found to be significantly higher in comparison to AEA hydrolytic 
rates in homogenised pancreatic samples (Figure 3.8B & 3.8C). Pre-incubation of 
homogenates with 1M URB597 was found to block fully AEA hydrolysis in liver 
samples (Figure 3.8B), but only blocked approximately a third of AEA hydrolytic 
activity in pancreatic samples (Figure 3.8C). Use of whole islets in the 
endocannabinoid metabolism assays was attempted on several occasions but 
measurable amounts of hydrolysis were not observed in islets as AEA hydrolytic rates 
were less than or equal to the AEA hydrolytic rates observed in the non-enzymatic 
control (Figure 3.9). 
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Figure 3.7  The effects of URB597 on AEA induced inhibition of glucose-mediated 
insulin secretion. A) Islets were pre-incubated with either vehicle (control) or 10M 
URB597. Insulin secretion was then determined at either 4mM or 20mM glucose. 
Results are presented as mean insulin secretion rates ± SD (n= 6). B) Islets were pre-
incubated with either vehicle (control) or 10M URB597. Insulin secretion was then 
determined at either 4mM or 20mM glucose in the absence or presence of 10μM AEA. 
Results are presented as mean insulin secretion rates ± SD (n= 7). * P< 0.05 vs. 
20mM glucose control. C) Division of the data presented in B, whereby experiments in 
which URB597 did not inhibit insulin secretion are shown on the left of the X axis 
break (n= 3) and experiments where URB597 was found to inhibit (> 25%) insulin 
secretion on the right of the X axis break (n= 4). Islets were pre-incubated with either 
vehicle (control) or 10M URB597. Insulin secretion was then determined at either 
4mM or 20mM glucose. Results are presented as mean insulin secretion rates ± SD. 
NS Not significant; *** P< 0.001 vs. 20mM glucose. 
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Figure 3.8  The effects of URB597 on AEA hydrolysis in homogenised samples of 
liver and pancreatic tissues. A) Samples of homogenised tissues were pre-incubated 
in the absence or presence of 1M URB597 for 15 minutes prior to an incubation with 
2M [3H]-AEA at 4mM or 20mM glucose for 30 minutes. Each condition was 
performed in triplicate. AEA hydrolysis is expressed as the % of [3H]-AEA hydrolysed. 
Data shown are the mean ± SD from one representative experiment. AEA hydrolysis 
in rat liver (B) and pancreas (C) where AEA hydrolytic activity was standardised 
according to wet weight of tissue used. Data shown are the mean ± SD (n= 3) * P< 
0.05 vs. total liver activity. 
C 
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Figure 3.9  The effect of URB597 on AEA hydrolysis in whole islets. Islets were pre-
incubated at 4mM glucose in the presence of 10M URB597 or a vehicle control for 
30 minutes prior to a 30 minute incubation with 2M [3H]-AEA. Each condition was 
performed in duplicate. AEA hydrolysis is expressed as the % of [3H]-AEA hydrolysed. 
Data shown are the mean hydrolytic activities from one representative experiment 
 
3.3.3 Effects of clonidine on insulin secretion at 20mM glucose 
The potent 2-adrenoceptor agonist clonidine was used to ascertain whether the 
responsive state of islets to AEA was due to the loss or degradation of cell surface 
receptors, which may have occurred during islet isolation.  When islets were 
incubated from 1 hour at either 4mM or 20mM glucose in the absence or presence of 
100nM clonidine or 10M AEA, it was found that clonidine consistently inhibited 
insulin secretion, whereas 10M AEA did not (Figure 3.10). 
 
Figure 3.10  The effects of 100nM clonidine and 10M anandamide (AEA) on insulin 
secretion at 20mM glucose. Islets were incubated at 4mM or 20mM glucose for 1 hour 
in the absence (control) or presence of clonidine or anandamide. Results are 
presented as mean insulin secretion rates ± SD (n= 5) ** P< 0.01 vs. 20mM glucose 
control. 
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3.4 Discussion 
 
The endocannabinoid AEA was found to inhibit insulin secretion in a glucose-
dependent manner. Further experimentation also found that the effects of AEA on 
insulin secretion were concentration-dependent. Furthermore, the concentration-
dependent effects of AEA on insulin secretion appeared to be governed by the 
responsive state of the islets as there appeared to be two populations of islets, 
responsive and non-responsive. In an effort to determine whether islet sensitivity to 
AEA was due to differing levels of AEA hydrolysis between populations of islets, 
methanandamide (a non hydrolysable analogue of AEA) was used. Methanandamide 
was also found to inhibit insulin secretion in a glucose- and concentration-dependent 
manner similar to AEA in AEA-responsive islets (Figure 3.3A & 3.4B). Pre-incubation 
of islets with the fatty acid amide hydrolase (FAAH) inhibitor URB597 did not affect 
islet responsiveness to AEA, but in some experiments URB597 was found to inhibit 
insulin secretion too. Endocannabinoid metabolism assays were performed to 
determine whether URB597 pre-treatment was effective in blocking FAAH activity. 
However, it was found that AEA hydrolysis in control islets was too low for the 
metabolism assay to detect, therefore, it remains unclear whether URB597 pre-
treatment in islets was effective in blocking AEA metabolism. 
 
3.4.1 Effects of anandamide on glucose-stimulated insulin 
secretion 
It was initially found that AEA inhibited GSIS, albeit with tissue variability (Figure 3.1). 
To date, five studies have examined the effects of AEA on insulin secretion in isolated 
islets. The studies by Juan-Pico et al. (2006) and Nataka & Yada (2008) have 
reported that AEA (in mouse islets) inhibits GSIS, whereas the study Bermudez-Silva 
et al. (2008) has reported that AEA (in human islets) potentiates insulin secretion. 
Therefore, the finding that AEA inhibits insulin secretion in this study is in agreement 
with the studies that have used mouse islets but not in studies that have used human 
islets, suggesting that AEA signalling in rodent islets is conserved but differs from that 
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in human islets (Juan-Pico et al., 2006; Bermudez-Silva et al., 2008; Nakata & Yada, 
2008). However, the recent study by Vilches-Flores et al. (2010) using islets isolated 
from Wistar rats, found that AEA produced effects similar to that found in Bermudez-
Silva et al. (2008), and disputes the species-dependent hypothesis. The islets used in 
this study and the studies by Juan-Pico et al. (2006) and Nataka & Yada (2008) were 
freshly isolated, whereas the islets used in the studies by Vilches-Flores et al. (2010) 
and Bermudez-Silva et al. (2008) were cultured at 5.5mM glucose for 16 hours or 3-5 
days in culture media, respectively. Differences between endocannabinoid signalling 
may be due to the activities of stress-related proteins being up-regulated in freshly 
isolated islets (as a result of the animals’ death and/or the process of islet isolation) in 
comparison to cultured islets (Ihm et al., 2009). Alternatively, islet culture could 
potentially bring about alterations in endocannabinoid signalling and/or metabolism 
pathways. Therefore, the differences in AEA signalling could be due methodological 
differences in the preparation of islets. 
 
Li et al. (2010) has recently reported that ACEA, a CB1 receptor agonist, potentiated 
insulin secretion from perifused ICR mouse islets at 20mM glucose but not 2mM 
glucose. Once again, this may be due to the use of cell culture affecting cannabinoid 
signalling as Li et al. (2010) cultured the islets overnight at 11mM glucose whereas, 
the previously mentioned study by Nataka & Yada (2008) found that ACEA inhibited 
insulin release from freshly isolated ICR mouse islets. This observation appears to 
provide further support the hypothesis that cell culture may affect cannabinoid 
signalling in islets. However, Li et al. (2010) measured insulin secretion from perifused 
islets whereas, Nataka & Yada (2008) used statically incubated the islets, therefore, 
differences in the affects of ACEA on GSIS may also be due to secondary signalling 
molecules being washed away before being able to affect -cell activity. Therefore, to 
test the hypothesis that cell culture affects cannabinoid signalling in islets, identical 
experiments should be performed with freshly isolated and cultured islets from the 
same preparation. 
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The findings in the present study indicate that AEA inhibits insulin secretion in a 
glucose-dependent manner which has not been reported in other studies (Juan-Pico 
et al., 2006; Bermudez-Silva et al., 2008; Nakata & Yada, 2008). However, it is not 
apparent whether the inhibitory effects of AEA within this study were limited by the 
glucose concentration at which the islets were incubated or whether inhibition of 
insulin secretion by AEA occurs once a threshold level of GSIS had been achieved. In 
this regard, the studies by Juan-Pico et al. (2006), Nataka & Yada (2008) and 
Bermudez-Silva et al. (2008) reported that the effects of AEA on insulin secretion 
rates occurred at the intermediate levels of GSIS. This was consistently not observed 
in the present study at 8mM glucose.  
 
In continuation to the static incubation studies, the effects of 30μM AEA were 
examined on insulin secretion from perifused islets. Overall, it did not appear as 
though AEA had an effect on insulin secretion but this was due to considerable 
variation. As discussed in Chapter 4, AEA may indirectly affect  cell activity by 
paracrine signalling (Section 1.2.3) which would depend on the release of secondary 
signalling molecules (e.g. somatostatin-14) which then bind to their receptors 
expressed on the  cell surface. Therefore, the variability in the effects of AEA on 
insulin secretion may have been due to the secondary signalling molecules being 
washed away before being able to affect  cell activity, as flow rate for the perifusions 
may have been too high. However, reduction of the flow rate to 0.7ml/minute was not 
found to to alter the variability. 
 
3.4.2 Characterisation of anandamide responsive and non-
responsive islets  
In light of the effects of 1M AEA on glucose-stimulated insulin secretion, further 
experiments were carried out to determine the concentration-response relationship. In 
these experiments, only a third of islets were found to be sensitive to 1M AEA found, 
determined by a greater than 25% inhibition of insulin secretion. Accordingly, the data 
were re-analysed and split into AEA responsive and non-responsive groups (Figure 
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3.3A) and were consistent with two separate islet populations. For consistency the two 
groups will be referred to as responsive and non-responsive, however, it would be 
more accurate to refer to the two populations as sensitive and less-sensative, 
respectively. That there are 2 distinct populations of islets with respect to the effects of 
anandamide is a novel observation and was not identified in other studies (Juan-Pico 
et al., 2006; Bermudez-Silva et al., 2008; Nakata & Yada, 2008). Additionally, there is 
no evidence in the literature that would readily explain this observation. In order to 
investigate the variability, the effects of the 2–adrenoceptor agonist clonidine were 
examined, to assess the viability of GiPCR signalling (Yamazaki et al., 1982). The 
results suggest that responsiveness of islets to AEA was not due to wide-spread 
degradation of plasma membrane receptors or defective Gi protein coupling. This was 
concluded as the responses to AEA were variable, whereas, clonidine consistently 
inhibited insulin secretion (Figure 3.10). As the effects of AEA were glucose-
dependent and only inhibited insulin secretion at maximal, but not intermediate, levels 
of GSIS this suggested that AEA may be inhibiting one or more amplification 
pathways (Section 1.2.2.3). Thus, in less glucose-responsive islets (where the 
amplification pathways are not as prominent) the effects of AEA may have appeared 
diminished. Subsequent analysis of the AEA glucose- and concentration-response 
data (Figures 3.4 & 3.5B) suggest that the sensitivity of islets to AEA does not 
correlate to how glucose responsive the islets are. Therefore, it appears that the 
responsiveness of islets to AEA was not a direct result of isolation or handling of the 
islets but may be due to inherent differences in the islets themselves. For instance, 
the study by Juan-Pico et al. (2006) found that the effects of AEA (but not 2-AG) on 
glucose-stimulated oscillations in [Ca2+]i varied between islets, as the effects of AEA 
appeared to be either CB1 or CB2 receptor-mediated. However, the reason why AEA 
signalling differed between islets when the effects of 2-AG appeared to be consistent 
in the study by Juan-Pico et al. (2006) was not investigated. Additionally, this 
observation is of limited value as changes in [Ca2+]i can be linked to insulin granule 
exocytosis but these changes cannot be readily quantified into insulin secretion rates 
(Barbosa et al., 1998).  
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Despite variations in potency, 100M AEA fully blocked GSIS in all of the AEA 
concentration response experiments. One possible explanation for these differences 
in potency could be endocannabinoid uptake and metabolism. In order to assess this, 
the non-hydrolysable analogue of AEA, methanandamide was used (Abadji et al., 
1994; Lin et al., 1998). The concentration-dependent effects of methanandamide were 
comparable to those of AEA. Specifically, 10M methanandamide consistently 
inhibited insulin secretion, even in islets which were found not to respond to 10μM 
AEA (see later, Figure 4.7B). This suggests that the islet responsiveness may be due 
to metabolism of AEA or, alternatively, minor differences in AEA and 
methanandamide pharmacology (e.g. differences in CB1 and CB2 receptor affinities) 
are exacerbated in islets (Lin et al., 1998). 
 
The expression of FAAH, a key enzyme in the degradation of AEA (Section 1.4.2.1), 
has been reported in mouse, rat and human islets (Starowicz et al., 2008; Tharp et al., 
2008). Therefore, if islet responsiveness to AEA was a result of differing levels of 
FAAH activity then inhibition of this enzyme prior to the application of AEA should 
overcome the variability. As with methanandamide, 10M AEA was chosen over the 
concentration of 1M, as it was found when reviewing the concentration-response 
curves for responsive and non-responsive islets that the difference in secretion rates 
between responsive and non-responsive islets was greatest at 10M (Figure 3.3A). 
To inhibit FAAH, islets were pre-incubated with 10M URB597 as this should inhibit 
even high levels of FAAH activity (Ahn et al., 2007; Zhang et al., 2007). Initial testing 
found that pre-treatment of islets with 10μM URB597 did not significantly alter basal or 
maximal levels of GSIS suggesting that 10M URB597 was suitable for use with AEA. 
However, it was noted that the effects of 10M URB597 at 20mM glucose were 
variable, so it was unclear whether there was an increased basal endocannabinoid 
tone (Section 1.4.3) within some islets as a result of URB597 pre-treatment. The 
variability of 10μM URB597 at 20mM glucose is probably not due to vehicle effects as 
the islets in the glucose controls were also exposed to an equivalent amount of 
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ethanol for an identical period time. Subsequently, it was found that pre-treatment with 
URB597 did not affect islet responsiveness to AEA but it was observed that in these 
experiments inhibition of insulin secretion by 10μM AEA coincided with 10M URB597 
inhibiting insulin secretion too (Figure 3.7C). It is unclear whether the linkage in the 
level of inhibition caused by 10M URB597 and 10M AEA can be attributed to islet 
responsiveness, as it was found in three of the AEA non-responsive concentration-
response experiments; 10M AEA caused a < 37% inhibition of insulin secretion at 
20mM glucose. It is unclear whether confirmation of the responsive state to AEA 
would have contributed to a deeper understanding of islet variability without first 
knowing whether URB597 pre-treatment was blocking FAAH activity. 
 
Data from Bermudez-Silva et al. (2008) suggests that 2-AG (and presumably other 
endocannabinoids) production in human islets is linked to GSIS and so the inhibition 
caused by URB597 may have been due to a full blockade of FAAH activity resulting a 
net increase in islet N-acylethanolamine levels. An increase in islet-derived AEA 
levels would lead to the inhibition of insulin secretion, assuming that rat islets produce 
AEA endogenously. Alternatively, the effects of URB597 could have been occurring 
as the result of non-specific inhibition of non-FAAH serine hydrolases or other 
enzymes (Alexander & Cravatt, 2006; Zhang et al., 2007). Therefore, if inhibition of 
insulin secretion was not observed when islets were pre-treated with URB597 at 
concentrations  1μM, this would imply that the effects of 10μM URB597 on insulin 
secretion were due to non-specific effects. Rather than conducting this experiment, it 
was chosen to perform endocannabinoid assays instead, as the results from these 
assays would allow a direct measurement of AEA hydrolysis within islets and 
establish whether the 10μM URB597 pre-treatment was effective in blocking AEA 
hydrolysis. The preliminary experiments with whole islets did not produce meaningful 
data as the protocol was not sufficient to account for islet viability and responsiveness. 
Firstly, liver samples could only act as a positive control for FAAH activities in the 
assay but does not control for the treatment of intact islets with URB597 (Figure 3.9). 
Ideally, additional islets would be needed to run a static incubation in parallel with the 
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AEA hydrolysis assays, to demonstrate islet viability and to determine the AEA 
responsive state of the islets, but islet yields at the time were not sufficient. It must 
also be noted that the endocannabinoid assay only detects metabolism of the [3H]-
AEA if the radiolabeled ethanolamine head group is separated from the arachidonic 
acid moiety. However, if AEA is inhibiting insulin secretion via a plasma membrane 
receptor’s extracellular binding site, then deactivation of AEA could occur by rapid 
uptake and retention within the islet cells. Therefore, AEA uptake studies may also be 
useful in probing whether variability in AEA responses are due to non-metabolic 
means. It must also be considered that if islets were found to have intrinsically low 
FAAH activity then alternate metabolic pathways may be of increasing importance 
(Section 1.4.2). For example, islets are thought to express several isoforms of the 
cyclooxygenase and lipoxygenase enzymes which can oxygenate various 
endocannabinoids, including AEA, thus making cannabinoid signalling more diverse 
(Yamamoto et al., 1983; Shannon et al., 1992; Ueda et al., 1995; Han et al., 2002; 
Kozak et al., 2002; Ross et al., 2002; van der Stelt et al., 2002; Heitmeier et al., 2004; 
Woodward et al., 2008). Factors such as these may also exacerbate differences in the 
pharmacology of AEA and methanandamide, which increases the need to 
characterise AEA signalling (Gardiner et al., 2009). Thus, the status of 
endocannabinoid metabolic activities within batches of islets may go some way to 
explaining the variability in islet sensitivity to AEA as observed in the current study. 
 
3.4.3 Conclusions 
The data presented in this chapter provide evidence that AEA acutely inhibits insulin 
secretion from statically-incubated islets, but the effects of AEA on insulin secretion 
was found to differ when islets were perifused. As the inhibition of insulin secretion 
caused by AEA is glucose and concentration-dependent, this indicates that the effects 
of AEA are controlled by receptor-specific signalling pathways. The nature of these 
signalling pathways were investigated and the findings are presented in Chapter 4. 
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Intriguingly, the concentration-dependent effects of AEA were variable which has not 
been documented by other groups. This may suggest that this variability is an artefact 
of the isolation and/or incubation process; however, attempts to identify the causes 
were unsuccessful. Hence, it was viewed that the responsive state of the islets may 
be due to integral rather than induced differences between islets. This led to the role 
of local metabolism (as the source of islet variability) being investigated using 
methanandamide and URB597. The data suggest that AEA hydrolysis by FAAH was 
not the cause of islet un-responsiveness, however, these findings are not conclusive 
without further evidence. Therefore, it remains unclear as to why the effects of AEA 
between islet preparations were variable in this study but alternate theories are 
suggested in later chapters. 
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4  
 
Characterisation of the 
signalling pathways involved 
in the anandamide-mediated 
acute inhibition of insulin 
secretion  
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4.1 Introduction 
 
In Chapter 3, anandamide (AEA) was found to inhibit insulin secretion in a glucose-
dependent manner and it was assumed that AEA was acting in a receptor-dependent 
manner. As discussed in Section 1.4.3., CB1-, CB2-, TRPV1-receptors, PPAR, and 
PPAR are all receptors linked to endocannabinoid signalling, but there are also data 
to suggest that endocannabinoids may act through GPR18, GPR55, and GPR119 
receptors. Therefore, AEA may be inhibiting insulin secretion via a number of 
receptors. However, it is uncertain whether all of these receptors are expressed in 
islets.  
 
It is also uncertain whether AEA is acting directly or indirectly to inhibit insulin 
secretion, as the expression of CB receptors have been detected on non- cells which 
are located in the periphery of the rat islet (Table 4.1). This may indicate that AEA can 
affect insulin secretion by altering paracrine signalling within islets (Section 1.2.3). 
Indeed, the study by Bermudez-Silva et al. (2008) reported that acute cannabinoid 
treatment in human islets not only affected the amount of insulin secreted but also 
affected that of glucagon and somatostatin-14 (sst-14). Therefore, the inhibitory 
effects of AEA on insulin secretion may have originated from a signalling pathway in 
non- islet cells.  
 
The inhibition of insulin release by AEA was glucose- and concentration-dependent. 
Therefore, the primary aim of this study was to characterise the receptor signalling 
pathway(s) by which AEA inhibits insulin release. There was also a secondary aim 
which was to determine whether AEA was inhibiting insulin secretion by paracrine 
means. In order to achieve these aims, receptor-specific antagonists were used in co-
junction with AEA in freshly isolated islets of Langerhans from male Wistar rats. 
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Table 4.1  Expression of CB1 and CB2 receptors in rat islets 
 
Reference Rat breed 
RT-PCR Immunohistochemistry 
CB1 CB2 CB1 CB2 
  	 PP   	 PP
Bermudez-
Silva et al. 
(2007) 
Wistar ND ND +? + ? ? +? + ? ? 
Starowicz et 
al. (2008) Wistar ND ND + - ? ? + + ? ? 
Vilches-Flores 
et al. (2010) Wistar + ND + - ? ? ND ND ND ND 
Tharp et al. 
(2008) 
Zucker lean 
control + - - - + - - - - - 
Bermudez-
Silva et al. 
(2009) 
Not 
specified1 ND ND + - ? ? + + ? ? 
 
RT-PCR was performed using RNA extracted from whole islets. 
Immunohistochemistry was performed using hormone-specific antibodies and 
receptor isoform-specific antibodies.1 Rat strain was not specified by Bermudez-Silva 
et al. (2009) but it is likely that the tissue originated from male Wistar rats, used 
similarly in their earlier study (Bermudez-Silva et al., 2007).  ND not determined; + 
expressed; - not expressed; +? expression in cell type confirmed by basic cell 
morphology; ? Expression of CB1 or CB2 receptors detected on the periphery of the 
islet but the cell types was not confirmed. 
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4.2 Methods 
 
4.2.1 Materials 
All drugs and buffers were prepared as described in Sections 2.2. The somatostatin-
14 enzyme-linked immunosorbent assay (ELISA) kit was purchased from Bachem 
(Bubendorf, Switzerland). 
 
4.2.2 Animals 
All procedures were performed using tissues obtained from male Wistar rats with body 
weights ranging from 230-350g. Animals were housed and killed as described in 
Section 2.1.  
 
4.2.3 Insulin secretion studies 
Islets were isolated from male Wistar rats according to the isolation procedure 
described in 2.4.2. 48-well plates with 70% confluent INS-1 823/13 cells (passages 
86-91) were prepared as described in 2.4.3. 
 
4.2.3.1 Static incubations 
Freshly isolated islets were used in 1-hour static incubation studies, as described in 
2.4.2. INS-1 823/13 cells were used in either 1- or 2-hour static incubation studies, as 
described in 2.4.3. The effects of AEA on insulin secretion from INS-1 823/13 cells did 
vary between 1 or 2 hour incubations. Once the incubations had finished, samples of 
incubation buffer were taken from each well and the amount of insulin in the samples 
was determined by RIA as described in 2.6. Analyses of experimental data were 
carried out as described in 2.5. Where indicated, the Spearman rank (non-parametric) 
correlation test was used to determine whether there was a significant correlation 
between two parameters. 
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4.3 Results 
 
4.3.1 Characterisation of signalling pathways involved in inhibition 
of insulin release induced by anandamide 
In light of the variability in the sensitivity of islets towards AEA treatment (Figure 3.3), 
a concentration of AEA greater than 10M was needed in order to cause a 
reproducible inhibition of insulin secretion. Accordingly, 30μM AEA was found to 
cause a reproducible and significant inhibition of insulin release at 20mM glucose, and 
was therefore used for all of the antagonist studies (Figure 4.1).  
 
 
Figure 4.1  The effects of 30M and 100M AEA on insulin secretion at 20mM 
glucose. Islets were incubated at 4mM or 20mM glucose in the absence (control) or 
presence of 30M or 100M AEA. Results are presented as mean insulin secretion 
rates ± SD (n= 10). *** P< 0.001 vs. 20mM glucose control. 
 
4.3.1.1 Effects of CB1 receptor antagonists, AM251 and O-2050, on 
responses to anandamide 
AM251 is a widely-used CB1 receptor-specific antagonist/inverse agonist which has 
been used to investigate CB1 receptor mediated signalling in both murine and human 
isolated islets (Savinainen et al., 2003; Juan-Pico et al., 2006; Bermudez-Silva et al., 
2008; Xiao et al., 2008). O-2050, another CB1 receptor-specific antagonist, was also 
used as a comparison (Martin et al., 2002). Unlike AM251, O-2050 is a relatively new 
compound that has primarily been used in in vivo behavioural studies and so 
information of its effects in vitro are limited. The concentrations of AM251 and O-2050 
were restricted to 100nM to limit non-selective effects (Section 5.3.2). AM251 did not 
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significantly affect insulin secretion at 20mM glucose and did not significantly affect 
the inhibition of insulin secretion caused by AEA (Figure 4.2A). As observed with 
AM251, O-2050 alone did not affect maximal levels of insulin secretion and O-2050 
did not affect the inhibitory effects of AEA (Figure 4.2B) 
 
A 
 
B 
 
Figure 4.2  The effects of the CB1 receptor antagonists AM251 and O-2050 on 
responses to AEA. Islets were incubated at either 4mM or 20mM glucose in the 
absence (control) or presence of 30μM AEA, with or without a CB1 receptor 
antagonist. A) Effects of AM251 on responses to AEA. Results are presented as 
mean insulin secretion rates ± SD (n= 5). * P< 0.05 vs. 20mM glucose control. B) 
Effects of O-2050 on responses to AEA. Results are displayed as mean insulin 
secretion rates ± SD (n= 5). ** P> 0.01 vs. 20mM glucose control. 
 
4.3.1.2 Effects of the CB2 receptor antagonist/inverse agonist AM630 on 
responses to anandamide 
AM630 is described as a CB2 receptor-selective antagonist/inverse agonist which has 
been used to attenuate CB2 receptor signalling in islets without affecting insulin 
secretion itself (Ross et al., 1999; Mukherjee et al., 2004; Juan-Pico et al., 2006; 
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Bermudez-Silva et al., 2008). The concentration of AM630 used here was 100nM to 
limit the possibility of AM630 affecting insulin secretion itself (see Section 5.3.3). In six 
experiments where AM630 was used in conjunction with AEA, it was found that that 
AM630 did not significantly affect 20mM glucose-stimulated insulin secretion (Figure 
4.3). The compiled results also suggest that AM630 did not affect the inhibition of 
insulin secretion caused by AEA (Figure 4.3). However, on further analysis, it appears 
that in four of the six experiments, 100nM AM630 attenuated or blocked the effects of 
30μM AEA, whereas in the remaining two experiments, AM630 appeared to potentiate 
the effects of AEA (Table 4.2). 
 
 
Figure 4.3  The effects of AM630 on responses to AEA. Islets were incubated at 
either 4mM or 20mM glucose in the absence (control) or presence of 30μM AEA with 
or without 100nM AM630. Results are presented as mean insulin secretion rates ± SD 
(n= 6). ** P> 0.01 vs. 20mM glucose control 
 
 
Table 4.2  Mean insulin secretion rates for the six individual experiments examining 
the effect of AM630 on AEA-induced inhibition of insulin release 
 
Experiment no 100nM AM630 30μM AEA 30μM AEA + 100nM AM630 
Net effect on 
30μM AEA 
1 100 ± 12.5 52.6 ± 18.5 96.3 ± 18.21 +43.7 
2 136 ± 10.0 54.0 ± 12.4 111 ± 7.2 +57 
3 148 ± 13.0 39.8 ± 20.6 70.9 ± 29.4 +31.1 
4 66 ± 8.6 15.7 ± 2.1 64.9 ± 9.3 +49.2 
5 89.7 ± 17.5 39.6 ± 12.5 24.3 ± 7.6 -15.3 
6 92 ± 27.7 51.5 ± 12.5 19.8 ± 9.6 -31.7 
  
All values are the mean insulin secretion rates expressed as a percentage of the 
20mM glucose control. Net effect on 30μM AEA was calculated as the mean 
experimental insulin secretion rate for 30μM AEA + 100nM AM630 minus mean 
experimental insulin secretion rate for.  
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4.3.1.3 Effects of the PPAR-antagonist GW9662 on responses to 
anandamide 
GW9662 (1M) did not affect basal, intermediate or maximal levels of glucose-
stimulated insulin secretion (Figure 4.4A). Subsequent testing found that GW9662 did 
not affect the level of inhibition caused by AEA at 20mM glucose (Figure 4.4B). 
 
A 
 
B 
 
 
Figure 4.4  The effects of GW9662 on glucose-induced insulin release. A) Islets were 
incubated at basal (4mM), intermediate (8mM) or maximal (20mM) levels of insulin 
secretion in the absence (control) or presence of 1μM GW9662. Results are 
presented as mean insulin secretion rates ± SD (n= 10, except for conditions at 8mM 
glucose where n= 3). B) Islets were incubated at either 4mM or 20mM glucose in the 
absence (control) or presence of 30μM AEA with or without 1μM GW9662. Results 
are displayed as mean insulin secretion rates ± SD (n= 5). 
 
4.3.2 Effects of AEA on insulin secretion from the INS-1 823/13 -
cell line 
To determine whether the inhibitory effects of AEA on insulin secretion were caused 
by a direct effect on -cell activity or through paracrine signalling insulin secretion 
experiments were performed in the INS-1 823/13 -cell line. In compliance with the 
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previous insulin secretion experiments with AEA in islets, 1M, 10M and 30M AEA 
were tested at 20mM glucose. AEA did not significantly affect insulin secretion at any 
concentration tested, Figure 4.5. 
 
Figure 4.5  The effects of AEA on insulin secretion at 20mM glucose from INS-1 
812/13 -cells. INS 812/13 -cells were incubated at 20mM glucose in the presence 
of vehicle (ethanol at a final concentration of 1% (v/v)) or with increasing 
concentrations of AEA for either 1 or 2 hours. Results are presented as mean insulin 
secretion rates ± SD (n= 3). 
 
4.3.3 Effects of somatostatin-14 on glucose-stimulated insulin 
secretion 
Next, a series of experiments were performed to investigate whether AEA inhibited 
insulin secretion via somatostatin-14 (sst-14) signalling within islets. Sst-14 potently 
inhibited insulin secretion at 20mM glucose in a concentration-dependent fashion, with 
inhibition occurring at concentrations as low as 10nM. The IC50 and Hill slope of sst-14 
were calculated as 3.8nM (95% CI: 1.2nM to 11.6nM; Figure 4.6A) and -5.9 ± 9.9, 
respectively. From the sst-14 concentration-response data (Figure 4.6), it was decided 
to use sst-14 at concentration of 100nM in future experiments to produce a 
reproducible inhibition of insulin secretion. Preliminary experiments with the putative 
SSTR5 antagonist BIM-23056 were unsuccessful as BIM-23056 (at concentration  
30nM) was found to inhibit insulin secretion at 20mM glucose (data not shown). 
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In a subsequent set of experiments, it was found that the effects of 100nM sst-14 and 
10μM AEA on insulin secretion at 20mM glucose were variable without marked overall 
inhibitory effects as observed previously, whereas 10μM methanandamide caused a 
consistent inhibition of insulin secretion (Figure 4.7A). Further analysis of the 
individual experimental results indicated that islet responsiveness to 10μM AEA 
appeared to coincide with islet responsiveness to 100nM sst-14 but did not reach 
statistical significance (Figures 4.7B & 4.7C). As with the AEA concentration response 
data islet sensitivity to 100nM sst-14 and 10μM AEA did not coincide with glucose 
responsiveness (data not shown). 
A 
 
B 
 
Figure 4.6  The effects of somatostatin-14 (sst-14) on insulin secretion at 20mM 
glucose. Islets were incubated at 20mM glucose in the presence of somatostatin-14 at 
increasing concentrations. A) Insulin secretion rates have been normalised against 
the 20mM glucose control. The mean basal secretion rate is represented as a triangle. 
B) Insulin secretion rates been normalised against the difference (glucose response) 
between the insulin secretion rates observed for the 4mM (0%) and 20mM (100%) 
glucose controls. All results are presented as mean insulin secretion rates ± SD (n= 
4). * P< 0.05, ** P< 0.01 vs. 20mM glucose control.  
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A 
 
B 
 
C 
 
Figure 4.7  The effects of somatostatin-14 (sst-14), AEA and methanandamide 
(metAEA) on insulin secretion at 20mM glucose. Islets were incubated for 1-hour at 
4mM or 20mM glucose in the absence (control) or presence of either 100nM 
somatostatin-14, 10μM AEA or 10μM metAEA. A) Compiled results which are 
presented as mean insulin secretion rates ± SD (n= 5). ** P< 0.01 vs. 20mM glucose 
control B) Individual experimental mean insulin secretion rates in the presence of sst-
14, metAEA and AEA. Results from each experiment were standardised against the 
difference between the insulin secretion rates observed for the 4mM (0%) and 20mM 
(100%) glucose controls. C) The individual experimental mean insulin secretion rates 
(from figure B) of 10μM AEA plotted against the corresponding data for 100nM sst-14.  
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4.3.4 Effects of lysophosphatidylinositol (LPI) on glucose-
stimulated insulin secretion 
LPI (10M), a putative endogenous GPR55 agonist, was used at basal and maximal 
levels of GSIS, and it was found that LPI did not significantly affect insulin secretion at 
4mM (Figure 4.8A). However, LPI was found to have a variable effect on insulin 
secretion at 20mM glucose (Figure 4.8B). 
  
A 
 
B 
 
 
Figure 4.8  The effects of the endogenous GPR55 ligand lysophosphatidylinositol 
(LPI), on insulin secretion. A) Islets were incubated at 4mM or 20mM glucose for 1 
hour in the absence or presence of 10μM LPI. Results are presented as mean insulin 
secretion rates ± SD (n= 8). B) The effects of 10M LPI on 20mM glucose-induced 
insulin secretion expressed as a histogram produced from the 20mM glucose + 10M 
LPI data presented in Figure A. 
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4.4 Discussion 
 
AEA at 30M caused a consistent and reproducible inhibition of insulin secretion at 
20mM glucose and therefore was used in all antagonism studies. Cannabinoid CB1, 
CB2, and PPAR receptor antagonists did not cause reproducible alterations in islet 
responses to 30M AEA. However, on closer examination results from antagonism 
studies with the CB2 receptor antagonist AM630 indicated that 30M AEA may inhibit 
insulin secretion by more than one inhibitory signalling pathway (including a CB2 or 
CB2-like receptor dependent signalling pathway). Despite attempts to establish a 
direct link between AEA and sst-14-mediated inhibition of insulin secretion preliminary 
results found that islet responsiveness to 10M AEA coincided with islet 
responsiveness to 100nM sst-14. Additionally preliminary findings with LPI, a putative 
GPR55 agonist, suggest that the effects of AEA are unlikely to be mediated by 
GPR55. 
 
4.4.1 Effects of CB1-, CB2-, and PPAR-receptor antagonists on 
responses to 30M AEA  
Classically, AEA is assumed  to act largely in a CB1 receptor-dependent manner but 
Juan-Pico et al. (2006) have also indicated significant activity at CB2 receptors. Due to 
recent interest in the involvement of PPAR in cannabinoid actions, as well as the use 
of PPAR agonists for the treatment of type 2 diabetes (Section 1.3.3), the role of 
PPAR signalling was also tested. Hence, the antagonists described as being CB1 
receptor (AM251 and O-2050), CB2 receptor (AM630) and PPAR (GW9662) 
receptor-specific were used in order to probe the mechanisms of action of AEA. When 
islets were co-incubated in the presence of AEA and a CB1, CB2, or PPAR receptor 
antagonist, none of the receptor antagonists examined were found to consistently 
attenuate the inhibitory effects of AEA. While there is little consensus on the 
expression patterns of the CB receptors in islet cells, it appears that the expression of 
the CB receptors within islet to be constant/consistent between lean, obese and type 
2 diabetic tissue (Bermudez-Siva et al., 2006; Juan-Pico et al., 2006; Starowicz et al., 
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2008; Tharp et al., 2008; Bermudez-Silva et al., 2009). Similarly, the expression of 
PPAR has been reported to be consistent between islets isolated from lean non-
diabetic rodents (Braissant et al., 1996; Patane et al., 2002). Therefore, it was 
assumed that if AEA was inhibiting insulin secretion through a single receptor type 
then use of the correct type of receptor specific antagonist should consistently 
attenuate or block the effects of AEA. Thus, the results presented in this chapter 
suggest that 30M AEA inhibits insulin via a mechanism that appears to be 
independent of CB1, CB2, and PPAR signalling pathway. This conclusion appears to 
be verified by initial observations in Chapter 5, which found that use of 1M ACEA 
(CB1 receptor-specific agonist) and 1M JWH133 (CB2 receptor-specific agonist) did 
not consistently reproduce the inhibitory effects of AEA.  
 
Although the present study would appear to exclude the involvement of ‘classical’ 
cannabinoid and PPAR receptors, this is based on the individual application of 
antagonists. It is conceivable that AEA might have a multiple sites of action and so 
future experiments might be designed with combinations of antagonists to address 
this possibility.  
 
Recent evidence from Vilches-Flores et al. (2010) suggests that CB1 receptor 
expression in islets (determined by RT-PCR and immunohistochemistry) is glucose-
dependent, as higher expression levels were described in islets isolated from Wistar 
rats that were fasted prior to death. It is unclear whether CB2 receptor expression 
within islets is influenced by the fasting state of the animal too. As the Wistar rats 
used in this study were fed ad libitum then it may be possible that CB receptor 
expression within islets also varied between preparations. Hence, it may be more 
reasonable to re-assess the experimental results from the antagonism studies on an 
individual islet batch basis as cannabinoid receptor signalling may differ between 
islets. When the data are viewed in this context, then it appears that AEA inhibited 
insulin secretion by a CB2 receptor-dependent signalling pathway, as in the majority of 
islets co-incubation with AEA and AM630 attenuated the inhibitory effects of AEA 
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(Table 4.2). Interestingly, in the remaining two experiments of this type, co-incubation 
of islets with AEA and AM630 resulted in a greater inhibition of insulin secretion 
(Table 4.2). Therefore, the effects of 30M AEA may be restricted to a CB2 (or CB2-
like) receptor signalling pathway in some islets, but in other islets AEA at 30M may 
act by other signalling pathways. It may also be that the responsive state of islets to 
AEA could be due to the presence or absence of a specific signalling pathway. As 
such, in non-responsive islets, 30μM AEA may be able to cause significant activation 
of signalling pathways that concentrations of AEA  10μM would not be able to 
stimulate. Therefore, future antagonism experiments should be designed around a 
complex, rather than a simplistic, pharmacological model of cannabinoid signalling 
within islets.  
 
4.4.2 Effects of lysophosphatidylinositol on glucose-stimulated 
insulin secretion 
LPI has been reported to be an endogenous ligand for the GPR55 receptor by several 
in vitro studies using transfected HEK293 cell lines and primary cells (Section 1.4.9). 
A concentration of 10M LPI was chosen as it has been reported to induce maximal 
or near maximal responses in GPR55 expressing cells at this concentration (Oka et 
al., 2007; Lauckner et al., 2008; Henstridge et al., 2009; Oka et al., 2009; Yin et al., 
2009).  LPI did not affect the basal insulin secretion rate but the effect of LPI at 20mM 
glucose varied. In some experiments, it was found that LPI caused significant 
potentiation (> 25%) of insulin secretion, whereas in others LPI potently inhibited 
insulin secretion.  
 
At present, there are no published data regarding the expression of GPR55 in islets or 
the pancreas as a whole. Hence, it is unknown whether any of the effects of LPI on 
insulin secretion were GPR55-mediated. As mentioned in Section 1.4.9, experimental 
evidence suggests that activation of GPR55 leads to activation of RhoA-ROCK 
signalling and/or PLC via G
12/13- or Gq-coupled receptor signalling, respectively. 
Information regarding RhoA-ROCK signalling in islets is limited but information from a 
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study using dispersed primary -cells, from male Wistar rat islets, suggests that 
activation of this signalling pathway inhibits GSIS by stabilisation of the F-actin 
cytoskeleton (Hammar et al., 2009). Based on the activation of other GqPCR 
receptors in -cells, it would be expected that if GPR55 were signalling via Gq 
signalling pathways, then this would result in the potentiation of insulin secretion 
(Sawaki et al., 1993; Iismaa et al., 2000; Duttaroy et al., 2004; Waldeck-Weiermair et 
al., 2008; Henstridge et al., 2009). Therefore, if both effects of LPI were GPR55-
mediated then this would suggest that AEA was inhibiting by a GPR55 receptor-
independent signalling pathway. 
 
Alternatively, the inhibitory and stimulatory effects of LPI on insulin secretion (Figure 
4.8D) could be due to alternate signalling pathways as 10M LPI has been reported to 
potentiate TRPV2 (transient receptor potential vallinoid-type 2, divalent ion channel) 
and TREK-2 (TWIK-related K+ channel 2) activity in transfected cell lines (Lesage et 
al., 2000; Monet et al., 2009). TRPV2 expression in mouse islets is believed to be 
restricted to -cells and information gathered from primary islet -cells and MIN6-cells 
suggests that activation of TRPV2 channels leads to the influx of extracellular Ca2+, 
which may also explain the potentiation of insulin secretion by LPI (Hisanaga et al., 
2009). TREK-2 has been described as a slightly inward-rectifying K+ channel in both 
transfected COS cell and natively-expressing MIN6 cells (Lesage et al., 2000; Kang et 
al., 2004). Lesage et al. (2000) postulated that activation of TREK-2 in -cells may 
lead to a reduction in GSIS by re-stabilisation of the resting (polarised) state as the 
channel was more active in the depolarised state than the hyperpolarised state 
(Lesage et al., 2000). Therefore, further work is needed to characterise LPI signalling 
within islets to ascertain whether either effect of LPI was GPR55-mediated. It may first 
be appropriate to determine whether islets express GPR55 mRNA by RT-PCR before 
characterising GPR55 signalling by pharmacological means. This could be further 
examined by determining whether islets express GPR55 receptors under 
experimental conditions by western blotting and/or immunohistochemistry too.   
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4.4.3 AEA as a paracrine mediator of islet activity 
As shown in Table 4.1, expression of cannabinoid receptors has been detected in rat 
islets on the surfaces of non- cells, therefore endocannabinoids may mediate 
inhibition of insulin secretion by activating CB receptors on the -cells or through 
paracrine signalling within islets. To determine whether the effects of AEA were due to 
cannabinoid signalling in -cells, the INS-1 823/13 -cell line was used (Hohmeier et 
al., 2000). The primary advantage of this approach over the use of purified -cells was 
that INS-1 823/13 -cells can be rapidly grown, whereas there was insufficient primary 
tissue available to produce the required amounts of primary -cells required for insulin 
secretion studies. Hence, the effects of AEA, at micromolar concentrations, on insulin 
secretion at 20mM glucose in INS-1 823/13 were tested but it was found that AEA did 
not significantly affect insulin secretion in these cells. The lack of effect of AEA in 
these cells may have been caused by de-differentiation of the INS-1 823/13 cells 
(through successive passages) which leads to the progressive loss of the -cell 
phenotype in -cell lines (Hohmeier et al., 2000; Nakashima et al., 2009). This could 
have occurred as the INS-1 823/13 were not found to be glucose-repsonsive. The 
results may also have been indicative that the inhibition of insulin secretion (caused 
by AEA in islets) was due to alterations in paracrine signalling, therefore, this was 
investigated further. 
 
Based on the information in Section 1.2.3, it was viewed that the most likely paracrine 
mechanism by which AEA could be inhibiting insulin secretion was through 
potentiation of sst-14 secretion from 	-cells. The general consensus is that sst-14 
inhibits insulin secretion by a SSTR5-mediated signalling pathway, but, as shown 
previously in Table 1.2, there is also evidence that inhibition may occur via SSTR2-
mediated signalling pathway (Rossowski & Coy, 1994; Atiya et al., 1997; Zambre et 
al., 1999; Strowski et al., 2000; Cejvan et al., 2003; Strowski et al., 2003; Wang et al., 
2004; Yao et al., 2005; Singh et al., 2007). In accordance with the literature, sst-14 
was found to inhibit insulin secretion at 20mM glucose in a concentration-dependent 
manner with high potency (Figure 4.6) and, from these data, it was decided that sst-14 
would be used at 100nM to produce a reproducible and consistent inhibition of insulin 
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secretion (Schuit et al., 1989; Hurst & Morgan, 1990; Rossowski & Coy, 1994; Wang 
et al., 2004). It was planned that SSTR antagonists would be used to verify the 
involvement of endogenous sst-14 in the mechanism of AEA-mediated inhibition of 
insulin secretion. However it was found that BIM-23056, a putative SSTR5 selective 
antagonist, inhibited insulin secretion itself. Hence, it was not possible to directly test 
whether AEA was inhibiting insulin secretion by a sst-14 mediated mechanism by 
pharmacological means. 
 
During the testing of BIM-23056, it was found that islet responsiveness to 100nM sst-
14, in common with AEA, was variable with islets appearing to either be responsive or 
non-responsive to sst-14. The data presented in Figure 4.7B suggest that AEA 
responsive islets are also responsive to sst-14, implying that at concentrations  
10M, AEA may inhibit insulin secretion by an sst-14-dependent mechanism. 
However, there was not a significant correlation between the inhibitory effects of sst-
14 and AEA but this may be due to the limited number of experiments in this data set. 
Therefore, additional experiments should be performed to verify whether the 
observation that inhibition of insulin secretion by 10μM AEA is mediated by sst-14. If 
AEA inhibited insulin secretion by an sst-14 dependent signalling mechanism then 
variability in AEA responsiveness may be dependent on the 	-cell content of the 
islets. The composition of islets (ratio of : : 	 cells) is known to differ between 
different regions of the pancreas (Tasaka et al., 1989). Therefore, the variation in islet 
responses to AEA and sst-14 may have inadvertently been pre-determined by the islet 
isolation step as a larger number of islets may have isolated from a certain region of 
the pancreas despite whole pancreata being used (especially as islet preparations are 
considered, at best, to be 50% efficient; van Suylichem et al. (1992)). Alternatively the 
SSTR receptors may have been degraded (Turcot-Lemay et al., 1975) or 	-cells lost 
(Hauge-Evans et al., 2009) during the collagenase isolation step. Thus, the 
responsiveness of islets to AEA may be linked to the number of functional SSTR 
receptors left on the plasma membranes of the -cells after the process of islet 
isolation. Therefore, use of islet culture may be beneficial to allow the -cells to 
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synthesis new somatostatin receptors but, as mentioned in Chapter 3, the use of islet 
culture may also affect CB signalling in islets. However, both theories are confounded 
with the observation that 10M methanandamide-mediated inhibited of insulin 
secretion consistently. Alternatively, 10M methanandamide might be able to inhibit 
insulin secretion through several different signalling pathways in a manner similar to 
30M AEA (Section 4.4.1). 
 
Measurement of sst-14 and insulin secretion by RIA in parallel could be used in future 
studies to determine whether alterations in somatostatin secretion coincide with the 
inhibition of insulin secretion. This was attempted in the current study but too few 
islets (5 islets/well) were used to reliably detect sst-14 secretion by ELISA. As 
described in Section 1.2.3, glucagon secretion may also contribute to maximal rates of 
insulin secretion. Therefore, determination of glucagon secretion by RIA may also be 
beneficial. This too could be expanded to determine if cannabinoid signalling may 
alter glucagon secretion at low glucose concentrations. This information would also 
develop a more complete understanding of the physiological role that cannabinoid 
signalling has in islets.  
 
On reviewing the literature regarding somatostatin signalling in islets, two studies 
found that binding of radiolabeled sst-14 increased in proportion to the external 
glucose concentration (Mehler et al., 1980; Draznin et al., 1985). Hence, AEA may be 
able to increase somatostatin signalling independently or in parallel to potentiating 
somatostatin secretion. Therefore, alternate approaches aside from measuring 
somatostatin secretion may be needed to confirm negative findings. Alternate 
approaches may include expansion of the INS-1 823/13 -cell work by co-culturing -
cells with 	-cell lines (and possibly -cell lines) to confirm the whether the effects in 
islets can be recreated in mixed islet-cell line populations. Finally, alternate SSTR 
antagonists could be tested to assess whether AEA-mediated inhibition of insulin 
secretion is dependent on SSTR5 and/or other SSTR receptor signalling.  
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4.4.4 Conclusions 
The experiments performed within this chapter were designed with the notion that 
cannabinoid signalling was conserved in islets and that variation in the 
responsiveness of islets to AEA (as observed in Chapter 3) was the result of local 
metabolism. Based on such a hypothesis, it was found that AEA inhibited insulin 
secretion in a CB1, CB2, and PPAR receptor independent manner. However, data 
from the AEA antagonism studies and the sst-14 studies suggests that AEA signalling 
within islets was more complex than originally thought. For instance, islet 
responsiveness to AEA at concentrations  10M may be solely dependent on a sst-
14 mediated signalling pathway, whereas at higher concentrations AEA may be able 
to inhibit insulin secretion by a sst-14 mediated signalling pathway and/or by a CB2 (or 
CB2-like) receptor signalling pathway and/or other unidentified pathway(s). 
Intriguingly, such a scenario may not only be dependent on the concentration of AEA 
used but may be influenced by the islet cell composition and fasting state of the 
animal prior to tissue collection. Unfortunately, the data within this chapter is not 
sufficient to verify such a model. 
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5  
 
The acute effects of 
cannabinoid receptor ligands 
on insulin secretion from 
Wistar rat isolated pancreatic 
islets 
 116
5.1 Introduction 
 
As discussed in Chapter 4, the expression of the cannabinoid (CB) receptors (CB1 
and CB2) have been detected in pancreatic islets isolated from rats. However, the 
specific roles of the CB1 and CB2 receptors in the control of insulin secretion have not 
been characterised. This information may clarify the signalling pathways involved in 
AEA-mediated inhibition of insulin release. Therefore, the principal aim of this chapter 
was to characterise the acute effects of CB1- and CB2-receptor activation on insulin 
secretion. Hence, CB1 and CB2 receptor agonists and antagonists were used in 
freshly isolated islets of Langerhans from male Wistar rats. 
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5.2 Methods 
 
5.2.1 Materials 
All drugs and buffers were prepared as described in Sections 2.2.  
 
5.2.2 Animals 
All procedures were performed using tissues obtained from male Wistar rats with body 
weight ranging from 230-350g. Animals were housed and killed as described in 
Section 2.1.  
 
5.2.3 Insulin secretion studies 
Islets were isolated from male Wistar rats according to the isolation procedure 
described in 2.4.1.1.  
 
5.2.3.1 Static incubations 
Freshly isolated islets were used in static incubation studies, as described in 2.4.2. 
Once the one hour incubation had finished, samples of incubation buffer were taken 
from each well and the amount of insulin in the samples was determined by RIA as 
described in 2.6. Analysis of experimental data was carried out as described in 2.4.5. 
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5.3 Results 
 
5.3.1 Effects of arachidonyl-2-chloroethylamide (ACEA), a CB1 
receptor agonist, on glucose-dependent insulin secretion 
ACEA, a CB1 receptor agonist, was chosen to investigate CB1 receptor signalling as it 
is reported to have a high affinity, efficacy, and selectivity for the CB1 receptor (Hillard 
et al., 1999). ACEA has been used in a number of cell types and tissues, with 1M 
ACEA typically reported in most studies to induce substantial CB1 receptor specific 
signalling events (Sterin-Borda et al., 2005; Mato et al., 2009; Cencioni et al., 2010). 
In isolated islets ACEA (1M) did not affect basal rates of insulin secretion and failed 
to consistently affect 20mM glucose stimulated insulin secretion, with a large degree 
of variability in the secretory response at 20mM glucose (Figure 5.1A). Subsequent 
experiments with 10μM and 30μM ACEA also appeared not to affect insulin secretion 
at 20mM glucose either but again there was wide variability (Figure 5.1B). 
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B 
 
Figure 5.1  The effects of ACEA, a CB1 receptor agonist, on glucose-dependent 
insulin secretion. A) Islets were incubated at 4mM or 20mM glucose in the absence 
(control) or presence of 1M ACEA for 1 hour. Results are presented as mean insulin 
secretion rates ± SD (n= 6). B) A distribution frequency presenting all the observed 
effects of ACEA at 1M (n= 6), 10M (n= 7) and 30M (n=6) on insulin secretion at 
20mM glucose.  
 
5.3.2 Effects of CB1 receptor antagonists, AM251 and O-2050, on 
glucose-dependent insulin secretion 
AM251 (a CB1 receptor antagonist) was tested at a concentration of 1M as it has 
been reported that 1M AM251 did not affect  glucose stimulated oscillations in [Ca2+]i 
or GSIS from murine islets, which may occur if higher concentrations of AM251 were 
used (Savinainen et al., 2003; Juan-Pico et al., 2006; Price et al., 2007). The effects 
of 1M AM251 were found to be highly variable with no consistent effect on insulin 
secretion being observed at any glucose concentration tested (Figure 5.2A). As the 
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observed effects of AM251 may have been due to non-specific concentration-
dependent effects, concentration-response experiments with AM251 were performed 
at 20mM glucose (Figure 5.2B). At concentrations > 100nM, AM251 inhibited insulin 
release more frequently as the concentration increased. At concentrations > 1M, 
AM251 consistently inhibited insulin secretion with the maximal inhibitory effects of 
AM251 being observed at 10M. The IC50 of AM251 for inhibition of 20mM GSIS was 
1.6M (95% CI: 507nM to 3.3M). The mean Hill slope was calculated as -3.1 ± 5.4. 
 
A 
 
B 
 
Figure 5.2  The effects of AM251, a CB1 receptor antagonist, on glucose-dependent 
insulin release. A) Islets were incubated at 4mM, 8mM or 20mM in the absence 
(control) or presence of 1M AM251. Results are presented as mean insulin secretion 
rates ± SD (n= 9). B) Islets were incubated at 20mM glucose with increasing 
concentrations of AM251. The mean basal insulin secretion rate is represented as a 
square. Results shown as mean insulin secretion rates ± SD (n= 6). ** P< 0.01, *** P< 
0.001 vs. 20mM glucose control. 
 
AM251 when used at a concentration of 10M, caused a marked inhibition of insulin 
secretion at 20mM glucose, but in islets incubated at 4mM and 8mM glucose, AM251 
did not significantly affect insulin release (Figure 5.3). The effects of 10μM AM251 
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may have been due to PPAR activation (O'Sullivan et al., 2007) or inverse agonism 
at the CB1 receptor (Section 1.4.3). Therefore, 10μM AM251 was used in antagonist 
studies with GW9662, a PPAR antagonist, and the CB1 receptor antagonist O-2050. 
Use of 1μM GW9662 did not affect islet responses to AM251 (Figure 5.4A). O-2050 
(100nM), which is structurally dissimilar to AM251, did not affect islet responses to 
20mM glucose and failed to modify the inhibitory effect of 10M AM251 (Figure 5.4B). 
At the higher concentration of 1M, O-2050 did not affect insulin secretion at 20mM 
glucose but significantly attenuated the inhibitory effects of 10μM AM251 on insulin 
secretion (Figure 5.5A). Again, there appeared to be some variability in the responses 
to O-2050 alone since subsequent sub-analysis revealed that O-2050 at 1M caused 
a slight inhibition of insulin release insulin secretion, whereas 100nM O-2050 did not 
(Figure 5.5B). 
 
 
 
Figure 5.3  The effects of 10M AM251 on glucose-dependent insulin secretion. Islets 
were incubated at 4mM, 8mM or 20mM in the absence (control) or presence of 10M 
AM251. Results are presented as mean insulin secretion rates ± SD (n= 7). * P< 0.05 
vs. 20mM glucose control. 
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Figure 5.4  The effects of the PPAR antagonist GW9662 and the CB1 receptor 
antagonist O-2050 on islets responses to 10M AM251. A) Islets were incubated for 1 
hour at 4mM or 20mM glucose in the absence (control), or presence of 10M AM251, 
with or without 1M GW9662 (GW). Results are presented as mean insulin secretion 
rates ± SD (n= 6). *** P< 0.001 vs. 20mM glucose control B) Islets were incubated for 
1 hour at 4mM or 20mM glucose in the absence or presence of 10M AM251 with or 
without 100nM O-2050. Results shown are mean insulin secretion rates ± SD (n= 5) * 
P< 0.05, *** P< 0.001 vs. 20mM glucose control. 
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Figure 5.5  The effects of 100nM and 1M O-2050 (O-2) on insulin secretion at 20mM 
glucose and islet responses to 10M AM251. A) Islets were incubated for 1 hour at 
4mM or 20mM glucose in the absence or presence of 10M AM251 with or without 
1μM O-2050. Results are presented as mean insulin secretion rates ± SD (n= 7). 
***P< 0.001 vs. 20mM glucose control; # P< 0.05. B) Distribution frequency of all the 
observed effects of 100nM and 1M O-2050 on insulin secretion at 20mM glucose. 
1M O-2050 n= 17; 100nM O-2050 n= 10. 
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5.3.3 The effects of CB2 receptor ligands on glucose-dependent 
insulin secretion 
AM630 is a CB2 receptor antagonist but at concentrations  1μM AM630 may also act 
as a CB1 receptor agonist in CB1 receptor-transfected Chinese hamster overy cells 
(Ross et al., 1999). Therefore, AM630 was not only tested at 100nM but at 1M too. 
Neither 100nM nor 1M AM630 significantly affected insulin release at 4mM or 20mM 
glucose (Figure 4.3 & 5.6A). JWH-133 has been reported to be a potent and selective 
(at concentrations  1M) CB2 receptor agonist and has been used in numerous 
studies performed in islets and other tissues to investigate the effects of CB2 receptor 
signalling (Huffman et al., 1999; Juan-Pico et al., 2006; Mule et al., 2007; Bermudez-
Silva et al., 2008). JWH-133 (1μM) failed to significantly alter insulin release at basal 
or maximal levels of GSIS (Figure 5.6B). However, on further experimentation, when 
used at 10μM, JWH-133 inhibited insulin secretion induced by 20mM glucose (by > 
25%) in the majority of experiments (Table 5.1). In the same set of experiments, islets 
were also co-incubated with 100nM AM630 and 10μM JWH-133 to determine whether 
JWH-133 was acting in a CB2 receptor-specific manner. Due to a large degree of 
variation in the effects of 100nM AM630, when used alone, it could not be verified 
whether the effects of 10μM JWH-133 were CB2 receptor-specific (Table 5.1).  
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Figure 5.6  The effects of JWH-133 (a CB2 receptor agonist) and AM630 (a CB2 
receptor antagonist) on basal and maximal levels of glucose-stimulated insulin 
secretion. A) Islets were incubated at 4mM or 20mM glucose for 1 hour in absence 
(control) or presence of AM630 at either 100nM or 1M. Results are presented as 
mean insulin secretion rates ± SD (n= 7, except for 100nM and 1M AM630 at 4mM 
glucose where n= 3). B) Islets were incubated at 4mM or 20mM glucose for 1 hour in 
the absence (control) or presence of 1M JWH-133. Results are shown as mean 
insulin secretion rates ± SD (n= 9).  
 
Table 5.1  The mean insulin secretion rates from 6 individual experiments detailing 
the effects of AM630 on islet responses to JWH-133.  
 
Experiment 
no. 
100nM 
AM630 
10M 
JWH-133 
10M JWH-133 + 
100nM AM630 
Net effect of 100nM 
AM630 on 10M 
JWH-133 
1 36.3 ± 3.4 36.3 ± 7.9 38.5 ± 7.1 +2.2 
2 148 ± 13 32.2 ±  9.4 82.3 ± 23.3 +50.1 
3 89.7 ± 6.8 32.7 ± 10.4 72 ± 14.3 +39.3 
4 92 ± 27.7 49.5 ± 9.2 37.5 ± 6.1 -12.0 
5 133 ± 23.4 66.8 ± 17.1 93.7 ± 7.6 +26.9 
6 174 ± 44.8 105 ± 42.3 50.3 ± 12.1 -54.7 
 
Islets were incubated for 1 hour at 4mM or 20mM glucose in the absence or presence 
of 10M JWH-133 (a CB2 receptor agonist) with or without 100nM AM630 (a CB2 
receptor antagonist). All values are the mean insulin secretion rate (expressed as a 
percentage of the 20mM glucose control) ± SD for n= 3-5 replicates per condition. The 
net effect of 100nM AM630 on 10μM JWH-133 was calculated as the mean insulin 
secretion rate for 30μM AEA + 100nM AM630 minus the mean insulin secretion rate 
for 10μM JWH-133.  
B 
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5.4 Discussion 
 
In this chapter, ligands which have been described as cannabinoid receptor-specific, 
were used to examine the involvement of CB1 and CB2 receptors in the regulation of 
insulin secretion. The CB1 receptor agonist ACEA did not affect basal insulin 
secretion. In addition, ACEA did not produce a clear-cut effect on maximal levels of 
GSIS despite being tested at several micromolar concentrations. Similarly, JWH-133, 
a CB2 receptor agonist, at 1M did not affect basal or maximal levels of GSIS, but at 
10M, it inhibited insulin secretion at 20mM glucose. It is uncertain whether the effects 
of 10M JWH-133 were CB2 receptor-specific. In conjunction with testing of CB 
receptor agonists, the effects of CB receptor antagonists on insulin release were 
examined. AM251 (CB1 receptor antagonist) inhibited insulin secretion in a glucose- 
and concentration-dependent manner at concentrations greater than 100nM. The 
inhibition of insulin secretion caused by 10M AM251 was attenuated by another CB1 
receptor antagonist O-2050 (1μM) but not by the PPAR antagonist GW9662. 
However, when used at 1μM, O-2050 behaved in a similar manner to AM251, causing 
an inhibition of GSIS in 53% of experiments in which it was used. 
 
5.4.1 Effects of ACEA on glucose-dependent insulin secretion 
In the present study, the CB1 receptor agonist ACEA was found to have an 
inconsistent effect on 20mM glucose, as ACEA potentiated insulin secretion in some 
islets but inhibited insulin release in others (Figure 5.1B). To date, ACEA has been 
used at 100nM in two other islet studies, and it has been shown to inhibit insulin 
secretion in mouse islets but to potentiate insulin secretion in human islets 
(Bermudez-Silva et al., 2008; Nakata & Yada, 2008). This may appear to suggest that 
there are species-dependent differences in the effects of ACEA between rodent and 
human islets. However, as discussed in Chapter 3, the difference in effect of ACEA 
could be due to how the islets were prepared, as Nakata & Yada (2008) using freshly 
isolated islets, whereas Bermudez-Silva et al. (2008) used cultured islets. Regardless 
of the effects of ACEA on insulin secretion, neither study reported ACEA to have 
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mixed effects on insulin secretion whereas, the effects of 1, 10 and 30μM ACEA in 
this study were variable (Figure 5.1B). CB1-receptors has been described to be 
expressed along the periphery of the islets, in -cells (Bermudez-Silva et al., 2007; 
Starowicz et al., 2008; Tharp et al., 2008; Bermudez-Silva et al., 2009; Vilches-Flores 
et al., 2010) and in 	-cells (Tharp et al., 2008). As shown in Figure 5.7, the 
potentiation and inhibition of insulin secretion by ACEA could be explained by the 
hypothesis that CB1 receptors, expressed on - and 	-cells, are postively linked to the 
secretion of glucagon and somatostatin, respectively. However, CB1 receptor-
mediated potentiation of glucagon secretion (and the resultant increase in insulin 
release) would only be apparent if sst-14 signalling was somehow blocked in islets. As 
discussed in Section 4.4.3, islet respones to 100nM sst-14 were found to be variable 
suggesting that sst-14 signalling could be blocked in some islets, therefore, both 
scenarios appear to be feasible. As suggested previously for AEA (see Chapter 4), 
several approaches could be used to test whether certain effects of ACEA are linked 
to alterations in paracrine signalling events. 
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Figure 5.7  Two schematics of ACEA signalling in islets at 20mM glucose based on 
the assumption that CB1 receptor signalling potentiates the secretion of glucagon, 
from -cells, and sst-14, from 	-cells. A) ACEA-mediated potentiation of somatostatin-
14 (sst-14) release inhibits the secretion of glucagon and insulin. B) ACEA potentiates 
the release of sst-14 but sst-14 signalling on the - and -cells is somehow blocked. 
Thus, allowing increased glucagon to be secreted from the -cells, which in turn 
potentiates insulin release from the -cells. Bold block arrows represent dominant 
signalling pathways and faint broken arrows signify recessive (A) or non-functioning 
(B) signalling pathways. + and - represent positive and negative effects on hormone 
secretion. 
 
The differential effects of ACEA may be due to the occurrence of CB1 receptor 
signalling in some islets, with non-CB1 receptor signalling in other islets, despite 
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ACEA being described as CB1 receptor-specific at 1μM (Hillard et al., 1999; Mule et 
al., 2007). The use of CB1 and CB2 receptor antagonists with ACEA would determine 
the specificity of ACEA signalling in islets. This would also help to clarify which effects 
of ACEA were associated with which CB receptor. However, as observed in this 
chapter, the availability of truly “neutral” antagonists at CB receptors which bind 
without affecting insulin secretion may be an issue. It should also be considered 
whether ACEA may be affecting insulin secretion via non-CB receptor(s). For 
instance, ACEA may be acting at GPR55 and/or a CB2-like receptor as LPI (Chapter 
4) and AM630 (discussed below) were the two only compounds, aside from ACEA, 
used in this study which were found to sporadically potentiate insulin secretion. The 
potentiation of insulin secretion by ACEA may have also been caused by activation of 
-cell TRPV1 channels but currently the literature suggests that primary -cells do not 
express TRPV1 channels (Akiba et al., 2004; Price et al., 2004; Razavi et al., 2006; 
Gram et al., 2007).  
 
5.4.2 Effects of JWH-133 on glucose-dependent insulin secretion 
In the literature, JWH-133 is described to act in a CB2 receptor-dependent manner, 
with nanomolar concentrations of JWH-133 being reported to significantly inhibit 
insulin secretion in islets (human and mouse) but potentiate insulin secretion in RIN-
m5F (-cell line) cells (Juan-Pico et al., 2006; De Petrocellis et al., 2007; Mule et al., 
2007; Bermudez-Silva et al., 2008). However, in the present study, JWH-133, used at 
a concentration of 1μM (several fold higher than that used in the studies described 
above) failed to affect insulin secretion in rat islets (Figure 5.6B). However, when used 
at 10M, JWH-133 was found to inhibit insulin secretion in 83% of experiments. This 
is in accordance with earlier experiments, in which 30M AEA was used in the 
presence of 100nM AM630, which lead to the suggestion that CB2 (or CB2-like 
receptors) may be negatively coupled to insulin secretion (Chapter 4). Assuming that 
CB2 receptor signalling directly affects -cell activity, the low potency of JWH-133 in 
islets may be due to the number of islet cells which express the CB2 receptor. Indeed, 
immunohistological data presented in Bermudez-Silva et al. (2009) suggest that CB2 
 129
receptors are not uniformly expressed by rat -cells. Therefore, it may be beneficial in 
future work to determine whether the potency of JWH-133 is linked to the ratio of CB2 
receptor expressing  cells to non-CB2 receptor expressing -cells. Information from 
studies performed in other tissues suggests that at 10μM, JWH-133 can also act via 
the CB1 receptor (Baldassano et al., 2008). Hence, the specificity of 10μM JWH-133 
should not only be examined in the context of CB2 receptor signalling on insulin 
secretion but CB1 receptor signalling too. As discussed with ACEA, this may not be 
easily implemented as it is uncertain whether other CB1 or CB2 antagonists would be 
able to block CB receptor signalling without affecting insulin secretion. It is also 
feasible that the effects of 10μM JWH-133 occurred independently of either 
cannabinoid receptor. 
 
5.4.3 Effects of AM251 and O-2050 on glucose-dependent insulin 
secretion 
Initial testing of the CB1 receptor antagonist AM251 began with use of 1μM AM251 at 
basal, intermediate and maximal levels of GSIS. Despite 1μM AM251 being reported 
by Juan-Pico et al. (2006) not to affect glucose-stimulated oscillations in [Ca2+]i in 
mouse islets, it was found in the current study that the effects of 1μM AM251 on GSIS 
were variable (Figure 5.2A). In subsequent experiments, AM251 displayed clear 
concentration-dependent effects on insulin secretion at 20mM glucose with 100nM 
AM251 not affecting insulin secretion, while 10μM AM251 fully inhibited insulin 
secretion. The study by Bermudez-Silva et al. (2008) confirms the finding that 100nM 
AM251 does not affect insulin secretion but the effects of AM251 at concentrations > 
1μM have not been reported in islets. At low micromolar concentrations, AM251 and 
its structural analogue rimonabant, are either known or thought to act as inhibitors of 
adenosine A1 receptors, dopamine transporters, voltage-gated L-type Ca2+ channels, 
KATP channels and large conductance Ca2+-activated K+ channels (White & Hiley, 
1998; Savinainen et al., 2003; Price et al., 2007). Therefore, the inhibition of insulin 
secretion caused by AM251 may have been CB1 receptor-independent. Subsequent 
experiments found that 10μM AM251 inhibited insulin secretion in a glucose-
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dependent manner (Figure 5.3). Similar findings have also been reported with 1M 
rimonabant on insulin secretion from Zucker Fatty rat islets but the results from the 
study by Getty-Kaushik et al. (2009) contrast with data presented in Chapter 6. This 
may be due to the use of overnight-cultured, instead of freshly isolated, Zucker Fatty 
rat isolated islets (Getty-Kaushik et al., 2009). Similarly, 1μM BAR-1, a novel analogue 
of AM251, was reported by Vilches-Flores et al. (2010) to potentiate insulin secretion 
at 3mM and 16mM glucose in islets from Wistar rats, which is again contrary to the 
present findings with AM251. The differences in the effects of the CB1 receptor 
antagonists on insulin secretion may be due to the use of freshly isolated islets in this 
study and the use of cultured islets in the study by Vilches-Flores et al. (2010). 
However, the contrasting findings between Vilches-Flores et al. (2010) and this study 
may be because AM251 and BAR-1 were affecting insulin secretion by different non-
CB1 receptor-mediated signalling events. 
 
As the effects of AM251 may have been caused by PPAR agonism, islets were co-
incubated with GW9662, a PPAR receptor antagonist (O'Sullivan et al., 2007). The 
results from these experiments suggest that 10M AM251 inhibited insulin secretion 
by a PPAR receptor-independent signalling pathway. Based on the study by Chaytor 
et al. (1999), an alternative mechanism by which 10μM AM251 may inhibit insulin 
secretion is by the blockade of gap junctions (Bertuzzi et al., 1999; Calabrese et al., 
2003; Rocheleau et al., 2006). The synchronised release of insulin from islets is 
mediated by the activity of gap junctions which electrically couple the -cells, allowing 
the co-ordinated release of insulin secretion from -cells within an islet (Ravier et al., 
2005). This can be observed using calcium imaging techniques, as GSIS is Ca2+ 
dependent (Section 1.2.2). Therefore, in islets where gap junction function is inhibited, 
oscillations in cytosolic Ca2+ levels will no longer be synchronised between all the -
cells within an islet (Ravier et al., 2005). Hence, Ca2+ imaging techniques could be 
used to determine whether 10μM AM251 was inhibiting gap junction functionality in 
islets. However, the study by Juan-Pico et al. (2006) has already investigated the 
affects of 1μM AM251 on glucose-stimulated Ca2+ oscillations and reported that 
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AM251 had no effect on glucose induced [Ca2+]i oscillations in mouse islets. 
Additionally, Ravier et al. (2005) found that genetic knock-out of Connexin36 in mice 
abolished gap-junction function in -cells. The resultant loss of gap junction function in 
islets was only found to significantly potentiate basal insulin secretion rates of insulin 
secretion but did not significantly affect GSIS (Ravier et al., 2005). Therefore, 
inhibition of gap junction function does not appear to account for 10μM AM251 
mediated inhibition of insulin release at 20mM glucose.  
 
O-2050, another CB1 antagonist, was used to determine whether the effects of AM251 
were CB1-receptor mediated, as CB1 receptor signalling may potentiate insulin 
secretion in islets. In such a model, CB1 receptors in islets may be constitutively-active 
(Section 1.4.3). Therefore, the inhibitory effects of AM251 on insulin release could be 
explained by inverse agonism (Xiao et al., 2008). However, the CB1 receptors may be 
constitutively activated by islet-derived endocannabinoids that are produced in a 
glucose-dependent manner (Konrad et al., 1994; Bermudez-Silva et al., 2008). 
Therefore, the apparent inverse agonistic activty of AM251 may also be due to 
blockade of an endocannabinoid tone in islets. O-2050 was chosen over other CB1 
antagonists despite being a relatively poorly-characterised CB1 receptor antagonist, 
as O-2050, at the time of use, was reported to be devoid of inverse agonistic 
behaviour. Additionally, O-2050 is structurally dissimilar to AM251, therefore, it is less 
probable that the two CB1 receptor antagonists would have the same non-CB1 
receptor mediated effects. Use of 100nM O-2050 did not consistently attenuate the 
effects of 10μM AM251. Therefore, the experiments were repeated with 1μM O-2050 
and it was found that 1μM O-2050 did not significantly affect insulin secretion but 
consistently attenuated the inhibitory effects of 10μM on AM251 on insulin secretion. 
On further analysis, 1μM O-2050 was found to inhibit insulin secretion (by > 25%) in 
approximately half of the experiments (Figure 5.5B). As mentioned above, the effects 
of AM251 and O-2050 could be rationalised by the blockade of an islet-derived 
endocannabinoid mediated CB1-receptor tone in islet. As ACEA did not consistently 
potentiate insulin secretion, the hypothesis that CB1 receptor signalling potentiates 
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then seems unlikely. This suggests that 1μM O-2050 was inhibiting insulin secretion 
by non-CB1 receptor-mediated signalling. This has also been suggested in the study 
by Gardner & Mallet (2006) which reported that O-2050 induced behavioural changes 
in vivo that were not associated with “classical” CB1 receptor signalling. So, O-2050 
may act similarly to AM251, with both molecules interacting through a common 
binding site at a CB1-like receptor. The results suggest that O-2050 (at concentrations 
greater than 100nM) has a similar or higher affinity for the CB1-like receptor compared 
to AM251 but is a partial agonist. 
 
The CB1-like receptor site could be GPR55, as AM251 is frequently reported to be a 
GPR55 agonist in GPR55 transfected cell lines and natively expressing primary cells 
(Janiak et al., 2007; Getty-Kaushik et al., 2009; Kapur et al., 2009; Yin et al., 2009; 
Henstridge et al., 2010a). The study by Janiak et al. (2007) reported that daily 
ingestion of rimonabant had beneficial effects on Zucker fatty islet morphology and 
function, which was believed to be due to blockade of CB1 receptor signalling. 
However, if some of the positive effects of rimonabant treatment were mediated by 
signalling via the CB1-like receptor site, then its identification should be considered in 
future studies.  
 
5.4.4 Effects of AM630 on glucose-dependent insulin secretion 
Neither 100nM nor 1M AM630 significantly affected basal or maximal levels of insulin 
secretion, which is in accordance with other studies performed in islets (Juan-Pico et 
al., 2006; Bermudez-Silva et al., 2008). There was a large variability in the secretory 
rates when islets were treated with AM630, with either potentiation or inhibition insulin 
release at 20mM glucose. Based on the finding by Bermudez-Silva et al. (2008), that 
2-AG production is positively linked to extracellular glucose concentration, there may 
be a constitutive endocannabinoid tone in islets at 20mM glucose. The constitutive 
endocannabinoid tone may then negatively affect GSIS via CB2 receptor signalling. If 
the theory is correct, then this may explain the instances in which AM630 potentiates 
insulin secretion. Yet, this theory does not explain the instances where AM630 inhibits 
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insulin secretion unless CB2 receptor signalling is compromised in some islets. In 
these instances, AM630 may block “non-functional” CB2 receptor sites allowing 
endocannabinoids to inhibit insulin secretion by non-CB2 receptor mediated means. It 
may also be that AM630 is affecting insulin secretion by CB1 receptors mediated 
signalling (Ross et al., 1999). Therefore, future experiments should establish whether 
endocannabinoid production is linked to GSIS. If there is an endogenous 
endocannabinoid tone in islets, it should then be determined what endocannabinoids 
(or endocannabinoid-like molecules) are produced by islets and what their effects on 
insulin secretion are.   
 
5.4.5 Conclusions 
The results from the present study suggest that CB or CB-like receptor signalling does 
occur within islets. Additionally, the effects of 10M JWH-133 appeared to corroborate 
previous findings in Chapter 4, that a large CB2 or CB2-like receptor mediated 
signalling event can lead to an inhibition of insulin secretion in a majority of islets. 
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6  
 
Acute effects of cannabinoids 
and fatty acid amide hydrolase 
enzyme inhibition on insulin 
secretion in a rat model of 
obesity and type 2 diabetes 
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6.1 Introduction 
 
As described in Section 1.3.1, several genetic and environmental risk factors have 
been identified or have been linked to the development of type 2 diabetes mellitus. 
The interactions between the different genetic and environmental risk factors are 
complex, and deliberate induction of diabetes in humans to assess these interactions 
would be unethical. Hence, a wide variety of animal models are used to study the 
progression  of islet dysfunction and/or insulin resistance, as well as for the testing of 
treatments for the control or prevention of type 2 diabetes, many of which have been 
reviewed by Srinivasan & Ramarao (2007) and Franconi et al. (2008). As discussed in 
these reviews, animal models used for the study of type 2 diabetes range from strains 
that were observed to become diabetic (either spontaneously or induced by high fat 
diet), had specific alterations made to their genome, through to those who had 
diabetes induced by surgery or drug treatment. 
 
6.1.1 The Zucker rat strain 
In the present study, Zucker Fatty (ZF) and Diabetic Fatty (ZDF) rats were used as 
models for obesity and obesity-induced type 2 diabetes. Zucker Fatty rats, in common 
with obese humans, have insulin resistant peripheral tissue, hyperinsulinaemia, high 
plasma triglycerides (TG) levels, hypertension (increases proportionately with body 
weight) and high plasma levels of non-esterified free fatty acids (Kurtz et al., 1989; 
Sreenan et al., 1996; Despres et al., 2005; Janiak et al., 2007; Di Nardo et al., 2009). 
Despite these factors, they do not develop diabetes and their plasma glucose levels 
remain similar to those of their lean littermates (Sreenan et al., 1996; Nolan et al., 
2006). ZDF rats, up to seven weeks of age, are considered to be pre-diabetic as their 
plasma glucose levels are similar to age-matched Zucker Lean Control (ZLC) rats and 
are phenotypically similar to age-matched ZF rats (Pick et al., 1998; Harmon et al., 
1999; Harmon et al., 2001; Nolan et al., 2006). After seven weeks of age, diabetes is 
known to occur spontaneously (without any special dietary requirements) in male ZDF 
rats, and by 12 weeks of age all untreated male ZDF rats have type 2 diabetes (Orci 
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et al., 1990). While the diabetic ZDF rats are still obese compared to age-matched 
ZLC rats, they are usually lighter than age-matched ZF rats (Pick et al., 1998). Unlike 
their male counterparts, obese female ZDF rats do not become spontaneously 
diabetic but diabetes can be induced by a high fat diet (Clark et al., 1983; Pick et al., 
1998; Corsetti et al., 2000). As discussed in the review by Franconi et al. (2008), the 
prevalence of type 2 diabetes between genders in humans is roughly equal, therefore 
this is a limitation of ZDF rat as a model of human type 2 diabetes.    
 
6.1.1.1 Establishment and maintenance of the Zucker rat strain 
The Zucker rat strain was originally derived from cross breeding Merck Stock M and 
Sherman rats, with the rats either having lean or spontaneously obese phenotypes 
(Bray, 1977). It was found that obesity was inherited following a simple Mendelian 
pattern, in which obesity was found to be caused by a single recessive allele of an 
unknown gene (Bray, 1977). The lean littermates were called Zucker Lean Controls 
(ZLC) and the genetically obese rats were called Zucker Fatty rats.  
 
Several years after the establishment of the Zucker rat strain, it was observed in a 
small colony of Zucker rats that some of the ZF animals became spontaneously 
hyperglycaemic (Clark et al., 1983). Subsequent testing established that the diabetic 
trait was only manifested in the genetically obese rats and diabetes could not be 
induced in the ZLC rats by a high fat and sucrose diet or by pregnancy (Clark et al., 
1983). The majority of the ZF rats which were hyperglycaemic were male, with only 
two of the rats being female (Clark et al., 1983). From this colony, an inbred line of 
Zucker rats was created consisting of ZLC rats and the diabetic ZF rats, which were 
renamed Zucker Diabetic Fatty rats. It was later found that the genetic cause for the 
obesity seen in the ZF and ZDF rat strains was due to a mutated, non-functional form 
of the leptin receptor which results in the blockade of leptin signalling (Wang et al., 
1998). The ZLC rats for ZF and ZDF rat strains are either homozygous for the wild 
type receptor (+/+) or are heterozygous for the mutated leptin receptor (fa/+), while 
the ZF and ZDF rats are homozygous with mutated form of the leptin receptor (fa/fa). 
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ZF rat colonies are maintained by outbreeding ZF (fa/fa) males with ZLC (fa/+) 
females, while ZDF rats colonies are maintained by inbreeding ZLC males (fa/+) with 
(fa/+) females (Charles River Laboratories International, 2010b, a).  
 
6.1.1.2 Islet dysfunction in the Zucker diabetic fatty rats 
Progression of diabetes in the ZDF rat brings about marked effects on islet 
morphology. Typically, the most notable change is increased islet size and 
subsequent loss of a regular spherical shape, which are the result of multiple factors 
reported to primarily affect -cells. A leading cause of islet size increase is the 
accumulation of triglycerides, which is common to islets isolated from ZF and ZDF rats 
(Nolan et al., 2006). Similarly, both ZF and ZDF islets are reported to have higher -
cell replication rate than their ZLC littermates, which also contributes to the increase in 
islet size (Tokuyama et al., 1995; Pick et al., 1998; Li et al., 2006; Larsen et al., 2008). 
Similarly, -cell apoptosis rates are increased too, but in ZF and pre-diabetic ZDF 
animals the apoptotic rate is exceeded by the rate of -cell proliferation (Pick et al., 
1998). As the ZDF animals become diabetic, -cell mass decreases; this is thought to 
be due to a shift in the -cell proliferation: apoptosis ratio, in the favour of apoptosis 
(Pick et al., 1998). Islet cell organisation is also affected in ZF and ZDF islets as it has 
been noted that the other non- cells (normally found on the periphery) are partially 
interspersed throughout the islet (Pick et al., 1998). 
 
It has also been observed in people with type 2 diabetes that their islets have lost their 
organised morphology (Tokuyama et al., 1995; Iki & Pour, 2007). In islets from human 
type 2 diabetics, the ratio of -cells to non--cells is decreased, with respect to islets 
from weight- and age-matched non-diabetic controls (Yoon et al., 2003; Iki & Pour, 
2007). As with ZDF rats, reductions in -cell mass in islets isolated from obese people 
with type 2 diabetes is also believed to be caused by increased rates of apoptosis 
(Butler et al., 2003).  
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The alterations in islet morphology also coincide with changes in glucose-stimulated 
insulin secretion responses, as the islets from ZF and ZDF rats adapt to meet the 
increased need for insulin due to increasing peripheral insulin resistance. This need 
for additional insulin is achieved by the islets by increases to both basal and maximal 
rates of insulin release (Sreenan et al., 1996; Harmon et al., 1999; Zhou et al., 1999). 
In ZF islets, it has been noted that there is a leftward shift in islet glucose 
responsiveness, particularly in the larger islets, as well as an increase in basal insulin 
secretion rates in comparison to islets isolated from ZLC rats (Chan et al., 1998; Zhou 
et al., 1999). As with ZF rats, pre-diabetic ZDF rats show similar changes in GSIS, 
with an increased basal secretion rate and a leftward shift in GSIS (Pick et al., 1998). 
When the ZDF rats develop diabetes, their islets no longer secrete insulin with a 
distinct increase in insulin secretion rates in response to increasing glucose 
concentrations (Sreenan et al., 1996; Zhou et al., 1999). The loss of glucose 
responsiveness by the ZDF islets is thought to be due to maximal levels of GSIS 
decreasing with increased rates of basal insulin secretion (Sreenan et al., 1996; 
Harmon et al., 1999; Zhou et al., 1999). In humans, the loss of the glucose-stimulated 
insulin release is thought to be due to the loss of a distinct first phase of insulin 
secretion rather than alterations in basal secretion rates, as observed in the Zucker 
rats (Bogardus & Tataranni, 2002; Festa et al., 2008; Nijpels et al., 2008). 
 
6.1.1.3 Secondary complications in the Zucker diabetic fatty rat 
As stated in Section 1.3, people with type 2 diabetes are at an increased risk of 
developing various secondary complications, many of which can be modelled in the 
ZDF rats. ZDF rats are employed as models of impaired wound healing, retinopathy, 
cardiac dysfunction, vascular dysfunction, nephropathy and neuropathy in type 2 
diabetes (Vrabec, 1998; Chatham & Seymour, 2002; Chander et al., 2004; Behl et al., 
2008; Brussee et al., 2008; Romanovsky et al., 2008; Sugimoto et al., 2008; Oltman et 
al., 2009). However, there are limitations in the relevance of ZDF rats as a model for 
secondary complications in type 2 diabetes. The study by Marsh et al. (2007) 
suggests that the Zucker rats (ZLC, ZF and ZDF) are susceptible to renal 
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abnormalities independent of phenotype. Therefore, increased risk in renal 
abnormalities may increase the incidence of cardiac dysfunction, especially in ZDF 
rats. 
 
6.2 Zucker Fatty and Diabetic Fatty rats as models of human 
obesity and type 2 diabetes 
As stated above, obesity in the Zucker strain is due to a defect in the leptin receptor, 
while obesity in humans is mainly attributed to hyper calorific diets (Wang et al., 
1998). As ZF rats display several characteristics associated with obesity in humans 
(Section 6.1), they are thought to be a good model of obesity. Metabolic syndrome is 
primarily based on the observation that people with central obesity and insulin 
resistance are at highest risk of developing type 2 diabetes and/or cardiovascular 
disease (Alberti et al., 2006). The 2006 World Health Organisation definition of 
metabolic syndrome  is the occurrence of central obesity with at least two of the 
following symptoms- raised triglycerides, low or reduced levels of HDL-cholesterol, 
raised blood pressure and IFG (or IGT, section 1.3.1; Alberti et al., 2006). Therefore, 
ZF rats can be used as models of metabolic syndrome as they posses central obesity, 
have impaired glucose tolerance and raised blood pressure (Section 6.1). However, 
as ZF rats are not considered to become diabetic and do not appear to be used as 
models of cardiovascular disease, their use in studying the progression of the 
syndrome is therefore limited. However, as ZDF rats become diabetic (Section 6.1.1) 
and develop cardiovascular disease (Section 6.1.1.3), they appear to be a good 
animal model for studying metabolic syndrome. 
 
With regard to ZDF rats as a model of type 2 diabetes in humans, they have several 
limitations with respect to -cell dysfunction (such as differences in the loss of GSIS), 
which have already been described in Section 6.1.1.2. There is also evidence to 
suggest that islet amyloid polypeptide (otherwise known as amylin) may be linked to 
the loss of -cell mass in type 2 diabetes in humans, as Butler et al. (2003) reported 
high incidence of amyloid plaque formation in islets obtained from people with type 2 
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diabetes. As rat amylin does not undergo fibrosis (Betsholtz et al., 1989), this would 
suggest that this is another limitation in the ZDF rat as a model of type 2 diabetes, but 
Yoon et al. (2003) who also studied amyloid plaque formation in pancreata from 
human type 2 diabetic did not reproduce the observations made by Butler et al. 
(2003). This may emphasise the ethnicity linked risk factor in the development type 2 
diabetes, as Yoon et al. (2003) used South Korean donors, whereas 98% of donors 
for the study by Butler et al. (2003) were Caucasian American of north European 
descent. 
 
Using islets from ZF and ZDF rats, the aim of this study was to assess whether any 
potential differences in cannabinoid signalling in islets may have occurred as a result 
of obesity or type 2 diabetes. Due to the limited availability of tissue, 10μM 
methanandamide and 10μM AM251 were used due their consistent inhibition of 
insulin secretion from normal Wistar rat islets (see Chapters 3 and 5). Additionally, the 
effects of fatty acid amide hydrolase inhibition, by 30 minute pre-incubation with 10μM 
URB597, was also used to assess whether any potential changes in endocannabinoid 
metabolism and/or endocannabinoid tone had occurred. 
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6.2 Methods 
 
6.2.1 Materials 
All drugs and buffers were prepared as described in Sections 2.2. 
 
6.2.2 Animals 
All procedures using tissues obtained from male Wistar rats were obtained from rats 
with body weight ranging from 230-350g. Six-week old male Zucker Fatty and Zucker 
Diabetic Fatty rats (Charles River, UK) were kept in-house until 9-11 weeks of age 
when they were used for experimentation. All animals were housed and killed as 
described in Section 2.1. Blood samples were taken and blood glucose levels were 
measured using a blood glucose meter (Medisense, Optuim). Unfortunately, ZLC rats 
were not available. 
  
6.2.3 Insulin secretion studies 
Islets isolated from male Wistar rats were produced according to the isolation 
procedure described in 2.4.1. Zucker rat isolated islets were prepared from a single 
pancreas and were isolated using an adapted version of the isolation procedure 
described in 2.4.1. The islets isolated from the ZF and ZDF rats varied in size, shape, 
and appeared grey in colour when examined on a dark background. This meant that 
the islets isolated from the Zucker rats could not be easily distinguished from exocrine 
tissue. Therefore, to identify islets, the digested tissue was stained with the zinc-
chelating substance dithizone (diphenylthiocarbazone; Sigma, Dorset, UK) at the end 
of the digestion. This allowed islets to be identified by their pink/red colour when 
viewed against a white background. 
 
Briefly, 50mg DTZ was dissolved in 2ml DMSO/3ml ethanol to produce a 10mg/ml 
stock solution. At the time of use, the 10mg/ml DTZ stock was then diluted 10-fold in 
70% (v/v) ethanol to produce a 1mg/ml solution. The collagenase-digested tissue was 
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resuspended in 10ml of buffer, to which 100μl of the 1mg/ml DTZ solution was added 
and then left to stand for 60 seconds. Once this time period had elapsed, the DTZ-
stained digest was briefly centrifuged at 3000rpm for 3 seconds. The supernatant was 
then poured off and the pellet resuspended in 10ml buffer. The islets (now pink in 
colour) were then handpicked in a clear Petri dish on a white background. 
 
6.2.3.1 Static incubations 
Incubation studies used freshly isolated islets with batches of 5 ZF islets or 10 ZDF 
islets. Islets were incubated in 0.5ml of Gey and Gey buffer (Section 2.3.1) with test 
reagents in 1.5ml micro-centrifuge tubes and incorporated the URB597 pre-incubation 
protocol described in Chapter 3. Briefly, islets were pre-incubated for 30 minutes at 
4mM glucose with either 10M URB597 or 0.7% (v/v) ethanol. Following the pre-
incubation period, test reagents were added, the 1.5ml micro centrifuge were agitated, 
briefly re-gassed, recapped and incubated for a further hour.  
 
Once the hour incubation had finished, the tubes were inverted and centrifuged at 
2000g (Hermle Z233MK-2) at room temperature for 3 minutes. Samples of the 
incubation media were removed for determination of insulin secretion rates by RIA 
(see section 2.6). The rest of the supernatant was then carefully removed from the 
tubes taking care not to disturb the pellet. The islets were then homogenised, using an 
Ultra Turrax T8 (Ika, Staufen, Germany), for 30 seconds (on setting 3) in 0.5ml acidic 
ethanol (ethanol: 0.8M HCl, 3:1). Following a brief centrifugation step, samples of 
supernatant were taken to determine islet insulin content by RIA (see section 2.6). 
Insulin secretion for each replicate was determined as the amount of insulin present in 
incubation media and expressed as a percentage of the total insulin (islet insulin 
content plus secreted insulin). Insulin secretion was then standardised against the 
4mM glucose control. 
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6.2.3.2 Comparison of basal insulin secretion rates 
The mean basal insulin secretion rates for Wistar rat islets was averaged from static 
incubation studies performed 1 week before and after the experiments when the 
Zucker islet studies were performed.  
 
6.2.4 Data analysis 
All data are presented as the mean ± SD. ZDF rat physiological parameters were 
compared against the corresponding ZF rat parameters using the unpaired two-tailed 
Student’s t-test. Analysis of insulin secretion data were carried out as described in 
2.4.5. Basal insulin secretion rates from Wistar, ZF and ZDF islets were compared 
using one-way ANOVA analysis. For all statistical comparisons, a P value < 0.05 was 
considered significant.  
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6.3 Results 
 
The ZDF rats had reduced body weight, were hyperglycaemic and had a lower islet 
insulin content compared to age-matched ZF rats (Table 6.1). Islets obtained from ZF 
rats had an approximate two-fold difference in the insulin secretion rates between 
4mM (basal secretion) and 20mM (maximal levels of secretion) glucose-stimulated 
insulin secretion (Figure 6.1A). The ZF islet insulin content was found to be ~2 fold 
higher than the ZDF islet insulin content (Table 6.1). Meanwhile, the ZDF islets 
showed minimal glucose responsiveness, as insulin secretion rates at 20mM glucose 
were only ~40% higher than basal release rates (Figure 6.1B). The mean basal insulin 
secretion rates for ZF and ZDF islet data sets were calculated as 0.56 ± 0.21 and 0.47 
± 0.30 ng of insulin secreted/islet/hour, respectively. In addition, the mean basal 
insulin secretion rate for Wistar rat isolated islets was determined as 0.34 ± 0.15 ng of 
insulin secreted/islet/hour (n=9). The mean basal insulin secretion rates for Wistar, ZF 
and ZDF did not significantly differ.  
 
The use of methanandamide, AM251 or URB597 (at 10M) did not significantly affect 
insulin secretion rates at 4mM or 20mM glucose in either ZF or ZDF islets. The same 
drug stocks were used in experiments with Wistar rat isolated islets (preceding these 
experiments) and it was found that the drugs performed in accordance with previous 
observations made in Wistar rat islets. Thus, the lack of drug effect in the Zucker 
islets, in comparison to Wistar islets, was due to differences in cannabinoid signalling 
pathways (rather than drug degradation).  
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Table 6.1  Physiological variables, including islet insulin content, of the ZF and ZDF 
rats used in the study 
  
Zucker rat type Zucker Fatty Zucker Diabetic Fatty
Number of rats 8 8 
Age in weeks 9-11 9-11 
Body weight (g) 362 ± 16.4 325 ± 18.9 *** 
Blood glucose (mM) 10.2 ± 1.7 18.3 ± 4.2 *** 
Islet insulin content 
(ng of insulin/islet) 15.8 ± 2.0 8.8 ± 0.9 
***
 
 
Data are presented as the mean ± SD (n= 8 except for ZDF rat blood glucose where 
n=6). *** p< 0.001 vs. corresponding ZF condition 
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A  Zucker Fatty islets  
 
B  Zucker Diabetic Fatty islets 
 
 
Figure 6.1  The effects of cannabinoid treatments in insulin secretion from isolated 
Zucker Fatty (A) and Zucker Diabetic Fatty (B) rats. Islets were pre-incubated with 
either vehicle (control) or 10M URB597. Insulin secretion was then determined at 
either 4mM or 20mM glucose in the absence or presence of 10M methanandamide 
(metAEA) or 10M AM251. Results are displayed as mean insulin secretion rates ± 
SD (n= 8). 
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6.4 Discussion 
 
ZDF rats had lower body weights but had significantly higher blood glucose levels 
than age-matched ZF rats. Unlike ZDF islets, ZF islets were found to be glucose 
responsive, and had higher insulin contents. Neither 10M methanandamide, 10M 
AM251 nor 10M URB597 significantly affected insulin secretion from ZF or ZDF 
islets. 
 
6.4.1 Pathology of the Zucker Fatty and Zucker Diabetic Fatty rats 
It was found that the ZDF rats weighed less than the age-matched ZF rats which is in 
accordance with observations made by Pick et al. (1998). The weights of the ZF and 
ZDF rats are also in agreement with other studies which used ZF and/or ZDF rats of a 
similar age range (Tokuyama et al., 1995; Chan et al., 1999; Liu et al., 2002). The 
blood glucose levels of the ZF rats were found to be similar to that typically reported 
(~8mM) by other groups (Pick et al., 1998; Li et al., 2006). As the average ZF rat 
plasma glucose concentration was 10.2mM, this may suggest that the ZF rats had 
raised plasma glucose levels which could be due to impaired glucose tolerance 
(Section 1.3.1). It was also found that the ZDF rats had blood glucose levels > 
11.0mM glucose which would suggest that these animals were diabetic (Section 
1.3.1). As discussed in the Introduction for this chapter, diabetes can occur 
spontaneously in ZDF rats past seven weeks of age, therefore, the occurrence of 
diabetes in the ZDF animals was expected. 
 
The islets isolated from the Zucker rats, especially the ZDF islets, were typically 
larger, irregularly shaped and more grey in colour which made it more difficult to 
distinguish between islet and exocrine tissues than experienced with age-matched 
Wistar rat islet. As discussed in the Introduction, these changes in islet morphology 
are typical of those reported for islets from ZF and ZDF. Therefore, DZT was used to 
identify the islets as -cells contain considerably higher levels of Zn2+ ions than any 
other cell type in the pancreas (Section 6.2). In addition to morphological changes, it 
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was observed that the ZF islets were glucose responsive, whereas, the ZDF islets had 
all but lost their glucose responsiveness. Both these observations were in line with 
other studies that have used similarly aged ZF and diabetic ZDF rats (Lee et al., 1994; 
Sreenan et al., 1996; Pick et al., 1998). The insulin contents of ZF and ZDF islets 
were lower than that reported by other group’s, but this anomaly may be due to the 
varying precisions in each groups insulin assay (Tokuyama et al., 1995; Zhou et al., 
1999; Harmon et al., 2001; Liu et al., 2002). The insulin content of the ZDF islets was 
approximately half that of the ZF islets. Pick et al. (1998) reported a 50% reduction in 
ZDF islet  cell mass in comparison to age-matched islets from ZF rats, which may 
explain the difference in islet insulin content. A similar deficit (~4 fold) in the insulin 
content of ZDF islets, in comparison to the insulin content of ZF islets, has also been 
reported in the study by Zhou et al. (1999). However, Zhou et al. (1999) reported that 
the ~4 fold deficit in ZDF islet insulin content was not due to alterations in insulin 
mRNA levels or alterations in -cell mass, and may be due, instead, to reductions in 
the level of insulin mRNA translation (Fred & Welsh, 2009).  
 
6.4.2 Effects of methanandamide, AM251 and URB597 on insulin 
secretion in ZF and ZDF islets 
Within this study, it was found that 10μM methanandamide, 10μM AM251 and pre-
incubation with 10μM URB597 did not affect basal or maximal levels of GSIS in ZF or 
ZDF islets. It was reported by Getty-Kaushik et al. (2009) that acute (30 minute) 
exposure of ZLC and ZF rat isolated islets to 1M rimonabant (a structural analogue 
of AM251) resulted in a lowering of insulin release at 16mM glucose. If the effects of 
AM251 were due to the blockade of islet-derived endocannabinoid CB1 receptor 
signalling or inverse agonism at the CB1 receptor then it would be expected that the 
results in ZF rat islets presented here would have been similar to those reported for 
rimonabant in Getty-Kaushik et al. (2009). As this was not the same, then the 
differences between AM251 and rimonabant may be due to differences in 
pharmacology, use of freshly picked vs. 24 hour cultured islets or variations between 
ZF rat colonies. 
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Despite methanandamide, AM251 and URB597 not significantly affecting insulin 
secretion, it appeared that all three compounds caused a slight increase in the basal 
insulin secretion rate in the ZF islets. Further examination of the data also indicates 
that methanandamide inhibited basal secretion in the majority of ZDF islets, but this 
was not observed in ZF islets. This suggests a cannabinoid signalling pathway may 
have become dysfunctional as insulin secretion at 4mM appeared to be affected by 
methanandamide, an effect not observed with methanandamide in Wistar rat islets 
(Chapter 3). Additionally, methanandamide also appeared to inhibit insulin secretion 
at 20mM glucose in the majority of experiments performed with ZF and ZDF islets. 
This may indicate that one or more pathways by which methanandamide could inhibit 
insulin release at 20mM glucose in Wistar islets may have been affected by obesity. 
Whether these findings indicate that cannabinoid signalling differs between obese and 
obese type 2 diabetic states is uncertain without a greater number of experiments 
being performed. 
 
Pre-incubation of islets with 10M URB597 did not significantly affect insulin secretion 
from ZF or ZDF islets at either 4mM or 20mM glucose. As discussed in Section 3.4.2, 
further work is needed to confirm the level of FAAH activity and specificity of URB597 
pre-incubation protocol within these islets before the affects of FAAH inhibition can be 
discussed with confidence. In Wistar rat islets, both 10M methanandamide (Chapter 
3) and 10M AM251 (Chapter 5) consistently inhibited insulin secretion. This would 
primarily suggest that the receptor signalling pathways through which these 
cannabinoids affected insulin release in the lean (Wistar) islets are altered as a result 
of obesity and/or type 2 diabetes in the Zucker rat islets. Yet without similar 
information from ZLC rats, it cannot be ascertained whether the differences in 
cannabinoid signalling in islets is primarily affected by the physiological state of the 
animal, a lack of leptin signalling, or differences between Zucker and Wistar strains. 
Indeed, future experiments must include islets from ZLC rats (that are age-matched to 
the Wistar rats), to establish whether islet responses to cannabinoids are comparable 
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between the rat strains before it can be determined whether endocannabinoid 
signalling is altered in diabetes. Future experiments should also include comparisons 
of islet responses between diet-induced obese ZLC and ZF rats to establish whether 
the lack of leptin signalling, rather than obesity, effects cannabinoid signalling within 
Zucker islets. 
 
6.4.3 Conclusions 
Methanandamide and AM251 have been demonstrated to inhibit insulin secretion 
from Wistar islets but failed to significantly affect insulin secretion rates from either ZF 
or ZDF islets. The results from this study suggest that cannabinoid signalling in islets 
is affected by obesity but it is unclear whether cannabinoid signalling is altered further 
when islets become dysfunctional at the onset of type 2 diabetes. However, as islets 
from ZLC rats were not used, it is uncertain whether cannabinoid signalling in islets 
fundamentally differs between Wistar and Zucker islets. It is also unclear whether the 
lack of leptin signalling also has an effect on cannabinoid signalling. Therefore, future 
experiments first need to determine whether the Zucker rat is a suitable model to 
study any potential cannabinoid dysfunction that may occur as a result of obesity 
and/or type 2 diabetes. If these studies confirm that Zucker islets are suitable then 
further work can then proceed to characterise whether cannabinoid signalling plays a 
causative role in the development of islet dysfunction in type 2 diabetes. 
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7  
 
General Discussion 
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The principal aim of this programme of research was to characterise the effects of 
cannabinoid signalling on insulin secretion from islets. A variety of ligands which are 
reported to interact with cannabinoid receptors, together with inhibition of 
endocannabinoid metabolising enzymes were used in secretion studies. Figure 7.1 
presents a schematic summary of cannabinoid signalling in islets based on results 
from Chapters 4 and 5, which suggest that CB1-receptor signalling in some islets can 
potentiate insulin secretion but inhibit insulin secretion in others, whereas CB2-
receptor signalling can only inhibit insulin secretion. These conclusions are based on 
the effects of the endogenous cannabinoid AEA (Chapter 4) and the synthetic 
cannabinoids, ACEA and JWH-133 (which are described as CB1- and CB2-receptor 
specific agonists; Chapter 5) on insulin secretion. These conclusions assume that 
both the potentiation and inhibition of insulin secretion caused by ACEA, in separate 
islet preparations, were CB1-receptor specific and as discussed in section 5.4.1 are 
due to differences in sst-14 signalling. These conclusions also assume JWH-133 was 
inhibiting insulin release in a CB2-receptor specific manner and that AEA, as 
implicated in cell lines and other tissues, displays a higher affinity for CB1 receptors 
over CB2 receptors (McPartland et al., 2007). These data have then been fitted to the 
expression of CB-receptor on specific cell types and is based on data from Table 4.1. 
The schematic also assumes that CB1 and CB2 receptors are expressed on 	-cells. 
However, this schematic diagram does not factor in the possibility that other receptor 
signalling events (e.g. CB-like and GPR55) may also be occurring. It also does not 
account for the source of the endocannabinoids nor the influence that different 
endocannabinoid metabolising pathways may have. 
 
Due to the variability of islet responses to the different cannabinoids used, it still 
remains unclear whether there is an archetypal endocannabinoid signalling system in 
islets, especially if cannabinoid responses are dependent on the fasting state of the 
animal, islet cell composition, expression of endocannabinoid metabolising enzymes 
and CB/CB-like receptor expression patterns. If cannabinoid signalling in islets were 
to be affected by these factors then it may explain why a consensus has not been 
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reached yet within this field. To address this question, it may be appropriate to 
perform immunohistological or in situ hybridization studies with whole pancreata. 
Ideally, such a study would address whether factors such as islet size, pancreatic 
location and fasting state influence the expression and/or activity of receptors and 
metabolising enzymes of the endocannabinoid system in islets.  
 
-cell
glucagon sst-14
sst-14
+
+
+
CB
1
CB
1
CB2
-cell-
+
CB
1
CB
1
CB2
-cell CB2
-
-
-
 
 
Figure 7.1  Schematic diagram of possible CB1- and CB2-receptor signalling events 
that may occur in islets at maximal levels of glucose-stimulated insulin secretion. 
Within the islet, glucagon secreted by -cells act on insulin-secreting -cells in a 
positive manner, while somatostatin (sst-14) secreted by 	-cells inhibit hormone 
release from both - and -cells. Activation of cannabinoid receptors (CB1 and CB2) 
expressed on islet cell potentiate (+) or inhibit (-) hormone secretion from the cell type 
indicated. 
 
In addition, the influence of endocannabinoid tone on islet function should also be 
assessed. As discussed in Chapters 3 and 5, endocannabinoid tone in islets may 
have also been a confounding factor when interpreting the effects of CB receptor 
antagonists (AM251, O-2050 and AM630) and the FAAH inhibitor URB597. Therefore, 
it should be determined which endocannabinoids (including endocannabinoid-like 
molecules) are produced by islets and whether endocannabinoid production is linked 
to GSIS. This could be accomplished using techniques such as liquid 
chromatography-tandem electrospray ionization mass spectrometry which can be 
used to detect and measure the levels of a number of different endocannabinoids in 
parallel (Richardson et al., 2007). This work could then be followed by RT-PCR 
(reverse transcriptase polymerase chain reaction) and Western blotting to explicitly 
characterise the expression of endocannabinoid synthetic machinery within islets. As 
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shown in Table 1.4, this has been done to a limited extent by other groups but these 
studies have not accounted for alternate biosynthetic pathways which may be 
important in the production of N-acylethanolamines (Section 1.4.1.1). Once pathways 
have been identified then genetic alteration in the expression of key enzymes (e.g. 
MAGL knock-out, overexpression of MAGL or use of siRNA to reduce MAGL 
expression) could be used to examine how endocannabinoid tone affects islets 
function, especially if enzymes inhibitors were not available or were themselves found 
to affect insulin secretion. As discussed in Section 5.4, it is possible that the effects of 
the CB receptor agonists and antagonists on insulin secretion, observed within this 
study, could have been due to a reduced specificity at the concentrations used and/or 
previously uncharacterised activites at non-CB receptors. Therefore, the use of CB 
receptor knock-out animals or siRNA techniques could also be used to study 
cannabinoid signalling in islets in future studies instead of the pharmacological 
approaches. 
 
7.1 Physiological role of the endocannabinoid system in islets 
It was also found in this study that the effects of the cannabinoids were limited to 
maximal levels of insulin secretion. Assuming the results are physiologically-relevant, 
they suggest that endocannabinoid signalling does not play a major regulatory role on 
insulin secretion within physiological ranges of plasma glucose levels. If 
endocannabinoid signalling in islets were restricted to supraphysiological plasma 
glucose levels, it could suggest that the endocannabinoid system in islets plays a 
protective role in hyperglycaemic states. For example, endocannabinoid signalling 
may limit over activation of signalling pathways in islets which could lead to a longer-
term desensitisation of these pathways which could attenuate future insulin secretory 
responses. Yet, at physiological ranges of plasma glucose levels the role of 
endocannabinoid signalling has not been investigated with regards to other aspects of 
islet function. For example, cannabinoid signalling currently has not been investigated 
with regard to insulin secretion in response to other secretagogues, such as free fatty 
acids, or whether cannabinoid signalling may affect other receptor signalling pathways 
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(Selley et al., 2004; Cinar et al., 2008; Kim et al., 2008b). It must also be considered 
that islet-derived endocannabinoids may affect islet endothelial cell function or islet-
associated neuronal function (by pre-synaptic inhibition). 
 
In addition to affecting islet function, the endocannabinoid system may also affect islet 
cell viability, which may have important implications in pathological states. As 
discussed in Section 1.3.3, the preservation of -cell function and mass is of key 
interest in the treatment and prevention of type 2 diabetes. Studies performed with 
islets and -cell lines have implicated various factors contributing to the fate of -cells 
in pathological states. Firstly, activation by phosphorylation of the serine/threonine 
protein kinase Akt through insulin receptor signalling promotes  cell survival 
(Srinivasan et al., 2002; Gonzalez-Pertusa et al., 2010; Natalicchio et al., 2010). 
Activation of mitogen-activated protein kinase (MAPK) signalling (by p38 and/or JNK 
signalling) promotes -cell death (Bachar et al., 2010; Ma et al., 2010). Cytokines, 
such as interleukin-1 (IL-1), tumour necrosis factor  (TNF) and interferon  
(IFN), also promote increased rates of -cell apoptosis and reductions in -cell 
replication rates (Heitmeier et al., 2004; Donath et al., 2010; Ma et al., 2010). This is 
achieved by increased reactive oxygen species (ROS) generation (through expression 
of inducible nitric oxide synthase) and MAPK signalling, but may also involve other 
mechanisms, such as increased lipoxygenase-12 (LOX-12) activity (Heitmeier et al., 
2004; Donath et al., 2010; Ma et al., 2010; Natalicchio et al., 2010). Endoplasmic 
reticulum stress (excessive protein production and protein misfolding) is another factor 
contributing to -cell apoptosis, as reviewed in Fonseca et al. (2009). 
 
CB2-receptor agonism (confirmed by a lack of effect in CB2-receptor knock-out mice) 
has been found to reduce the incidence of apoptosis in several in vivo studies, each 
examining a different model of apoptosis in different tissues (Defer et al., 2009; 
Viscomi et al., 2009; Mukhopadhyay et al., 2010). The anti-apoptotic effects of CB2-
receptor signalling were linked to reduced ROS generation, reduced cytokine 
expression and increased Akt signalling (Defer et al., 2009; Viscomi et al., 2009; 
Mukhopadhyay et al., 2010). As rat -cells express CB2 receptors (Table 4.2) and CB 
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receptor expression patterns in islets have not been reported to in differ type 2 
diabetes, then CB2 receptor agonism in physiological and pathological states may 
have beneficial effects on -cell function and survival (Srinivasan et al., 2002; Tharp et 
al., 2008; Natalicchio et al., 2010). Use of thiazolidinediones (TZDs) in genetically 
obese animals has been observed to preserve islet mass, insulin content and glucose 
responsiveness of the -cells (Shimabukuro et al., 1998; Ishida et al., 2004; Kawasaki 
et al., 2005). Additionally, in vitro testing in human islets found that rosiglitazone 
reduced rates of -cell apoptosis and -cell stress induced by islet amyloid protein 
and palmitate (Lin et al., 2005; Vandewalle et al., 2008). As mentioned in Section 
1.4.5, endocannabinoids also possess agonistic activities at the PPAR receptor, thus 
in lipotoxic conditions, endocannabinoids may also reproduce the protective effects of 
TZDs, through PPAR agonism, on -cell survival and function. Yet, endocannabinoid 
signalling may also have pro-apoptotic effects in -cells. For instance, chronic 
activation of pro-survival signalling pathways by CB2 signalling may make -cells 
susceptible to free fatty acid (FFA) induced apoptosis (Gonzalez-Pertusa et al., 2010). 
Furthermore, CB2 signalling (involving TRPV1 signalling) has been reported to reduce 
mononuclear cell survival, which may involve increased ER stress (Saunders et al., 
2009). Meanwhile, CB1 receptor signalling may negatively affect -cell survival 
indirectly by upregulating cytokine production, leading to the promotion of apoptosis in 
-cells (Heitmeier et al., 2004; Donath et al., 2010; Ma et al., 2010; Mukhopadhyay et 
al., 2010). Cannabinoids have also been found to negatively affect mitochondrial 
activity which could also contribute to -cell dysfunction and may trigger apoptotic 
signalling through cytochrome c release (Athanasiou et al., 2007; Catanzaro et al., 
2009). Finally, in islets the phytocannabinoid 9-tetrahydrocannabindiol was found to 
increase arachidonic acid oxidation by LOX-12 (Laychock et al., 1986). As stated 
above, increased LOX-12 activity is linked to increased rates of apoptosis through 
MAPK signalling, which again may suggest that the endocannabinoid system 
upregulates apoptotic signalling in -cells (Ma et al., 2010). Altogether, the literature 
suggests that the endocannabinoid system may play a role in the development and 
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progression of type 2 diabetes by directly affecting -cell viability and therefore 
warrants further investigation. 
 
Long-term incubation studies, where islets are co-incubated with cannabinoids in the 
absence or presence of hyperglycaemic and/or lipotoxic conditions, are a feasible 
means to assess the effects of prolonged CB-receptor signalling on islet function and 
insulin secretion. These types of experiments were originally planned at the start of 
this study with THC and rosiglitazone, to examine whether THC could exert effects 
similar to rosiglitazone through PPAR receptor agonism. However, there was not 
sufficient time to perform these experiments but they still appear to be viable and 
should also included in future studies. In addtion to THC and rosiglitazone the use 
CB1 and CB2 receptor agonists/antagonists should also be tested in order to verify the 
predictions in the previous paragraph.  
 
7.2 Establishing the role of the endocannabinoid system in 
glucose homeostasis 
As described previously (Section 1.1), the regulation of blood glucose levels is 
achieved by the coordinated release of islet hormones which then affect peripheral 
tissue function. Hence, cannabinoid signalling may not only affect the release of 
insulin, and other islet hormones, but may also affect insulin-mediated glucose uptake 
too. Research into the role of the endocannabinoid system in peripheral tissue over 
recent years suggests that prolonged exposure to endocannabinoids promotes insulin 
resistant states (Esposito et al., 2008; Motaghedi & McGraw, 2008). This research 
field has primarily focused on the pathological state induced by chronic cannabinoid 
exposure and the benefits of global CB1 receptor blockade. As introduced in Section 
3.1, CB1 receptor antagonism may become a future treatment for type 2 diabetes as it 
promotes weight loss and increases glycaemic control. However, a viable CB1-
receptor antagonist for the treatment of type 2 diabetes may never be developed due 
to adverse side-effects, such as depression and risk of suicide (Johansson et al., 
2009). Therefore, more work needs to be performed to define and understand how 
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cannabinoid signalling affects insulin release from islets and insulin signalling in 
peripheral tissue (liver, skeletal muscle and adipose tissue). Such information would 
also be of wider use as research into the manipulation of the endocannabinoid system 
is being carried outside of the fields of obesity and type 2 diabetes. Hence, if 
treatments were used that affected the endocannabinoid system globally then other 
systems may also be affected promoting dysfunction in other systems. For instance, 
there is interest in the use endocannabinoid metabolising enzyme inhibitors and CB1 
receptor agonists for the treatment of inflammatory disorders (Cluny et al., 2010; 
Sagar et al., 2009). Therefore, therapeutic potential in one area might be negated by 
adverse effects on glucose homeostasis. 
 
As discussed in Chapter 3, AEA appears to inhibit insulin secretion from freshly-
isolated islets (which were used in this study) but potentiate insulin secretion when 
islets have been cultured. Therefore, it needs to be determined whether freshly-
isolated or cultured islets reproduce the affects of cannabinoid signalling on islet 
function in vivo. A similar in vivo approach to that used in Bermudez-Siva et al. (2006) 
could be used but changes in plasma insulin and glucagon levels should be measured 
alongside changes in plasma glucose levels. This will help to determine whether 
alterations in glucose tolerance were due to changes in islet function and/or insulin 
signalling (Section 1.1). This information could then be used to address the role of the 
endocannabinoid system in glucose-stimulated insulin secretion and its wider role in 
glucose homeostasis. 
 
As described in Section 1.4.10, chronic studies suggest that the endocannabinoid 
system appears to play a role in peripheral tissue dysfunction in dietary-induced 
obesity and affects several processes involved in glucose homeostasis. Thus, in co-
junction with the possible alterations in islet activity, other parameters should be 
measured to gain a greater understanding of acute cannabinoid signalling in other 
peripheral tissues. As discussed in Sections 1.2.5 and 1.3.3, the incretin hormones 
have an important effect on insulin secretion in response to orally ingested glucose 
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and also promote -cell survival but whether cannabinoid signalling affects the release 
of the incretin hormones appears to be unknown. Therefore, changes in the plasma 
levels of the incretin hormones should be measured as this would affect islet function. 
If cannabinoid signalling in the gut was also involved in glucose homeostasis, it may 
be informative to compare the effects of cannabinoid signalling when glucose was 
loaded intra-peritoneally or intra-venously to oral ingestion. Another aspect would be 
to measure the acute effects of cannabinoid signalling and endocannabinoid 
metabolism on insulin-mediated glucose uptake in hepatic, adipose and skeletal 
muscle tissues. For instance, this could be tested in vitro and/or in vivo (Nogueiras et 
al., 2008) by measuring radiolabeled 2-deoxyglucose uptake. Chronic rimonabant 
dosing has also been demonstrated to affect hepatic glucose production, therefore, 
this parameter should also be measured in response to acute treatment (Nogueiras et 
al., 2008). 
 
The discussion, thus far, has focused on the role of endocannabinoid signalling once 
plasma glucose levels were high enough to induce GSIS but endocannabinoid 
signalling may be important during fasting states. Studies performed in the gut 
suggest that CB1 receptor expression is upregulated during extended periods of 
fasting (Burdyga et al., 2004). It has also been noted that the circulating levels of N-
acylethanolamines are highest during periods of fasting and in physiological states 
decrease once feeding has occurred (Matias et al., 2006; Matias et al., 2007). With 
regard to islet function the obvious question is, does cannanabinoid exposure during 
periods of fasting affect insulin secretory responses when glucose levels increase 
sufficiently to induce GSIS? This could be tested in vitro by culturing islets for 
increasing periods of time (e.g. 0.5, 1, 2, 4, 8 and 12 hours) in the absence or 
presence of endocannabinoids at non-stimulatory concentrations of glucose ( 4mM 
glucose) followed by acute secretion studies. In initial tests, comparisons between 
vehicle and endocannabinoid-treated islets could then assess whether -cell glucose 
responsiveness, islet content and/or insulin secretion kinetics had been altered. The 
initial tests could also examine whether cannabinoid treatment had altered - and/or 
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	-cell secretory activity and hormone content too. Experiments in islets could also be 
performed to assess whether the expression and/or activity of the cannabinoid 
receptors, endocannabinoid synthesising and metabolising enzymes are affected by 
different periods of -cell activity and inactivity. 
 
As mentioned above, the endocannabinoid system appears to be most active during 
periods of fasting (Burdyga et al., 2004; Matias et al., 2006; Matias et al., 2007). Thus, 
the physiological role of the endocannabinoid system in the periphery may be to 
promote effective food assimilation. This could be achieved by promoting the 
upregulation of lipogenic pathways in the periphery as well as increasing nutrient 
absorbtion and increasing the amount of time food is in the gut (Carr et al., 2008; 
Duncan et al., 2008; Quarta et al., 2010; Zhao et al., 2010). Therefore, by 
understanding how the endocannabinoid system adapts in response to different 
physiological states in peripheral tissues, it would then help determine if and why 
endocannabinoid signalling may become dysfunctional in the periphery during obesity 
and/or type 2 diabetes. 
 
7.3 Conclusions 
While this PhD has not provided full characterisation of the endocannabinoid system 
within islets, it has highlighted that cannabinoid signalling within islets is more 
complex than has been reported by other research groups. For example, islet 
responsiveness to AEA at concentrations  10M varied between islet preparations in 
a FAAH-independent manner (Chapter 3). Results from Chapters 4 and 5 suggest 
that CB-receptor signalling pathways may differ between islets and may account for 
the variations in the potency of AEA between islet preparations. In addition, putative 
CB-receptor specific ligands, as discussed in Chapter 5, may possess extra non-CB-
receptor mediated activities within islets. It is hoped that the information obtained from 
these studies will aid future investigations in this field to gain a more complete 
understanding of the role of endocannabinoid system in glucose homeostasis. 
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